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"Our truest life is when we are in dreams awake."  
Henry David Thoreau 
 
“If a man has lost a leg or an eye, he knows he has lost a leg 
or an eye; but if he has lost a self—himself—he cannot know 
it, because he is no longer there to know it.”  
Oliver Sacks  
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Insulin-like growth factor 1 (IGF-1) is a circulating hormone that is mainly produced by 
the liver in response to the growth hormone from the adenohypophysis. Previous data from our 
laboratory have shown that, in the adult, IGF-1 is able to cross the blood-brain barrier (BBB) to 
enter the central nervous system (CNS) through a tonic (constitutive) and a phasic mechanism. 
The last process is coupled to neuronal activity, what means that active brain areas accumulate 
IGF-1 from the blood, and as a result it has been named “neurotrophic coupling”.  
On the other hand, Alzheimer’s disease (AD) is the most prevalent neurodegenerative 
disease and a major cause of dementia among the worldwide population. Despite a century of 
research has elapsed, its etiology and pathogenesis are yet to be fully defined. As a result, it 
remains one of the biggest medical challenges of our time. Due to the recent failure of many 
clinical trials based on the amyloid cascade hypothesis, there is an unmet need to find new 
etiological hypothesis and to reach an earlier diagnosis of AD. Previous experiments done on 
our laboratory demonstrated that IGF-1 plays a protective role in AD by clearing amyloid beta 
(Aβ) away from the brain and resolving chronic neuroinflammation. Based on this and on 
abundant literature describing an impaired central insulin system in AD, we posited the 
existence of a dysfunction in IGF-1 access to the brain that would play a pathogenic role in AD 
and would be an early event in disease progression.  
With the project I hereby present as my PhD thesis, I intended to test this hypothesis and 
to try to translate the potential outcomes into an early diagnostic tool for AD. 
Environmental enrichment (EE) is an experimental protocol used for diffuse 
physiological stimulation of the brain and so susceptible of inducing IGF-1 input to the engaged 
brain areas. However, little was known about the regulation of the latter and, because of it, we 
decided to study it in more detail. Because cell signaling of growth factors is tightly regulated 
in time and IGF-1 is one of the most potent mitogens in the organism, we hypothesized that its 
entrance to the brain would be similarly limited in homeostasis. As a result, we found out that 
in wild type (WT) animals the response to IGF-1 was maximal after 2h of EE in the 
hippocampus, whereas mice with liver IGF-1 deficiency did not display any activation of the 
IGF-1 receptor (IGF-1R). At longer exposures of EE there were fluctuations in the levels of 
phosphorylated (active) IGF-1R, which ultimately led to the development of tolerance in the 
chronic stimulation of one month. When we analyzed the response of asymptomatic AD mice 
(APP and APP/PS1) to acute EE, we detected that their expected response was dramatically 
impaired as compared to WT controls. We discovered an intrinsic brain resistance to IGF-1 in 
AD mice that we considered the main cause of the observed disrupted transport of circulating 
IGF-1 into the CNS. 
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Previous findings of the laboratory suggested that IGF-1 enhances neuronal excitability 
and others had reported that peripheral insulin modified the electroencephalogram (EEG) in 
humans. Taking this into account we proposed that systemically injected IGF-1 would affect 
brain electrical activity. We confirmed this in WT anaesthetized mice, in which IGF-1 was able 
to potentiate the fast component of the electrocorticogram (ECoG). As for AD mice, the 
injection of IGF-1 did not exert any effect on the ECoG (in APP/PS1) or it did it feebly (APP). 
Because this pattern perfectly matched that of the phospho-IGF-1R evoked by EE, we believe 
this test is an easily accessible and non-invasive way of determining brain IGF-1 sensitivity. If 
ECoG/EEG response to a peripheral injection of IGF-1 was diminished, this might be used as a 
biomarker of AD. Nonetheless, this ought to be done in concurrence with other biomarkers used 
for risk assessment of AD in healthy subjects, such as those detecting amyloidopathy or subtle 
neurodegeneration before the onset of clinical symptoms. 
To further explore the pathogenic implications of IGF-1 system in sporadic AD we have 
recently started using a diet-induced model of the metabolic syndrome (MetS), an established 
risk factor for dementia. So far we have identified that, after a short time, a high-fat diet (HFD) 
induces the entrance of IGF-1 in the cerebrospinal fluid (CSF) of WT mice. This may be related 
to the prolonged hippocampal IGF-1 signaling and the dendritic abnormalities seen in the 
dentate gyrus and CA1 regions of diet-induced obese (DIO) mice. Nevertheless, more work is 
still needed to assess the true role of IGF-1 brain signaling in these events, also including other 
pathogenic markers found in DIO brains such as the increase in mitochondria fission and tau 
abnormal phosphorylation. 
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El factor de crecimiento insulínico de tipo 1 (IGF-1) es una hormona circulante que se 
produce principalmente en el hígado en respuesta a la hormona del crecimiento 
adenohipofisaria. Datos previos del laboratorio han demostrado que, en el adulto, IGF-1 es 
capaz de cruzar la barrera hematoencefálica para entrar al sistema nervioso central a través de 
un mecanismo tónico (constitutivo) y/o fásico. El último está asociado a la actividad neuronal, 
lo que implica que en áreas activas del cerebro se acumula IGF-1 de la sangre, y por ello es que 
se ha denominado “acoplamiento neurotrófico”. 
Por otra parte, la enfermedad de Alzheimer es la más prevalente de entre las 
neurodegenerativas y la mayor causa de demencia en la población mundial. A pesar de que ya 
ha pasado un siglo de investigación, su etiología y patogenia aún no están del todo definidas. 
Como consecuencia, continúa siendo uno de los mayores retos clínicos de nuestra era. Debido 
al reciente fracaso de muchos ensayos clínicos apoyados en la hipótesis de la cascada amiloide, 
existe una gran necesidad de encontrar nuevas hipótesis etiológicas y de adelantar el 
diagnóstico de la enfermedad de Alzheimer. Experimentos previos del laboratorio muestran que 
IGF-1 tiene un papel protector en esta patología a través del aclaramiento del péptido beta 
amiloide (Aβ) del cerebro así como de la resolución de la neuroinflamación crónica asociada a 
la enfermedad. Basándonos en esto y en la abundante literatura que describe la alteración 
central del sistema de insulina en el Alzheimer, postulamos la existencia de una disfunción 
temprana en el acceso de IGF-1 al cerebro y que ello podría jugar un rol patogénico en la 
misma. 
Con el proyecto que aquí presento como mi tesis doctoral, he intentado probar esta 
hipótesis y trasladar los posibles resultados hacia el desarrollo de una herramienta de 
diagnóstico temprano de la enfermedad de Alzheimer. 
El enriquecimiento ambiental es un protocolo experimental utilizado para la estimulación 
fisiológica difusa del cerebro y por lo tanto es susceptible de inducir el paso de IGF-1 desde la 
sangre hacia las zonas cerebrales activas. No obstante, se sabe poco de cómo esto se regula y, 
por esto, decidimos estudiarlo más en detalle. Debido a que la señalización de los factores de 
crecimiento se encuentra firmemente regulada en el tiempo y a que IGF-1 es uno de los más 
potentes mitógenos del organismo, hipotetizamos que su entrada al cerebro se encontraría 
similarmente controlada en la homeostasis. Mediante experimentos en animales silvestres o 
wild type (WT) encontramos que la respuesta al enriquecimiento fue máxima tras 2h y en el 
hipocampo, mientras que ratones sin producción hepática de IGF-1 no mostraban activación del 
receptor de IGF-1 (IGF-1R). En exposiciones más largas encontramos fluctuaciones en los 
niveles de IGF-1R fosforilado (activo, pIGF-1R), que en último lugar llevaron al desarrollo de 
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tolerancia en la estimulación crónica de un mes. Cuando analizamos la respuesta al 
enriquecimiento agudo de los ratones de Alzheimer en etapas asintomáticas (APP y APP/PS1), 
detectamos que ésta se encontraba dramáticamente alterada en comparación con los controles 
WT. Descubrimos en estos ratones una resistencia cerebral intrínseca a IGF-1, que 
consideramos como la causa principal del trastocado transporte de IGF-1 circulante al cerebro. 
Anteriores hallazgos del laboratorio sugerían que IGF-1 aumenta la excitabilidad 
neuronal y otros investigadores habían descrito que la insulina periférica modifica el 
electroencefalograma (EEG) en humanos. Teniendo ambos hechos en cuenta, propusimos que 
la inyección sistémica de IGF-1 afectaría a la actividad eléctrica del cerebro. Esto fue 
confirmado en animales WT anestesiados, en los que IGF-1 potenció el componente rápido del 
electrocortigorama (ECoG). En animales transgénicos modelo de la enfermedad de Alzheimer, 
la administración intraperitoneal de IGF-1 o bien no tuvo ningún efecto sobre el ECoG (en 
APP/PS1) o bien fue muy débil (APP). Ya que este patrón encaja a la perfección con lo 
observado para el pIGF-1R en el enriquecimiento, creemos que esta prueba es una forma no 
invasiva y fácilmente accesible para la determinación de la sensibilidad cerebral a IGF-1. Si la 
respuesta del ECoG/EEG a la administración periférica de IGF-1 estuviera disminuida, se 
podría utilizar como biomarcador de la enfermedad de Alzheimer.  Aun así, ello debería hacerse 
en concurrencia con otros biomarcadores utilizados para la evaluación del riesgo de Alzheimer 
en sujetos sanos, como por ejemplo aquellos enfocados hacia la detección de amiloidopatía o 
neurodegeneración sutil previos a la aparición de los síntomas clínicos. 
Con el objetivo de explorar más en profundidad la implicación patogénica del sistema 
IGF-1 en el Alzheimer esporádico, hemos comenzado a utilizar recientemente un modelo 
basado en la inducción de síndrome metabólico (un conocido factor de riesgo para la 
enfermedad de Alzheimer) a través de la dieta. Hasta ahora hemos encontrado que una dieta 
rica en grasas induce la entrada de IGF-1 hacia el líquido cefalorraquídeo en animales WT. Este 
hecho podría estar relacionado con la prolongada señal de IGF-1 hipocampal y las 
anormalidades dentríticas del giro dentado y CA1 que se observan en los ratones obesos. No 
obstante, aún es necesario más trabajo para asegurar el verdadero papel de la señalización 
central de IGF-1 en estos eventos, incluyendo otros marcadores patogénicos encontrados en el 
cerebro de los animales obesos tales como el incremento de la fisión mitocondrial y la anormal 
fosforilación de tau. 
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1.1.  IGF-1 physiology: 
 1.1.1.  Discovery 
The existence of peripheral endocrine mediators of whole body growth induced by 
growth hormone (GH) was first proposed in the late 50s (Salmon and Daughaday, 1957). These 
were named somatomedins, or insulin-like growth factors (IGFs), and almost 20 years elapsed 
before human IGF-1 was isolated and its structure resolved, showing its high homology with 
proinsulin (Rinderknecht and Humbel, 1978). Ever since, the IGFs have been include in the 
insulin superfamily of peptides which comprises two main groups of proteins: the insulin-like 
peptides or ILPs (i.e. insulin, IGF-1 & IGF-2) and a second group that includes relaxins and 
insulin-like hormones (Fernandez and Torres-Alemán, 2012). 
 1.1.2.  Biosynthesis, secretion, transport (IGFBPs) & degradation 
The mature IGF-1 protein is a 7.649 kDa peptide and the final product of IGF1 gene 
transcription and translation. However, it has several mRNA splice variants that translate to the 
so-called E-peptides, whose role in modulating IGF-1 activity has recently been pointed out 
(Brisson and Barton, 2013; Hede et al., 2012). 
IGF-1 is expressed by virtually all cell types in the body, all of them respond to it  and it 
can be synthesized following both an endocrine and a paracrine/autocrine fashion during 
development and also in adulthood (Fig 1.1) (LeRoith et al., 1995). The former somatomedin 
hypothesis postulated that the main source for serum IGF-1 in mammals is the liver 
(Daughaday et al., 1972). This would be definitively proved later in time by showing that liver-
specific IGF-1 knock-out dramatically diminished its blood levels (Yakar et al., 1999), even 
though it did not knock them out completely due to potential extrahepatic sources of circulating 
IGF-1 (i.e. bone, fat, muscle, kidney and spleen). As for its local synthesis, it has been 
demonstrated that peripheral tissues can produce IGF-1, independently of GH, responding to 
diverse physiological and/or noxious stimuli (D’Ercole et al., 1980; Isaksson et al., 1987; 
Schlechter et al., 1986). In this regard, it is vital for normal brain development (D’Ercole et al., 
1996) and, even in the adult, it is de novo synthesized for recovery after brain injury (Guthrie et 
al., 1995; Lee et al., 1996; Walter et al., 1997). 
In the blood, IGF-1 is transported in a ternary complex by binding mainly to IGF binding 
protein 3 (IGFBP-3) and an acid-labile subunit (Baxter, 2000). Up to date it has been described 
the existence of at least six IGFBPs isoforms with high affinity for IGFs (even higher than its 
receptor, Firth and Baxter, 2002) and around ten IGFBP-related proteins with low affinity, none 
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of them binding insulin (Hwa et al., 1999). All IGFBPs are expressed in the brain although with 
regional differences, for example IGFBP5 is the most abundant in cerebellum (Ye and 
D’Ercole, 1998). These IGFBPs will ultimately regulate IGFs bioavailability because only free 
IGF-1 is able to interact with its receptor in cells. 
Figure 1.1. Diagram of IGF-1 neuroendocrine system in the adult organism.  It depicts the two main gates 
through which liver-derived circulating IGF-1 accesses the brain: the blood-CSF barrier and the BBB. Addition-
ally, IGF-1 may be synthesized locally by brain cells.  
Finally, when IGF-1 interacts with its receptor, the complex is internalized and 
dissociated in the mildly acidic endosomal compartment where IGF-1 proteolysis will be 
carried out by peptidases (Auletta et al., 1992; Furlanetto, 1988; Navab et al., 2001), such as 
cathepsin B (Authier et al., 2005) and probably also cathepsin L (Navab et al., 2008). This is 
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thought to be of utterly importance for the cellular response to IGF-1 and receptor recycling to 
the cell surface. 
 1.1.3.  Receptors. ILPs system and cross-interaction 
Among the ILPs there is a certain degree of promiscuity due to their structural homology 
whereby the different peptides can interact with the different receptors. However, these 
bindings show dissimilar affinities ultimately determining which one is the canonical receptor 
for each ligand (Fernandez and Torres-Alemán, 2012; Mynarcik et al., 1997). The main 
receptor for IGF-1 is the type 1 IGF receptor (IGF-1R) which can also bind IGF-2 and insulin 
but with lower affinity (6-fold and 100-fold respectively, Annunziata et al., 2011). In fact, IGF-
2 binds to IGF-1R more strongly than to IGF-2R and when in so doing leads to IGF-1-like 
signaling (Harris and Westwood, 2012). More recently, IGF-2 has been postulated to mainly 
use the IR-A splice variant as its main tyrosine kinase receptor (Ziegler et al., 2014). Likewise, 
IGF-1 can interact with type 2 IGF receptor (IGF-2R) and insulin receptor (IR) but also with 
lower affinities (see Fig 1.2).  
Figure 1.2. Receptor and ligand promiscuity within the insulin-like peptides (ILPs) system. Adapted from 
Annunziata et al., 2011. 
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IGF-1R is a heterotetrameric tyrosine kinase receptor (RTK) that shares a high sequence 
identity with IR (Ullrich et al., 1986) and can form functional hybrids with it (Bailyes et al., 
1997; Belfiore et al., 2009). It is constituted by two disulphide-linked homodimers each of 
which is composed of an alpha chain (N-terminal and extracellular) and a beta chain (C-
terminal and with transmembrane and intracellular domains) as oppose to other RTKs that 
dimerize only upon activation (Heldin and Ostman, 1996). Upon interaction with its ligand, IGF
-1R suffers a conformational change, whose exact mechanism has been recently defined 
(Kavran et al., 2014), that stimulates its kinase activity promoting autophosphorylation in 
specific tyrosine residues (1131, 1135 & 1136) within the A-loop domain (Favelyukis et al., 
2001; Jacobs et al., 1983) and further recruitment and activation of downstream signaling 
elements. 
 1.1.4.  Intracellular signaling pathways.  
Traditionally, IGF-1R has been considered to activate several kinases pathways. 
Specifically, concretely the PI3K/Akt and the MAPK survival pathways, following an OFF/ON 
mechanism triggered by ligand-binding common to all RTKs (Laviola et al., 2007; Lemmon 
and Schlessinger, 2010). Outcomes of this signaling include proliferation, differentiation, cell 
growth, survival (i.e. universal cytoprotector), increased protein synthesis… and so it is 
considered as a powerful mitogen. 
Activated (phosphorylated) IGF-1R serves as docking site for adaptor proteins such as 
insulin-receptor substrates (IRS1-4), especially IRS1/2, and the SH2-containing-proteins (Shc 
A-D), that will transduce IGF-1 signal downstream (Fig 1.3). The first group reaches maximal 
binding within 1-2 min after IGF-1R phosphorylation and activates both PI3K/Akt and MAPK 
pathways, whereas the Shc does it at around 5-10 min and only activates the MAPKs. Other 
less explored pathways potentially activated by the IGF-1R include crosstalk with β-arrestin 
and heterotrimeric G-protein coupled receptor (GPCR) signaling (Girnita et al., 2014). 
Besides tyrosine phosphorylation, several others posttranslational modifications have 
been shown to regulate IGF-1R function over the years. One of them is ubiquitination, which is 
ultimately responsible for IGF-1R internalization in the endosomal compartment for either 
recycling or degradation (downregulation). This will depend on if it is multiubiquitinated 
(single ubiquitin molecules at multiple lysine residues, Monami et al., 2008) or 
polyubiquitinated (full chains of ubiquitin are added, Mao et al., 2011). More recently, a 
nuclear pathway for the IGF-1R has been described upon ligand binding: it has been described 
that IGF-1R translocates to the nucleus in response to sumoylation (Sehat et al., 2010), where it 
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exerts genomic activities related to transcription factors (Sarfstein and Werner, 2013). The 
relevance of this new way of action is under intense scrutiny. Finally, dephosphorylation of the 
IGF-1R has been little studied and only some phosphatases such as SHP2 (Rocchi et al., 1996) 
and PTP1B (Buckley et al., 2002) have been shown to participate in it.  
 
 1.1.5.  IGF-1 in brain physiology 
For a long time IGF-1 has been known to be a central component of the somatotropic axis 
of endocrine regulation and thus a key factor in body growth, tissue differentiation and, in 
general, is thought of as a very potent mitogen practically affecting every organ and cell 
(Annunziata et al., 2011).  
More specifically it is indispensable for normal brain development, when local IGF-1/IGF
-1R expression is maximal (Bondy and Lee, 1993) thus strongly affecting proliferation, 
differentiation and survival of brain cells at several stages (Fernandez and Torres-Alemán, 
Figure 1.3. Schematic representation of IGF-1 intracellular signaling. Adapted from Giardiani et al., 2014. 
1. Introduction 
25 
2012; Russo et al., 2005). This has been thoroughly confirmed by the smaller brains and severe 
retardation observed in mice lacking Igf-1 (Baker et al., 1993) and in human IGF-1 deficiencies 
(Camacho-Hübner et al., 2002; Puche and Castilla-Cortázar, 2012). Nonetheless, IGF-1 
expression in the brain decreases with time until it reaches a minimum in the adult, whereas its 
receptor still shows a wide expression in the central nervous system (CNS). This mismatch may 
be explained because systemic IGF-1 is able to cross the blood-brain barrier (BBB) postnatally 
(Nishijima et al., 2010; Reinhardt and Bondy, 1994).  
In the adult brain, it has been demonstrated that peripheral IGF-1 promotes both 
neuroprotection in response to brain injury and neurodegenerative diseases (Benarroch, 2012; 
Carro et al., 2003), and beneficial effects of exercise such as neurogenesis (Carro et al., 2000; 
Cassilhas et al., 2012; Trejo et al., 2001). Besides, as observed in serum IGF-1 deficient LID 
mice, it has a great impact on memory and synaptic plasticity (Trejo et al., 2007), regulating 
LTP and LTD balance (Wang and Linden, 2000). This is also true for insulin (Wan et al., 1997) 
and IGF-2, recently shown to participate in memory consolidation (Chen et al., 2011). Thus, it 
might be one of the mechanisms by which systemic IGF-1 levels positively correlate with 
cognitive function in healthy people, and may also explain the contribution of age-associated 
reduction in serum IGF-1 levels to the physiological cognitive decline occurring in the elderly 
(Aleman and Torres-Alemán, 2009). 
1.2.  Blood-brain barrier 
 1.2.1.  Discovery 
More than a century ago it was observed that intravenous administration of water soluble 
dyes did not stain the brain (Ehrlich, 1885) and that nor bile acids nor ferrocyanide did exert 
any pharmacological effects on the brain (Lewandowsky, 1900). The existence of a barrier 
between the brain and the blood but not between the brain and the CSF would be confirmed 
when it was observed that Trypan Blue injection in the blood did not stain the brain but it did so 
when injected intracerebroventricullarly (Goldmann, 1913) as seen in Fig 1.4. 
 1.2.2.  Types: CSF, brain parenchyma & others. CVOs 
Since then, it has been discovered that the barrier isolating the CNS from the rest of the 
organism is not only physical or structural (due to the tight junctions, TJs, and adherent 
junctions sealing the paracellular pathway between adjacent cells) but also functional, given 
that there are transport systems regulating its permeability to many blood substances (Abbott et 
al., 2010).  
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Moreover, as seen in Fig 1.5 there are several barriers according to their exact brain 
location (Neuwelt et al., 2011), whose structure and function slightly differ: 
 Brain microvessels: here it is found the blood-brain barrier per se forming the so-
called “neurovascular unit”, where the endothelial cells attached to the basal lamina 
are the ones with the TJs. Through them neurons within brain parenchyma have fast 
access to oxygen and nutrients vital for their normal function (i.e. glucose, ions, and 
aminoacids). The neurovascular unit is formed by complex interactions among its 
cellular elements (endothelial cells expressing the TJs, astrocytic endfeet, neuronal 
terminals, pericytes and smooth-muscle cells), their transporters and the extracellular 
matrix (Hawkins and Davis, 2005), which together guarantee BBB integrity. In the 
broadest sense, this unit also comprises microglia and even peripheral immune cells 
that may influence it (Neuwelt et al., 2008, 2011). 
 Choroid plexus; in this case only these epithelial cells form the real barrier in the blood
-CSF barrier because here the endothelial layer is fenestrated. 
 Leptomeninges: where the blood-arachnoid barrier is formed.  
 Other barriers: blood-retina barrier, blood-labyrinth barrier… 
On the other hand there are some areas of the brain “outside the barrier” in direct contact 
with the blood named the circumventricular organs (CVOs) (Hofer, 1958), which are an 
integral part of the neuroendocrine system. These comprise several structures classified in 
Figure 1.4. First experiments describing the existence of a physical barrier between the blood and brain pa-
renchyma. When injected a dye in systemic circulation it did not permeate nor to brain parenchyma or to the CSF 
(A), but when injected in the CSF it did spread to the rest of the brain (B). C, model showing the isolation of the 
CNS from the rest of the organism. Adapted from Zlokovic, 2008. 
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sensory organs (area postrema, subfornical organ and organum vasculosum of the lamina 
terminalis) and secretory organs (subcommissural organ, neurohypophysis, median eminence 
and pineal gland). The CVOs have a primary role in maintaining homeostasis because its their 
neurons connect with several centers governing autonomic functions, body fluid homeostasis 
and initiation of immune responses (Mimee et al., 2013; Sisó et al., 2010). However these do 
not constitute a leak in the barrier since an external glial barrier isolate them from the rest of the 
CNS (Abbott, 2005). 
Figure 1.5. Main cellular elements of the neurovascular unit (left) and the blood-CSF barrier (right). Adap-
ted from Neuwelt et al., 2011. 
On the other hand there are some areas of the brain “outside the barrier” in direct contact 
with the blood named the circumventricular organs (CVOs) (Hofer, 1958), which are an 
integral part of the neuroendocrine system. These comprise several structures classified in 
sensory organs (area postrema, subfornical organ and organum vasculosum of the lamina 
terminalis) and secretory organs (subcommissural organ, neurohypophysis, median eminence 
and pineal gland). The CVOs have a primary role in maintaining homeostasis because its their 
neurons connect with several centers governing autonomic functions, body fluid homeostasis 
and initiation of immune responses (Mimee et al., 2013; Sisó et al., 2010). However these do 
not constitute a leak in the barrier since an external glial barrier isolate them from the rest of the 
CNS (Abbott, 2005). 
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1.2.3.  Neurovascular unit & BBB physiology  
One traditional explanation for which the BBB exists is that the CNS may be considered as 
the most vulnerable organ of the body and at the same time invaluable for survival. Thus, it 
must be protected against aggressions such as accumulation of toxic endogenous metabolites 
(e.g. ammonia, glutamate…), xenobiotics (e.g. heavy metals, ethanol, drugs…) and microbial 
pathogens. This is achieved by both preventing their entrance into the brain (thanks to its 
“selective permeability”) and by promoting their efflux through diverse non-specific pumps 
(e.g. P-glycoprotein, ABC transporters…) (Miller, 2010).  
Figure 1.6. Transporters at the blood brain-barrier. The BBB is in fact permeable to many nutrients (i.e. gluco-
se, aminoacids…) and even some proteins (i.e. insulin, transferrin, leptin, IGF-1…). This usually involve the use of 
a specific transporter or a receptor-mediated transcytosis as is the case for IGF-1. Adapted from Neuwelt et al., 
2011. 
A whole myriad of transporters (Fig 1.6) are expressed at the BBB surface (Abbott et al., 
2010; Zlokovic, 2008) allowing for nutrients and some macromolecules to enter the brain to 
cope with neuronal demands. The process described long ago by which neuronal activity 
selectively increases cerebral blood flow in the microvasculature of active brain regions is 
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known as “neurovascular coupling” (Kuschinsky and Paulson, 1992; Roy and Sherrington, 
1890) and pericytes has been recently reported to play a central role in it (Bell et al., 2010; 
Winkler et al., 2011). Especially important is the ability of the BBB to help maintaining ion 
gradients in the extracellular space without which synaptic transmission would not work 
properly. Besides, neuronal activity is also “coupled” with a number of other processes such as 
metabolism (Leybaert, 2005), angiogenesis (Daneman et al., 2009) and trophic-support (Lok et 
al., 2007; Nishijima et al., 2010) what underscores the importance of the BBB in brain 
homeostasis, yet to be fully understood. 
IGF-1 & the BBB: neurotrophic coupling 
For a long time it was thought that proteins and peptides could not enter the brain. 
However, it was discovered that several of them can actually do it (Banks and Kastin, 1985) by 
using a transport mechanism different to the carrier-mediated diffusion of nutrients. This refers 
to receptor-mediated transcytosis through the endothelial/epithelial layer of the BBB 
(Pardridge, 1993). Accumulating evidence clearly demonstrates that peripheral insulin (Banks 
et al., 1997, 2012; Schwartz et al., 1991) and IGF-1 (Nishijima et al., 2010; Reinhardt and 
Bondy, 1994; Trejo et al., 2001; Yu et al., 2006) cross the BBB in the adult, whereas the 
choroid plexus and the meninges are still thought to be major sources for brain IGF-2 (Logan et 
al., 1994).  
As previously described, systemic IGF-1 is the main source for brain IGF-1 and so it is 
ultimately responsible for its numerous central effects. However, the exact mechanisms 
regulating this entrance are not completely elucidated and little is known about how brain 
disease affects it or how disturbances in IGF-1 brain access alters brain homeostasis.   
Firstly, it has been described that physical exercise (Carro et al., 2000; Duman et al., 
2009; Trejo et al., 2001) and brain stimulation (Nishijima et al., 2010) are able to selectively 
open the BBB for IGF-1 passage. One proposed mechanism involves a “neurotrophic 
coupling” (see Fig 1.7) by which glutamate released by neuronal activity stimulates the glia to 
secrete vasoactive mediators that, apart from increasing regional cerebral blood flow, will 
activate matrix metalloproteases (i.e.MM9). These will in turn cleave the IGF-1/IGFBP 
complex circulating in the bloodstream and, once the IGFBPs are degraded, IGF-1 will be free 
to interact with its receptor and LRP1 to be carried out to the other side of the barrier (Nishijima 
et al., 2010). There it will be able to signal to neurons both directly and indirectly, through 
astrocyte endfeet, providing them trophic support.  
One tempting corollary of this mechanism is that an active brain is better protected 
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against insults such as neurodegenerative diseases, thus offering a molecular basis for the 
Figure 1.7. IGF-1 neurotrophic coupling in homeostasis. Active brain areas release mediators that activate a 
matrix metalloprotease (MMP9) to degrade IGFBP3. Thus, IGF-1 will be freed and able to interact with its recep-
tor to travel into the brain (Nishijima et al., 2010). Taken from Fernandez & Torres-Aleman, 2012. 
cognitive and brain reserve theories stating precisely that  (Stern, 2012). 
Secondly, in the choroid plexus it has been observed that IGF-1 entrance is dependent on 
the simultaneous interaction with both IGF-1R and a multi-cargo protein transporter known as 
megalin or low density lipoprotein-receptor related protein 2 (LRP2) with its highest expression 
in this structure (Carro et al., 2005). It is also indirectly related to GSK3β activity, given that its 
inhibition increased IGF-1 brain uptake (Bolós et al., 2010); this is probably because GSK3β 
phosphorylates LRP2, preventing it from participating of IGF-1 transcytosis. Elsewhere it has 
been suggested that the passage of IGF-1 through the choroid plexus is tonic, saturable and 
directly related to plasmatic changes on IGF-1, whereas the one going through the brain 
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microvasculature is phasic and brain activity-dependent (Nishijima et al., 2010; Torres-Aleman, 
2010). 
Conversely, it has been reported that in LID mice with blunted serum IGF-1 levels there 
are learning difficulties and memory impairment (Trejo et al., 2007), reduced exploratory 
activity (Svensson et al., 2005) and increased anxiety (unpublished). Furthermore, when 
disturbing the choroid plexus ability to properly carry circulating IGF-1 into the CSF, it 
develops an Alzheimer’s disease (AD)-like phenotype presenting amyloidosis, tau 
hyperphosphorylation, cognitive deficits, gliosis and synaptic damage (Carro et al., 2006a). The 
role of plasmatic IGF-1 in AD will be discussed further below. 
 
 1.3  Alzheimer’s disease (AD) 
 1.3.1.  Discovery 
The first case of Alzheimer’s disease (AD) was described by Dr. Alois Alzheimer back in 
the early 1900s (Alzheimer, 1907; Stelzmann et al., 1995) in a middle aged woman named 
Auguste Deter who showed early onset dementia and whose postmortem brain autopsy revealed 
extensive neuritic plaques, neurofibrillary tangles (NFTs) and neurodegeneration. These same 
marks were afterwards detected in elder people cognitively impaired and so were considered as 
late-onset cases of the same disorder (Blessed et al., 1968). 
 
 1.3.2.  Epidemiology and clinical course 
Currently, AD is one of the major public health concerns due to its increasing prevalence 
(it is the most common form of dementia), the lack of disease-modifying therapies and the so 
far useless billionaire investments in its research as oppose to the good results harvested by that 
made in the rest of leading causes of death (i.e. cancer, heart disease, stroke & HIV). Its 
prevalence in 2005 was calculated by the Delphi study in 24.2 million people worldwide, being 
highest in North America and Europe (Ferri et al., 2005). Furthermore, it has been estimated to 
quadruplicate by 2050 with a total AD-derived costs, only in the US, of $203 billion in 2013 
(Hebert et al., 2013; Thies and Bleiler, 2013). 
Classifying AD according to the age of clinical onset we may distinguish between early 
onset AD (EOAD) and late onset AD (LOAD). The first is presented before the age of 65 and 
accounts for less than 5% of cases whereas the second develops later on and is responsible for 
the majority of cases (95%) (Reitz and Mayeux, 2014). Autosomal dominant mutations in only 
three genes (APP, PSEN1 and PSEN2) have been found to be responsible of EOAD (Goate et 
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al., 1991; Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995) whereas 
several genetic and environmental risk factors, which will be later explained, may lead to 
LOAD. 
As for the gender differences, it has been reported a higher lifetime risk in females than in 
males (Genin et al., 2011; Mielke et al., 2014; Thies and Bleiler, 2013), meaning that there are 
more demented females than males. Sex-related differences in the rate of progression after a 
diagnosis of AD and in the response to treatments have also been reported. On the contrary, 
some studies suggests that males display a higher risk of mild cognitive impairment (MCI) 
(Petersen et al., 2010) and there are also others showing no association between sex and AD 
(Hebert et al., 2001). Possible explanations to the observed vulnerability of women to AD 
include higher lifetime expectancy (and so more time to develop dementia), more pronounce 
effects of some genetic risk factors (i.e. APOE-ε4, Met66 allele of BDNF) , loss of 
neuroprotective sex hormones after menopause or less cognitive reserve due to 
psychosociocultural differences (Mielke et al., 2014). 
The clinical course of the disease involves an initial episodic memory dysfunction that 
will evolve to affect other aspects of cognition such as visuo-spatial orientation, language, 
calculation, executive functions and even praxis (the ability to synthesize and sequence motor 
tasks). Thus, AD results in progressive decline of cognitive abilities with respect to the patient’s 
previous baseline that will severely interfere with daily life. In the final stages of dementia, 
patients will probably have trouble with sphincters control and experience major personality 
and behavioral changes, including suspiciousness and delusions (such as believing that their 
caregiver is an impostor) or compulsive, repetitive behaviors. Finally, they will no longer 
respond to environmental stimuli (even stop talking) and movement control will be altered (i.e. 
abnormal reflexes, stiffness and impaired swallowing) (Holtzman et al., 2011). One of the most 
commons systems for staging patients for dementia severity is the Clinical Dementia Rating, 
resulting from neuropsychological testing and interviews with relatives/friends: 0, cognitively 
normal; 0.5, very mildly impaired (compatible with MCI); 1 mildly impaired; 2, moderately 
impaired; 3, severely impaired (Morris, 1993). Also, one of the most used neuropsychological 
tests for screening purposes, even in clinical trials, is the Mini Mental State Examination 
(MMSE) (Folstein et al., 1975), which is composed of 30 questions assessing the cognitive 
status of the subject. When equal to or below 26 indicates cognitive impairment, which is 
greater with lesser scores (severe if ≤ 9, moderate if between 10 and 18, and mild if 19-24). 
This is the result of the spreading of the underlying pathology from the entorhinal cortex 
and hippocampal formation towards lateral temporal regions, the parieto-occipital cortex and 
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frontal lobe structures. However, not all the patients will show the exact same symptoms or rate 
of progression, and there are even atypical forms of AD with a completely altered 
symptomatology, usually wrongly leading to a diagnosis of other dementia  (Alves et al., 2012). 
It may be concluded that the real threat of AD is not a quick death but a weakening one 
that leaves the patients in need of care for many years due to the slow progression of the disease 
once the symptoms appear: the average of its time course is around 7 to 10 years. This makes 
them totally dependent on caregivers to fulfill normal daily tasks, unproductive for society and 
with a completely altered quality of life (Holtzman et al., 2011).  
 1.3.3.  Risk & protective factors 
Several genetic and epidemiologic studies have found that age is not the only risk factor 
for developing AD dementia, even though it is the most important (Ferri et al., 2005).  In the 
last decades there have been identified several genetic risk factors, especially through genome-
wide association studies (GWAS), and among them the APOE ε4 allele has been repetitively 
appointed as the one conferring the strongest susceptibility (2-3 fold increase with one copy and 
5 or more with two) (Farrer et al., 1997; Kuusisto et al., 1994). Several other loci with much 
smaller contribution have been identified ever since: CLU/ApoJ, PICALM, CR1, BIN1, SIRL1, 
Figure 1.8. Environmental risk factors for AD. This table comprises epidemiological evidence out of several 
meta-analysis linking lifestyle habits and comorbidities to the development of Alzheimer’s dementia. Adapted 
from Ballard et al., 2011. 
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CD33, MS4A4A/4E/6E cluster, ABCA7, CD2AP, EPHA1… (Reitz and Mayeux, 2014). Most of 
them are ascribed to APP processing, immune response, tau pathology, cell migration or lipid 
metabolism and endocytosis pathways. However almost all of these studies have been 
conducted in non-Hispanic Caucasian individuals and thus the results may be different in other 
ethnic groups as shown for the African-Americans in which ABCA7 had a similar effect to that 
of APOE ε4 (Reitz et al., 2013). 
On the other hand, there are many epidemiological studies linking AD to several 
environmental risk and protective factors summarized in Fig 1.8. It is well known that cognitive 
and brain reserve (that is, having an “active trained brain” due to education, intellectual and/or 
social activity) (Valenzuela and Sachdev, 2006), exercise (Hamer and Chida, 2009) and alcohol 
(Anstey et al., 2009) are protective factors against AD. Conversely, there are several vascular 
risk factors such as obesity (Beydoun et al., 2008), type 2 diabetes mellitus (T2DM) (Biessels et 
al., 2006), cerebrovascular disease, midlife hypertension, smoking and hypercholesterolemia 
which increase the risk of AD and serve as basis for the vascular hypothesis of AD (Ballard et 
al., 2011; de la Torre, 2010). A clinical condition comprising many of these risk factors in Fig 
1.8 is the metabolic syndrome (MetS). This is a relatively new endocrine disorder defined as the 
concurrence of obesity, insulin resistance (or T2DM), hypertension and dyslipidemia, and 
whose incidence has been greatly increased in the last decades due to sedentarism and bad 
dietary habits (Alberti et al., 2009). There are indeed a number of studies directly showing that 
Figure 1.9. Brain atrophy in AD. Medial temporal lobe atrophy is markedly detected as AD progresses in pa-
tients (B) as compared to controls (A). The most predictive regions of interest are the hippocampus (red), the en-
torhinal cortex (blue) and to a lesser degree the perirhinal cortex (green). Adapted from Duara et al., 2008. 
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MetS increases the risk of AD. However, the molecular pathogenic mechanisms that link them 
remain relatively unexplored. 
 1.3.4.  Pathogenesis: Hallmarks & Amyloid cascade hypothesis 
AD is a neurodegenerative disease causing widespread neuronal and synaptic loss in 
cortical and subcortical areas such as the hippocampal formation. Its major neuropathological 
hallmarks were long ago described by Alois Alzheimer himself and Oskar Fischer (Goedert, 
2009). At the macroscopic level, characteristic atrophy of the AD brain is easily detectable in 
the latter stages of the disease (Fig 1.9) by a very significant reduction in cortical and 
hippocampal gray matter thickness, a severe ventricular expansion and also major 
disappearance of white matter, especially in the temporal lobe.  
Upon microscopic examination, it can be observed the massive neuronal death, synaptic 
loss (including early development of synaptic transmission defects) (Walsh and Selkoe, 2004) 
and finally brain deposition of amyloid β or Aβ (in senile plaques) and hyperphosphorylated tau 
(in neurofibrillary tangles, NFTs). The first aggregates are extracellular and the second 
Figure 1.10. Senile plaques & NFTs in AD brain. As AD pathology develops, Aβ accumulates in senile plaques 
(A, C & D) whereas hyperphosphorylated tau remains in intreneuronal deposits (B, C & E). Taken form Serrano-
Pozo et al., 2011. 
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intracellular as observed in stained postmortem human tissue (Fig 1.10). In fact, AD may be 
considered as the most common cerebral proteopathy (Jucker and Walker, 2013). 
Aβ is the main component of the plaques and derives from the amyloid precursor protein 
(APP) anchored in the neuronal membrane. It is the result of aberrant cleavage of APP 
following the amyloidogenic processing pathway by sequential proteolysis of beta and gamma 
secretases (Glenner and Wong, 1984). Depending on where exactly is the cleavage made, there 
are different Aβ peptides with different physicochemical properties, the main two Aβ1-40 and 
Aβ1-42. Both of them are prone to aggregation into β-sheet enriched products (i.e. oligomers and 
fibrils) due to their random coiled structure; however, Aβ1-42 is the fastest in so doing and thus 
the most aggregating whereas the Aβ1-40 is the most abundant (Perl, 2010). The aggregation 
reaction has several steps generating different intermediate products, each of them in 
equilibrium with the previous: monomers, oligomers (2-12 monomers), protofibrils, mature 
fibrils and plaques (Fig 1.11). When it accumulates in the walls of the blood vessels of the brain 
it produces cerebral amyloid angiopathy (CAA), which plays an important role in AD 
pathogenesis as reflected by the vascular damage and microhemorrhages (Nicoll et al., 2004). 
There are many reports trying to identify which Aβ species is the toxic one: the oligomers (still 
soluble), the plaques (insoluble) or a combination of both (Benilova et al., 2012), given that the 
plaques can function as sinks (and biological reservoirs) for smaller toxic Aβ species.  
Figure 1.11. A dynamic model for Aβ aggregation in AD. Aberrant overproduction or lack of tissue clearance of 
Aβ leads to its pathological self-assembly firstly into oligomers and fibrils (soluble), and lastly into insoluble ag-
gregates. Extracted from O’Neil et al., 2012. 
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As for the NFTs, the hyperphosphorylated form of tau protein was identified to be its 
major component (Grundke-Iqbal et al., 1986; Kosik et al., 1986). Tau is a microtubule-
associated protein (MAP) highly expressed in the CNS, mainly found in the axon of neurons 
(Trojanowski et al., 1989) even though, in certain situations, it may also be located in the 
somatodendritic compartment (Tashiro et al., 1997). Tau has an intrinsically disordered 
structure and may be subjected to many different posttranslational modifications: serine/
threonine/tyrosine phosphorylation, acetylation, glycation, isomerization, nitration… pointing 
to a complex regulation. Its phosphorylation around the microtubule binding domain detaches it 
from the microtubules, what leaves tau to accumulate and aggregate in the cytoplasm (first into 
oligomers, then filaments and finally NFTs). Thus, it disrupts the structure and function of the 
neuron (e.g. axonal transport). This has also been detected in several neurodegenerative 
diseases and not only in AD: tau accumulation has been shown to occur in a series of conditions 
commonly referred to as tauopathies (e.g. AD, frontotemporal lobe dementia, Pick’s disease…)
(Morris et al., 2011). In AD, tau accumulation starts in the transentorhinal cortex (stages I-II, 
subclinical), spreads towards entorhinal regions (III-IV, MCI) and further affects almost the 
whole neocortex (V-VI, full dementia) (Braak and Braak, 1995) as in Fig1.12, even though it 
has recently been observed pre-tangle material able to induce NFT formation in the locus 
coeruleus prior to transentorhinal cortex involvement (Braak and Del Tredici, 2011). 
 
The so-called “amyloid cascade hypothesis” (Fig 1.13) (Hardy and Higgins, 1992) 
posits that the first pathological event happening in AD is indeed Aβ aggregation in the brain as 
a result of higher production and/or less degradation/clearance as evidenced by the already 
Figure 1.12. Proposed model for the progression and spreading of Aβ and tau pathology throughout the 
brain in AD. . t, time. Adapted from Jucker and Walker, 2013.  
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described gene mutations discovered in early onset AD. Besides the direct toxicity exerted by 
Aβ aggregates, it would trigger a secondary neurotoxic cascade including tau 
hyperphosphorylation and aggregation, ultimately leading to synaptic loss, neuronal 
dysfunction and death. Oxidative stress and neuroinflammation would also be second 
messengers of Aβ toxicity contributing to disease progression (Hardy, 2006; Hardy and Selkoe, 
2002; Karran et al., 2011). 
 1.3.5  Need for alternative hypothesis 
During the last decades, large investments in search for new AD therapeutics based on the 
amyloid cascade have so far failed to produce new useful pharmacological entities (Franco and 
Cedazo-Minguez, 2014; Mullane and Williams, 2013), even though around 100 compounds 
have been tested, and at the time there are over 450 actively recruiting clinical trials (http://
clinicaltrials.gov/ct2/results?term=alzheimer&recr=Open). Thus, there is a great need for 
alternative hypothesis that may integrate previous findings, explore other pathogenic 
mechanisms of AD and give birth to successful therapies (Golde et al., 2011; Holtzman et al., 
2011).  
Figure 1.13.  Amyloid cascade hypothesis. In the last decades, this has been the most accepted etiological hypot-
hesis for AD. According to it, Aβ accumulation is the trigger for all the observed pathological events which finally 
lead to the appearance of full-scale clinical dementia. Taken from Karran et al., 2011. 
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  -  Vascular/BBB component 
As previously suggested there is an important vascular component to AD and it is now 
widely recognized that most AD patients have mixed vascular pathology and small vessels 
disease (Jellinger, 2010; Marchesi, 2011), even though often disregarded as an accompanying 
secondary phenomenon. In fact, several risk factors for sporadic AD (reviewed above) overlap 
with those for cerebrovascular disorders (e.g. diabetes, hypertension, hypercholesterolemia, 
obesity), including vascular dementia. The “two-hit vascular hypothesis”, drawn in Fig 1.14A, 
postulated by Zlokovic and colleagues (de la Torre, 2010; Marchesi, 2011; Zlokovic, 2005), 
states that these risk factors produce, in the long-term, vascular damage and BBB breakdown as 
Figure 1.14.  Vascular hypothesis. Borrowed from Zlokovic, 2011. 
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the first hit in AD. This will cause capillary hypoperfusion (i.e. hypoxia due to reduced 
cerebrovascular blood flow), focal microhemorrhages, silent infarcts and accumulation of 
neurotoxins (e.g. excess glutamate, thrombin, fibrin, plasmin…). As a consequence, it would 
follow less Aβ clearance and aberrant overproduction, what ends up in its accumulation inside 
the brain to initiate the amyloid cascade (the second hit). Tau pathology may be initiated by 
both hits independently and the final neuronal injury would be the result of all these parallel 
events leading to neurodegeneration and dementia (Sagare et al., 2012; Zlokovic, 2011).  
  -  IGF-1/Insulin in AD 
Several epidemiologic and postmortem studies in humans have consistently linked the 
presence of type 2 diabetes mellitus (T2DM) with a higher risk of developing AD (Akomolafe 
et al., 2006; Arvanitakis et al., 2004; Hofman et al., 1997; Leibson et al., 1997; Luchsinger, 
2001; Ott et al., 1999; Rivera et al., 2005; Schrijvers et al., 2010; Watson and Craft, 2003; Xu et 
al., 2004). Even though the involved mechanisms are not yet fully defined, the cerebrovascular 
damage (in form of small infarcts) produced by T2DM may be a possible trigger (Arvanitakis et 
al., 2006) in accordance to the above hypothesis. The role of insulin in AD has been much more 
studied than that of IGF-1(Bosco et al., 2011; Craft, 2012; De Felice and Ferreira, 2014; El 
Khoury et al., 2014; Qiu and Folstein, 2006; Spielman et al., 2014; Williamson et al., 2012), 
even culminating in several clinical trials that aimed to evaluate its therapeutic potential as a 
disease-modifying agent in AD (Chapman et al., 2013; Chen et al., 2014; Freiherr et al., 2013).  
Regarding other non-vascular pathogenic mechanisms linking T2DM to AD, it has been 
recently reported that in AD brains there is a resistant state to both insulin and IGF-1 
stimulation (Talbot et al., 2012), what had been previously suggested (Carro and Torres-
Aleman, 2004). This also confirmed earlier indirect findings in post-mortem tissue and in a 
mouse model of AD (Moloney et al., 2010). Moreover, a reduced CSF/plasma IGF-1 ratio was 
observed in AD patients (Johansson et al., 2013), and GSK3β activity, which is directly 
involved in AD pathogenesis by promoting tau hyperphosphorylation, Aβ production and 
inflammation (Hooper et al., 2008), was inversely correlated to IGF-1 brain entrance in AD 
mice (Bolós et al., 2010). Altogether it would imply a complete altered insulin/IGF-1 signaling 
(IIS) in the brain and so a diminished trophic support to neurons in this disease, decreasing its 
resilience against insults down in the cascade. Furthermore, it is known that IGF-1 promotes Aβ 
clearance (Carro et al., 2002), fights back AD brain hypoperfusion by inducing angiogenesis 
(Lopez-Lopez et al., 2007) and reduces brain amyloid plaque load and neuroinflammation in 
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mouse models of AD (Carro et al., 2006b; Fernandez et al., 2012). Besides, when blocking the 
entrance of serum IGF-1 into the CSF, an AD-like syndrome develops (Carro et al., 2006a). 
On the other hand, there are controversial findings challenging this view. Firstly, it has 
been shown that reducing IIS in worms protects them against toxic protein aggregation in 
muscles (Cohen et al., 2006). This was also observed in the brains of AD mice when removing 
one allele of the Igf1r gene: it improved cognitive performance but at the same time increased 
Aβ plaque load, what was explained by the authors as a hypothetical Aβ oligomer sequestering 
mechanism and thus regarded as positive (Cohen et al., 2009). Other supporters of this 
hypothesis have found that partially impaired IGF-1/IRS-2 signaling, by specifically knocking 
out IGF-1R in neurons or IRS2, prevented premature death and delayed amyloid accumulation 
in AD mice (Freude et al., 2009).  
These observations are in line with reported increases in lifespan of animals with reduced 
IGF-1 signaling (Kappeler et al., 2008; O’Neill et al., 2012; Svensson et al., 2011). 
Nevertheless, other authors have been unable to reproduce some of those findings (Bokov et al., 
2011), plus there are others showing that IGF-1 treatment in mouse models of progeria 
(accelerated aging) actually improved its phenotype (Mariño et al., 2010), what makes it 
difficult to interpret the real role of IIS in normal aging. 
Finally it has been observed that insulin dysfunction, one of the hallmarks of T2DM, 
promotes tau hyperphosphorylation by direct or indirect means (i.e. through hypothermia) (El 
Khoury et al., 2014; Planel et al., 2007). Up to date there are few studies assessing the 
relationship between IGF-1 and tauopathy. One of them showed that in the brains of Igf1-/- 
mice, tau was hyperphosphorylated (Cheng et al., 2005), whereas serum IGF-1 inability to enter 
the CSF also ends in tau hyperphosphorylation (Carro et al., 2006a). Thus, this relationship 
remains to be further explored. 
 1.3.6.  Diagnosis & disease biomarkers 
Nowadays, AD final diagnosis can only be done post-mortem by anatomopathological 
examination of the brain and finding of senile plaques and NFTs as described (Ball et al., 
1997), what leads to the classification of AD pathology and its progression according to Braak 
stages I-VI (Braak and Braak, 1991). Ante-mortem diagnosis is made following recently 
published NIH guidelines (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011), 
which modify previous criteria from the 80s (McKhann et al., 1984) and recommend three 
different diagnosis of dementia due to AD: (1) probable AD dementia, (2) possible AD 
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dementia and (3) probable or possible AD dementia with evidence of the AD 
pathophysiological process. Besides this refined clinical classification of AD and the 
accompanying clinical criteria to better evaluate cognitive function, the new guidelines 
introduce earlier stages in disease progression reflecting the fact that AD is thought to start 
many years before the onset of clinical symptoms (Ballard et al., 2011). To this regard, they 
state the criteria for the diagnosis of mild cognitive impairment (MCI) due to AD and a 
biomarker fingerprint describing a potential preclinical stage of AD (this one only for research 
purposes). Furthermore, they review current knowledge on the validation and/or development 
of several biomarkers to be used both in clinical settings and in research/clinical trials. In fact, 
some of them are included to augment certainty in the clinical diagnosis of AD (3, possible or 
probable with evidence of AD pathophysiology). Thus, biomarkers (with the exception of the 
described autosomal dominant inherited mutations) do only determine disease risk and increase 
the specificity of diagnosis but do not make it definitive. 
Some of these biomarkers rely on neuroimaging (PET, MRI…) while others do on the 
biochemical determination of several proteins in CSF or blood/plasma (Reitz and Mayeux, 
2014). Regarding their target, there are two main types of AD biomarkers: ones pursuing direct 
or indirect evidence of Aβ accumulation in the brain, and those assessing neuronal damage (e.g. 
tau pathology, brain atrophy, decreased glucose utilization). The firsts are a logical outcome of 
the amyloid cascade hypothesis assuming that the more Aβ accumulating in the brain, the more 
advanced it is the subclinical pathology. The FDA and the EMA have recently approved a new 
drug (florbetapir) (Yang et al., 2012) which, similarly to the Pittsburgh compound B (PiB), 
binds to Aβ deposits in the living brain and can be detected by PET scan, with a longer half-life 
than PiB (Clark et al., 2012). While a negative florbetapir/PiB scan would wipe out the 
possibility of a dementia due to AD, a positive scan does not imply a positive diagnosis of AD 
dementia. This may reflect what was previously reported: that Aβ deposits are also present in 
the brains of MCI patients and in 20-40% of cognitively normal elderly people (Aizenstein et 
al., 2008; Price and Morris, 1999; Rowe et al., 2007). However, whether the last represents a 
preclinical asymptomatic stage of AD in individuals who, had they survived long enough, 
would have developed full scale dementia remains to be demonstrated. More recently, it has 
been developed a class of tau ligands  to detect tau pathology in vivo using also PET in a similar 
way (Maruyama et al., 2013). 
Other vastly studied biomarkers are CSF levels of Aβ1-42, phospho tau and total tau. 
Reductions in the first are considered to be the result of heavy Aβ brain deposition in plaques, 
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and the increases in the others are thought to be due to their release from damaged and dying 
neurons containing dystrophic tau neurites and tangles (Blennow et al., 2010; Sunderland et al., 
2003). Many authors have stablished further standardization and validation of this signature for 
AD, MCI and normal subjects using this shift in Aβ1-42 and total tau CSF values, which might 
even separate MCI subjects that will progress to full AD from those that will not (Hansson et 
al., 2006; Molinuevo et al., 2014; Shaw et al., 2009). However, a meta-analysis of many studies 
found a modest sensitivity for these three CSF values in preclinical AD (Schmand et al., 2010). 
Glucose utilization by the brain has been shown to be reduced in MCI and AD patients as 
determined by fluorodeoxyglucose (FDG)-PET when compared to controls (Landau et al., 
2011; Langbaum et al., 2009) following a lateral temporal-parietal and posterior cingulate, 
precuneus distribution. This is a direct measure of neuronal metabolism and synaptic activity, it 
is directly related to cognitive performance and thus it is a good surrogate of synaptic 
dysfunction in AD. However, despite its high sensitivity it has a low specificity (~75%) 
(Silverman et al., 2001). 
Structural MRI has been used to assess brain atrophy rates characteristic of AD, which are 
different in LOAD than in EOAD. In LOAD, there is atrophy in the (para)hippocampus and the 
amygdala, whereas in EOAD it may spread to affect the posterior cortex, occipital lobe, 
posterior cingulate and precuneus (Reitz and Mayeux, 2014). Nevertheless, whereas this has 
been shown to perfectly correlate with cognitive impairment, it is not specific for AD. There are 
some studies trying to add specificity to MRI measures, including diffusor tensor imaging that 
have identified a reduction in white matter in MCI and AD patients. 
A dynamic model of AD biomarkers (Fig 1.15) has been developed in the last years in 
order to show a temporal correlation between them and disease onset and progression (Jack et 
al., 2010). According to it, biomarkers detecting Aβ accumulation in the brain would be the 
firsts to raise the alarm, even capable of detecting the asymptomatic stage of AD in cognitively 
normal individuals. It would follow measures of neuronal damage and brain atrophy, which 
show better correlation with clinical dementia and post-mortem findings (i.e. 
anatomopathological AD staging). Many other approximations (e.g. plasma biomarkers, fMRI, 
SPECT tracers…) are still being investigated or on their way to validation, so as to discard 
confounding factors and explain controversial results. However none of them and even none of 
the previous ones, although potentially applicable, are yet prepared for routinely clinical use 
(Frisoni et al., 2011, 2013). 
                                                                                                                                    1. Introduction 
44 
Figure 1.15.  Dynamic model of AD Biomarkers. This graph integrates the different technologies which have 
been used so far in the development of AD biomarkers. All are gathered into conceptual fields, mainly depending 
on their target. There are those assessing Aβ accumulation in the brain (the earliest, in red) whereas others focus on 
the resultant neurodegeneration (FDG-PET, brain atrophy, memory impairment). Taken from Jack et al., 2010. 
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MAIN HYPOTHESIS 
1. Alzheimer’s disease pathogenesis involves an early disruption of blood-brain barrier 
permeability to circulating IGF-1, what constitutes a suitable pathophysiological target to 
develop an early biomarker. 
2. Exogenously administered IGF-1 modifies the electroencephalogram and so this may 
serve as the technological approach to assess the previous impairment. 
 
 GENERAL & SPECIFIC OBJECTIVES 
1. To study how the entrance of serum IGF-1 into the brain is modified in animal models of  
 Alzheimer’s disease at presymptomatic stages. 
 1.1. To stablish a time-course of the transport of IGF-1 into the brain as evoked by  
  environmental enrichment in WT mice. 
 1.2. To determine how central IGF-1 system of young APP and APP/PS1 transgenic  
  mice respond to acute environmental enrichment. 
 1.3. To find a mechanism explaining why APP and APP/PS1 mice respond differently  
  than WT. 
 1.4. To investigate the role of IGF-1 on lifestyle risk factors associated to dementia by  
  using diet-induced obese mice. 
2. To evaluate the power of electroencephalography to detect potential changes on brain  
electrical activity induced by exogenous IGF-1. 
 2.1. To examine if a single dose of IGF-1 is able to modify the electrocorticogram of  
  WT mice and/or the electroencephalogram of healthy macaques in a reasonable  
  time of recording.  
 2.2. To inspect if APP and APP/PS1 mice display a distinct pattern of brain electrical  
  activity than that of WT after IGF-1 administration. 
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2.1.  In vivo procedures  
 2.1.1.  Animal models 
Several animal models were used. Age and sex-matched wild type C57BL6 mice (Harlan 
Laboratories, Indianapolis, USA) were used as controls in all the experiments unless otherwise 
stated (i.e. when littermates were available). Adult male and female mice of different ages and 
genotypes were used so as to minimize the number of animals, except for the high fat diet 
(HFD) which was carried out in males. Mice were kept on cages of at least two animals until 
the time of the experiment, with food and water ad libitum, and under constant humidity (55 ± 
10%), temperature (22 ± 2ºC) and 12h light-dark cycle conditions. Genotyping was routinely 
made in-house through standard PCR protocols using DNA extracted from the tail at weaning. 
All animal procedures followed European guidelines (86/609/EEC & 2003/65/EC, European 
Council Directives) and approval of local Bioethics Committees. Further details for each animal 
model are depicted below: 
  -  APP & APP/PS1 mice 
The double APP/PS1 mouse was the result of breeding the single transgenic strains APP 
& PS1 (a gift from P. Mouton from the NIH, USA). It faithfully models the predementia phase 
of AD (with the appearance of Aβ plaques and memory impairment) and it is widely used and 
accepted in the field despite developing no NFTs and little or no neuronal loss (Ashe and Zahs, 
2010; Van Dam and De Deyn, 2011; LaFerla and Green, 2012). APP/PS1 mice overexpress two 
transgenes under the control of independent mouse prion protein (PrP) promoters: a human 
APP with the Swedish mutation (K670N/ M671L) (Hsiao et al., 1996) and a truncated PS1 with 
a deletion in exon 9 (Savonenko et al., 2005), which produces no neuropathology but 
potentiates plaque deposition. Both mutations are related to the metabolism of Aβ and result in 
its overproduction and subsequent aggregation, what triggers the disease according to the 
amyloid hypothesis. The single APP strain was re-obtained by cross-breeding with WT mice. 
The double transgenic model displays a similar phenotype to the single but presents earlier 
onset and accelerated disease progression (Fig. 2.1). For the EEG and EE experiments, we used 
42 APP/PS1 mice (3.96 ± 0.61 months old) and 23 APP (3.8 ± 0.67 months old). For 
determining IGF-1 levels in the CSF and CSF/serum ratio in APP/PS1 mice we used animals of 
6.8 ± 2.5 and 7.1 ± 2.9 months, respectively. In this particular case we used a wider range of 
ages of APP/PS1 mice to improve comparison with human data, somehow matching different 
clinical stages of AD. 
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Figure 2.1. Phenotype of transgenic AD mouse models. This scheme depicts the time-dependent progression of 
AD-like pathology in AD mice. 
  -  Liver IGF-1 deficient (LID) mice 
This strain is a conditional IGF-1 knock out that results from crossing the floxed IGF-1 
mice (where the Igf1 gene is flanked by loxP sequences) with the Alb-Cre line (which expresses 
the Cre recombinase under the control of the albumin promoter) thereby deleting the Igf1 gene 
selectively in the liver (Yakar et al., 1999). As a result, and because this organ is the main 
source of circulating IGF-1, they show a massive decrease in peripheral IGF-1 levels. 
Phenotypic characterization of these animals has revealed several CNS dysfunctions such as 
reduced exploratory activity (Svensson et al., 2005), impaired hippocampal LTP and spatial 
learning/memory deficits (Trejo et al., 2007) and increased anxiety (unpublished data). A total 
of 15 mice of 4.01 ± 0.55 months old of this genotype were used for the EE experiments. 
  -  Diet-induced obese (DIO) mice 
These mice were used as a model of the MetS, which includes a compendium of several 
risk factors for sAD such as obesity, insulin resistance, T2DM, hypertension and dyslipidemia. 
DIO animals were obtained by exposing adult WT male mice (two months old) to a high fat 
diet (HFD) diet for 5 or 10 weeks. This sort of nutritional intervention was first described in the 
1940s (Samuels et al., 1942) and it has been extensively used ever since. Diets were purchased 
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from ssniff® (control, ref. E15000-04; HFD, ref. E15744-34) and its composition can be seen 
in the appendix: both are purified equilibrated diets with the only difference that in the control 
diet only a 10% kcal comes from fat and in the DIO group 45% kcal comes from fat (with an 
extra supplement of 1.25% cholesterol). With this we can assure that the differences we 
observed are due to the HFD content rather than out of insufficient protein or micronutrients 
(vitamins, minerals…) balance (Buettner et al., 2007). A control group for each time point was 
included, and the two were pooled together when no differences between them were observed, 
which was in every case except in body weight. Throughout the HFD diet experiment, body 
weight was recorded weekly and metabolic tests were performed 1-2 weeks prior to sacrifice 
(see Fig. 2.2). 
   -  Non-human primates (NHP) 
With the objective of studying the translational potential of the EEG findings in mice, we 
reproduced these experiments on nine adult macaques (two Macaca fascicularis and seven 
Macaca mulata) aged 14 ± 2.7 years and weighing 8.29 ± 2.47 kg. Saline and IGF-1 injections 
were given in separate days. All of the monkeys were males except for one M. fascicularis 
female. They were purchased from R.C. Hartelust BV (Tilburg, The Netherlands) and housed at 
the animal facility of the Faculty of Medicine at UAM (register number EX 021-U).  
 
  2.1.2.  Human samples 
IGF-1 levels were determined in the CSF and plasma from 35 patients diagnosed with AD 
dementia and 10 age-matched healthy controls. Twelve AD patients were enrolled in a 
multicentric multinational clinical trial (http://clinicaltrials.gov/ct2/show/ NCT01350362?
Figure 2.2. Experimental protocol followed in the HFD diet experiment. W, week; GTT, glucose tolerance 
test; ITT, insulin tolerance test. 
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term=NP031112&rank=3) whose study protocol (ClinicalTrials.gov NCT01350362) had been 
approved by the corresponding National Authorities and by the Independent Ethics Committee 
or Institutional Review Board for each site. The rest of the patients and controls were recruited 
at the Memory Unit, Hospital de Sant Pau (Barcelona) by the team of Dr. Alberto Lleó. 
Experimental procedures were approved by the corresponding Ethics Committees and all 
participants gave written consent for the study. All patients underwent an extensive 
neuropsychological evaluation (Sala et al., 2008), and were diagnosed as probable mild to 
moderate AD according to the NINCDS-ADRDA criteria and had a score of 16 to 26 in the 
MMSE. Plasma was obtained from whole blood samples after centrifugation during 5 minutes 
at 3300 rpm. CSF was obtained through lumbar puncture and centrifuged for 10 min at 3200 
rpm. All samples were processed in the first 2 hours after extraction and stored in 
polypropylene tubes at -80ºC until the ELISA for human IGF-1 was performed. 
 
 2.1.3.  Animal behavior 
  -  Environmental Enrichment (EE) 
The paradigm of EE is a protocol of physiological brain stimulation that includes a series 
of simultaneous stimuli: novelty (exploration of all the novel objects in the cage), increased 
physical activity (larger space and climbable surfaces) and social interaction (big groups of 
animals). However, no running wheels were included in this study to avoid exercise effects on 
the brain, thus maximizing the cognitive component of EE (Bechara and Kelly, 2013). EE has 
been proposed to be an experimental protocol generating cognitive and brain reserve and hence 
a protective factor against neurological diseases (Petrosini et al., 2009). 
Animals were kept under inverted circadian cycle conditions (dark: 5am-5pm/ light: 5pm-
5am) for 1 week before acute exposures to EE so that they would be in the active phase during 
the experiment. Then, they were split into two groups: control animals, which remained under 
standard housing conditions (370-530 cm2 cage, 2-5 mice per cage and no objects) and enriched 
animals, which were placed in a large polycarbonate cage (1815 cm2, 55x33x20 cm), up to 10 
animals per cage and with several objects (cardboard tunnels, shelters of different materials, a 
plastic net, toys, chewable and nesting material), see Fig. 2.3. For chronic EE (one month), 
objects and their location were randomly changed twice a week and the cage cleaned to always 
maintain novelty.  
  -  Y-maze test 
 Spontaneous alternation and total entries in the arms of a dark grey methacrylate Y-maze 
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test were measured as a correlate of working memory (Sarter et al., 1988). Mice were placed in 
the center of the maze and left alone to explore its arms (A, B & C) for a single trial of 8 
minutes while being video-recorded. After the end of each trial, the maze was cleaned with 
70% ethanol to remove olfactory cues. Offline analysis of the videos was carried out to obtain 
the sequence of entries during the whole time of the experiment (i.e.ABCBCABCB). Then, 
consecutive triplets were analyzed (ABC, BCB, CBC, BCA, CAB, ABC, and BCB) and the 
alternate behavior was calculated as the percentage of real alternation (number of triplets with 
non-repeated entries) versus total alternation opportunities (total number of triplets). In the 
example, alternation would be (4 out of 7) x 100= 57.14%.  
 
  2.1.4.  Metabolic Tests 
 Mice were conscious (non-anaesthetized) during the procedures and had been fasted for 6 
hours, isolated in individual cages (with water but no food) and left to rest for at least 30 min 
before starting with the tests to avoid any stress-related effect on glycaemia (Ayala et al., 2010). 
At time zero, the tip of the tail was cut so that blood samples could be extracted constantly over 
a period of 120 min (by “milking” the tail from the base to the tip) to measure glucose levels 
with a glucometer (Menarini Diagnostics, Italy). For the glucose tolerance test (GTT) an 
overload of glucose was injected intraperitoneally (2 g/kg) and blood samples taken at 15, 30, 
60, 90 and 120 min. The aqueous glucose solution was left O/N at RT so that it was enriched in 
Figure 2.3. Environmental Enrichment (EE) cage. 
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the β-form (transported ~2-fold faster than the α). For the insulin tolerance test (ITT) a dose of 
0.75 U/kg of recombinant human insulin (Humulina-R, Lilly, USA) was injected 
intraperitoneally and glucose levels determined as in the GTT. Both tests were performed at 
least 5 days apart to assure animal recovery between them; also mice were sacrificed after a 
minimum of 5 days to avoid acute interferences on further analysis. 
 
  2.1.5.  Sample collection (CSF, serum, brain) & transcardiac perfusion  
 At the end-point of the in vivo experiments, mice were anaesthetized with an overdose of 
pentobarbital (50-100 mg/kg) and then CSF and blood were extracted prior to transcardiac 
perfusion: 
   -  CSF  extraction 
 Anaesthetized mice were placed prone on a stereotaxic device in contact with a heating 
pad and CSF was extracted from the cisterna magna as explained by others (Liu and Duff, 
2008). A sagittal incision was made inferior to the foramen magnum, and with the help of a 
dissection microscope the subcutaneous tissue and the different muscle layers were cut with a 
scalpel to expose the cisterna magna. Then, the body of the animal was laid down to allow a 
continuous flow of CSF, and an ultra-fine needle syringe (31-33G) was inserted lateral to the 
arteria dorsalis spinalis to perforate the meninges and collect the CSF, which was snap frozen 
and stored at -80ºC until further use. 
   -  Serum extraction, transcardiac perfusion and tissue dissection  
 Blood was extracted directly from the heart, then left to clot at RT for several hours, 
stored O/N at 4ºC to allow contraction of the clot and finally centrifuged  at 2000 xg, 10 min 
and 4ºC. Serum was then collected from the supernatant, aliquoted and stored below -20ºC. 
Subsequently, mice were intracardially perfused with 50 ml freshly prepared saline (0.9% 
NaCl) and the brain was dissected to obtain the cortex, cerebellum, and hippocampi, which 
were snap-frozen and stored at -80ºC until further use. For histological studies, the animal was 
further perfused after saline with 30 ml 4% PFA (only when no tissue was needed for 
biochemical analysis) and then post-fixed by O/N immersion in 4% PFA, washed with 0.1N PB 
three times and stored at 4ºC until sectioning (with 0.02% sodium azide supplementation). 
 
 2.1.6.  Electrocorticogram (ECoG) recordings in mice 
This study required the following number of animals: 9 WT + Saline mice of 3 ± 0 
months, 14 WT + IGF-1 mice of 3 ± 0 months, 7 APP/PS1 mice of 3.52 ± 0.44 months and 7 
APP mice of 3.75 ± 0.53 months old. Mice were anesthetized with isoflurane (3-4% for 
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induction and 1-1.5% for maintenance) mixed with O2 (0.5-1 L/min) and placed prone on a 
stereotaxic device with a mouse adaptor (Kopft Instruments, USA) in direct contact with a 
circulating water heat pad to preserve body temperature without introducing electrical artifacts 
in the recordings. Ophthalmic ointment was applied to the eyes of the animal to prevent cornea 
dehydration. A 0.5 mm craniotomy was made in the primary somatosensory area (S1; 0 to -1 
mm anteroposterior, 2 to 4 mm lateral, 0.2 to 1 mm deep from Bregma according to the Paxinos 
and Watson, 2001) and a tungsten macroelectrode of 0.5 MΩ was placed there to register the 
electrical activity of the cortex, the ECoG. Once the recording was stable, the baseline of the 
ECoG was registered for 20 mins and then either saline or 25 μg IGF-1 (in 100 μl saline) were 
injected intraperitoneally. The ECoG was then recorded for another extra 60 mins after 
injection. Recordings were filtered between 0.3-30 Hz, amplified by a P15 Grass amplifier 
(Grass, West Warwick, USA) and signals were stored in a PC through an analogic-digital 
converter card (1401, Cambridge Electronic Design, Cambridge, UK) for off-line analysis with 
Spike 2 software (Cambridge Electronic Design, Cambridge, UK) at a sampling frequency of 
100 Hz. We confirmed that IGF-1 injection did not induce hypoglycemia (data not shown) by 
measuring glucose levels through a glucometer (Menarini Diagnostics, Italy). 
 
 2.1.7.  Electroencephalogram (EEG) recordings in NHPs 
Monkeys were fasted overnight before the experiment to minimize the risk of pulmonary 
aspiration due to anesthesia. On the following morning, they were sedated with an 
intramuscular injection of ketamine (5-10 mg/kg) to allow transport from the animal facility to 
the laboratory where they were anaesthetized with isoflurane (3-4% for induction and 1-1.5% 
for maintenance) mixed with O2 (2 L/min for induction and 1.5 L/min for maintenance). EEG 
recording began 30 min later to assure ketamine clearance and a stable EEG. To avoid potential 
reported effects of hypoglycemia on the EEG (Bjørgaas et al., 1998) after intravenous IGF-1 
administration, glucose blood levels were monitored and clamped at a normoglycemic level (M. 
fascicularis: 50-70mg/dl; M. mulata: 40-60mg/dl) by means of a 3.3% glucosaline solution 
infused systemically through the saphenous vein. EEG recordings were performed through 
three surface electrodes placed in Fpz, Cz & Oz according to the International 10-20 System. A 
conductive electrode gel was applied between the skin and the electrode to improve signal 
recording. The experimental protocol was the same as in mice except for the different doses 
used (now 100 µg IGF-1/kg diluted up to 1 mg/ml in saline solution) and the administration 
route that now was an intravenous bolus through the saphenous vein. Signal recording 
procedures were similar to the one described above. 
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 2.1.8.  ECoG & EEG data analysis and representation 
ECoG and EEG segments of 5 minutes were analyzed with Spike 2 software, using the 
fast Fourier transform algorithm to obtain the power spectra. The ECoG/EEG was decomposed 
in four frequency bands: delta (0.3-4 Hz), theta (4-8 Hz), alpha (8-12 Hz) and beta (12-30 Hz) 
and the sums of power densities were calculated for every single band every 5 minutes. 
Afterwards we determined the percentage of each band in the total wavelength of the ECoG/
EEG (band power*100/ sum of total band powers) and normalized it against the baseline 
(defined as the mean value of the 20 min prior to the injection of saline or IGF-1). Thus, the 
results plotted in the figures show the fold increase in the contribution of each band to the total 
ECoG/EEG every 5 minutes.  
Lastly, to compare ECoG/EEG to the EE data, we calculated the area under the curve 
(AUC) of the beta band for every animal for the 60 minutes post- injection using the trapezoidal 
rule. Mean values of the beta wave AUC (AUCβ) for each group were plotted against the 
corresponding value of phosphoIGF-1R/IGF-1R after environmental enrichment. For that, WT 
saline was matched with WT control, and IGF-1 injected animals were matched with enriched 
animals. 
2.2.  In vitro procedures  
 2.2.1.  Histology 
  -  DAB immunostaining of free-floating sections  
Fixed brains were embedded in 3% agarose 0.1N PB and coronal 50 µm thick sections 
were cut with a vibratome (Leica, Germany), serially collected in 0.02% sodium azide 0.1N PB 
and stored at 4ºC. A standard avidin-biotin DAB amplification protocol was used. For detection 
of human Aβ plaques, was the tissue pre-treated with 70% formic acid solution for 20 min to 
retrieve the epitope. Then, sections were blocked and permeabilized with washing solution (1% 
Triton X-100, 1% BSA, PB 0.1M), treated with 3% H2O2 in 100% methanol to inactivate 
endogenous peroxidase and incubated with primary antibody (see table 2.2). After several 
washes in PB, sections were incubated with a biotinylated donkey anti-rabbit antibody, 
followed by amplification with the ABC system (1:250) and developed with DAB or with 
enhanced Niquel-DAB reaction (i.e. c-fos). Finally, sections were mounted, air dried, 
dehydrated and coverslipped with Depex. Controls included: no primary antibody incubation 
and wild type tissue for transgenics (i.e. human Aβ plaques); no immunostaining was observed 
(not shown). Pictures were taken with a light microscope Eclipse 80i (Nikon, NY, USA) with a 
color camera Retiga 2000R using QCapture software (QImaging, BC, Canada).  
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  -  Micro-iontophoresis and 3D reconstruction  
Fixed brain coronal sections 200 µm thick were used in the procedure. To visualize cell 
bodies the slices were labeled with DAPI and then, neurons from the CA1, CA3 & DG regions 
of medial hippocampus were intracellular and individually injected with Lucifer-Yellow (8% in 
0.05% Tris-buffer, pH 7.4; Sigma) by passing a hyperpolarizing current (10-20 nA). 
Immunostaining was performed in free-floating sections using standard avidin-biotin protocols 
with anti-Lucifer-Yellow antibody (1:100.000) (Elston et al., 2001; Suárez et al., 2014). Finally, 
sections were used for 3D morphological neuron reconstruction using the Neurolucida software 
(MicroBrightField Inc., Williston, VT, USA) to trace the dendritic arbors of the injected 
hippocampal neurons in 3D and at the same time mark their spines. Only neurons that were 
completely filled were included in the final analysis. Quantifications were done by a researcher 
blind to the experimental conditions. This experiment was performed in collaboration with the 
group of Prof. Rosario Moratalla in the Cajal Institute (Madrid, Spain). 
 
 2.2.2.  Cell biology 
  -  Glial cells primary culture: astrocytes and microglia 
The cortex of postnatal P3-4 rats was used to isolate glial cells as reported (Fernandez et 
al., 2012, 2007; Franco et al., 2012; Pons and Torres-Aleman, 2000). Briefly, animals were 
decapitated, brains dissected and meninges and blood vessels removed under the microscope. 
Then, cortical hemispheres were separated, collected in EBSS and mechanically disaggregated 
by passing them through a Pasteur pipette with flame-rounded tip. The resultant cell suspension 
was centrifuged, resuspended in DMEM-F12 (GIBCO) supplemented with 10% FBS (GIBCO) 
and 100 mg/ml antibiotic/antimicotic (GIBCO) and seeded onto a poly-L-lysine coated 75 cm2 
flask. Cells were left for 7-15 days on a 37ºC incubator (95% O2, 5% CO2) until total confluence 
and the medium was changed once a week. This mixed glial cell culture was incubated under 
constant agitation at 230 rpm for 3 hours (and 37ºC) to isolate microglial cells (99% OX42+) 
and afterwards at 280 rpm O/N to remove other contaminating cells; thus, purifying astrocytes 
(>95% GFAP+, OX42-, A2B5-). Isolated cells were trypsinized (when needed) and seeded at 
different cell densities depending on the experimental requirements. Before the experiment, 
cells were washed with PBS 1x pH 7.4 and serum-starved for at least 3 hours in DMEM-F12 
without supplements. 
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  -  Cerebellar granule neurons (CGN) primary culture 
These cells were isolated (> 99% βIII-tubulin+) from the cerebellum of postnatal P7 rats 
(Gonzalez de la Vega et al., 2001). Similarly to the previous protocol, cerebella were dissected 
and placed in cold EBSS to remove the meninges. The tissue was minced with a scalpel and 
incubated with activated papain (Worthington) and DNase (100 U/ml, Sigma) for 1h at 37ºC 
and constant agitation (200 rpm) in a saturated carbogen atmosphere. Enzymatic disaggregation 
was stopped by centrifuging in a gradient of ovomucoid (papain inhibitor) following the 
manufacturer instructions. Cells were pelleted by centrifugation and resuspended in 0.22 µm 
filtered neurobasal medium (GIBCO) supplemented with B27 (GIBCO), 4 mM glutamine 
(Sigma) and 25mM KCl (Merck). Finally cells were seeded at a cell density of 450.000 cells/
well in p12 plates and 900.000 cells/well in p6 plates over a poly-L-lysine coating. After 7 days 
in culture, neurons were serum starved for 1h in neurobasal medium supplemented with 25 mM 
KCl before proceeding with the experiment. 
  -  Rat brain endothelial cells (RBEC) primary culture 
Endothelial cells from the microvasculature of the brain were isolated following an 
established protocol (Nishijima et al., 2010; Trueba-Sáiz et al., 2013). As explained above, the 
cortex of postnatal P7-10 rats were dissected and meninges removed. Then, the tissue was 
minced with a scalpel and incubated in collagenase II (270 U/ml, GIBCO), dispase (0.1 g/ml, 
Roche) and DNase (10 U/ml) in DMEM for 1.5 hours at 37ºC and constant agitation 
(>200rpm). Further mechanical disaggregation was achieved passing the suspension through a 
20G needle several times followed by centrifugation and resuspension of the pellet in human 
endothelial serum free medium (HE-SFM) supplemented with 20% FBS, 100 mg/ml antibiotic/
antimicotic, 1 µg/ml hydrocortisone (Sigma) and 3 µg/ml puromycin (Sigma). Cells were then 
seeded onto collagen IV/fibronectin coated wells and kept in puromycin HE-SFM during 72h 
for selection, taking advantage of the fact that brain endothelial cells are naturally resistant to 
the toxicity induced by this antibiotic (Perrière et al., 2005). On the 4th day, cells were changed 
to “complete HE-SFM” in which puromycin was substituted for 2 ng/ml FGFβ and 0.05 mg/ml 
of a homemade growth supplement from bovine brain (Gálvez et al., 2001). Cells were serum-
starved at least 3h before the experiments in HE-SFM without supplements. 
  -  Choroid plexus epithelial cells (CP) primary culture 
Similarly, choroid plexus from the lateral, 3rd and 4th ventricles of postnatal P7 rats were 
extracted under the microscope, enzymatically digested with 1 mg/ml pronase (Sigma) for 25 
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min at 37ºC in constant agitation and for another extra 5 min adding 12.5 µg/ml DNase to the 
medium. Several mechanical disaggregation steps followed (with a Pasteur pipette with flame-
rounded tip), then a wash with PBS, a 5 min re-incubation in DNase and further mechanical 
disaggregation. Finally, cells were filtered through a 100 µm pore diameter nylon membrane 
(Falcon), washed three times with PBS by centrifugation, resuspended in DMEM-F12 
supplemented with 10% FBS, 10 ng/ml EGF, 5 ng/ml FGFβ and seeded at 150.000/p12 wells 
onto laminin (Sigma) coated wells (Bolós et al., 2010). Before the experiments cells were 
serum-starved on DMEM/F12 with no supplements for at least 3 hours. 
  -  Biotinylated rhIGF-1 uptake assay 
To study IGF-1 internalization we used confluent monolayers of different cell types and 
incubated them with biotinylated recombinant human IGF-1 or bhIGF-1 (Bolós et al., 2010; 
Trueba-Sáiz et al., 2013). Serum-starved cells were treated for 1h with several drugs (mainly 
inhibitors of signaling pathways, see table 2.1) before bhIGF-1 (0.2 µg/ml, Ibt systems, 
Germany) was added to the media. After 1h at 37ºC, cells were placed on ice, washed once with 
PBS 1x pH 6.0 (to remove unspecific binding to the cell membrane), twice with PBS 1x pH 7.5 
(to restore neutral pH) and incubated in lysate buffer for 10 min on ice to extract proteins (see 
below). Samples were analyzed by western blot and bhIGF-1 was loaded on the gel as input 
control. 
Figure 2.4. Protocol used for in vitro IGF-1 internalization assay.  bhIGF-1, biotinylated human IGF-1. 
Drug/ 
Inhibitor Use Concentration Producer 
rhIGF-1 
In vitro stimulation 
In vivo: i.p. mice 
              i.v. macaques 
10-9 M & 10-7 M 
1 mg/kg 
0.1 mg/kg 
GroPep 
bhIGF-1 IGF-1 uptake assay 0.2 μg/ml Ibt systems 
LY 294002 PI3K inhibition 25 μM Calbiochem 
NP031112 GSK3β inhibition 25-100 μM Noscira 
U0126 MEK inhibition 20 μM Tocris 
Table 2.1. List of drugs and pharmacological inhibitors used. 
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 2.2.3.  Biochemistry 
  -  Preparation of protein extracts/lysates 
Tissue samples were homogenized with an Ultraturrax (IKA, Germany) in protein 
extraction buffer pH 7.4 (150 mM NaCl, 20 mM Tris HCl, 5 mM EDTA, 10% glycerol, 1% 
NP40) supplemented with protease and phosphatase inhibitors (protease inhibitor cocktail, 
Sigma; 1 mM PMSF, 1 mM sodium o-vanadate). Lysates from cell cultures were prepared 
similarly but incubating with the lysis buffer directly on the plate and scratching the wells 10 
mins later. Lysates were cleared by centrifugation at 14000 rpm/4ºC/10 min to remove any 
insoluble material. 
When RNA and protein from the same sample were needed, a standard guanidinium 
thiocyanate-phenol-chloroform extraction was carried out with the commercial reagent Trizol 
(Life Technologies, USA). The obtained protein pellet was resuspended in 1% SDS and used 
for western blot only. Total protein quantity was determined using Bradford (Bio-Rad) or the 
bicinchoninic acid (BCA and Cu2+ sulfate solution, Sigma) assay for the SDS lysates (Mallia et 
al., 1985), using bovine serum albumin as standard in both cases. 
  -  Immunoprecipitation (IP) of hippocampal IGF-1R   
One hippocampus was homogenized in lysis buffer pH 7.4 (10 mM Tris HCl, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 mM sodium o-
vanadate, 1 mM PMSF and protease inhibitor cocktail), centrifuged at 14000 rpm/4ºC/10 min 
and the resultant lysate incubated O/N with agarose-conjugated rabbit anti-IGF-1R antibody (sc
-713AC, Santa Cruz Biotech, USA). On the next day, the beads (with the immunocomplexes 
attached) were washed three times with the same lysis buffer diluted 1:2 in distilled water and 
then resuspended on 2x Laemmli buffer supplemented with 5% β-mercaptoethanol. Samples 
were then run by SDS-PAGE (see below). 
  -  Western Blot  
Protein lysates were mixed 5:1 with 5x Laemmli buffer (10% SDS, 50% glycerol, 375 
mM Tris HCl pH 6.8, 0.1% bromophenol blue, 5% β-mercaptoethanol) and boiled at 95ºC for 5 
min. Then, protein samples were loaded onto 8-15% acrylamide/bis-acrylamide SDS gels 
(Laemmli, 1970). Denatured proteins were separated according to its molecular weight using 
the Mini-Protean 3 electrophoresis system (Bio-Rad, USA), transferred to nitrocellulose or 
PVDF membranes (Bio-Rad, USA), blocked for 1-2h in 5% non-fat dry milk TTBS (0.05% 
tween TBS), incubated with the primary antibody (O/N at 4ºC or 3h at RT), washed three times 
with TTBS, incubated with HRP-conjugated secondary antibody (1h at RT), washed again and 
developed with ECL reagent (Thermo Fisher, USA). The resultant chemoluminescence was 
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captured in x-ray films (Agfa, Belgium) and the detected bands quantified by densitometric 
analysis using GS-800 Calibrated Densitometer and Quantity One software (both from Bio-
Rad). Membranes were reblotted (using re-blot plus mild, Millipore) either with the same 
antibody used for immunoprecipitation (total immunoprecipitated protein), anti β-actin or anti-
tubulin to normalize for protein load. The ratio of relative expression was established after 
subtraction of the background intensity and normalized against total protein load in each lane. 
Antibody Host Species Dilution Incubation Producer Ref. 
β-actin Mouse monoclonal 1:50000 (WB) * Sigma A5316 
Amyloid β 
(clone 6F/3D) Mouse monoclonal 1:50 (IHC) 3 O/N, 4ºC Dako M0872 
c-Fos Rabbit polyclonal 1:2000 (IHC) O/N, 4ºC Santa Cruz sc-52 
Fis1 Rabbit polyclonal 1:1000 (WB) * Protein Tech 10956-1-AP 
GFAP Rabbit polyclonal 1:2000 (WB) * Dako Z0334 
IGF-1Rβ Rabbit polyclonal 1:1000 (WB), AC: 5μg/ml (IP) O/N, 4ºC Santa Cruz 
sc-713/
AC 
IGF-1Rβ Rabbit monoclonal 1:1000 (WB) * Cell signaling #9570 
IRβ Rabbit polyclonal 1:1000 (WB) * Santa Cruz sc-711 
IRS-1 
[pS616] Rabbit polyclonal 1:1000 (WB) * Invitrogen 44-550G 
IRS-1 Rabbit polyclonal 1:500 (WB) * Invitrogen AHO1222 
LRP1 Rabbit monoclonal 1:40000 (WB) * Abcam ab92544 
Lucifer-
Yellow Rabbit polyclonal 1:100000 (IHC) 
3-5 O/N, 
4ºC 
Prof. Javier 
de Felipe - 
MFN-2  
(clone 4H8) Mouse monoclonal 1:1000 (WB) * Sigma 
WH00099
27M3 
Tau [pS262] Rabbit polyclonal 1:1000 (WB) * ProSci 79-152 
Tau  
(clone 5) Mouse monoclonal 1:1000 (WB) * Millipore #MAB361 
βIII-tubulin Mouse monoclonal 1:2000 (WB) * Promega G712A 
pTyr Mouse monoclonal 1:1000 (WB) * Millipore #05-1050 
Anti-mouse 
HRP Goat polyclonal 1:10000 (WB) 1h, RT BioRad 170-6516 
Anti-rabbit 
HRP Goat polyclonal 1:10000 (WB) 1h, RT Cell signaling #7074 
Streptavidin 
HRP - 1:10000 (WB) 1h, RT Invitrogen SNN2004 
Table 2.2. List of antibodies used. *For WB, all primary antibodies were incubated either 2h at RT or O/N at 4ºC 
IHC: immunohistochemistry, IP: immunoprecipitation, WB: western blot 
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  -  Murine IGF-1 & insulin ELISA 
A commercial kit from R&D systems was used for the determination of IGF-1 in serum, 
CSF and brain extracts following the manufacturer’s instructions. Serum and CSF were assayed 
directly, albeit diluted 1/500 and 1/10 respectively. Brain samples (i.e. cortex or hippocampus) 
underwent peptide extraction as follows: they were homogenized in 1N acetic acid, boiled at 
100ºC for 20 min and centrifuged (14000 rpm/4ºC/10 min). The supernatant was recovered, 
frozen at -80ºC, lyophilized and kept at 4ºC until the day of the ELISA. Finally, samples were 
reconstituted on PBS 1x pH 7.4 and assayed both by IGF-1 ELISA and Bradford, to express the 
results as quantity of IGF-1 per total brain protein. 
Commercial kits were also used for insulin determination in serum (Mercodia, Sweden & 
Crystal Chem, USA). When CSF and brain samples (using the same extraction as for IGF-1) 
were analyzed, values fell below the detection limit of the tests. 
 
 2.2.4.  Molecular Biology 
  -  RNA Isolation 
A standard guanidinium thiocyanate-phenol-chloroform extraction was carried out with 
the commercial reagent Trizol (Ambion) following the manufacturer’s instructions for the 
simultaneous extraction of RNA and proteins from either cultured cells or tissue samples. 
Reconstitution of purified RNA was done in nuclease-free water (not DEPC treated, Ambion) 
to a range of 0.1-0.5 µg/µl. To evaluate the quality of the isolated RNA, the absorbance ratios 
260/280 & 260/230 were measured with the NanoDrop 1000 Spectrophotometer (Thermo 
Scientific) and used as makers of contaminants from the extraction such as proteins or organic 
compounds (i.e. phenol or guanidine thiocyanate). In addition, RNA integrity was confirmed by 
running 0.5 µg RNA per sample in a 1% agarose gel. Finally, samples were kept frozen at -
80ºC until further use. 
  -  Retrotranscription & Quantitative real-time PCR (qPCR) 
For the relative quantitation of mRNA, first the RNA was isolated as above and then 
retrotranscribed to cDNA with the “High Capacity cDNA Reverse Transcription kit” (Applied 
Biosystems) and used directly for qPCR or stored at -20ºC until then. For the qPCR, we used 
Taqman probes complementary to the splice junction of target genes (not detecting genomic 
DNA, *_m1)  (see table 2.3). The 18S ribosomal RNA probe was included as endogenous 
control.  Samples were diluted at 12.5 ng cDNA/µl and 50 ng cDNA per reaction were mixed 
with the probe and the Taqman Universal PCR Master Mix (Applied Biosystems) in a final 
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volume of 20 µl as instructed. Each sample was run in triplicate on a 7000/7500 Real-Time 
PCR System (Applied Biosystems) with the following program: 2 min at 50ºC (1 cycle), 10 
min at 95ºC (1 cycle), 15 secs 95ºC and 1 min at 60ºC (40 cycles). Off-line analysis for the 
determination of relative mRNA quantity was performed using a modified 2(-ΔΔCT) method 
(Pfaffl, 2001). Results on the graphs depict the fold increase of relative mRNA expression in 
experimental groups with respect to controls. 
2.3.  Statistics 
 All statistical analyses were carried out using the GraphPad Prism 5 software. For in 
vitro assays, a minimum of 3 different experiments in duplicate/triplicate have been done; the 
exact number of them are indicated for each case. The Kolmogorov-Smirnov test was used to 
check if the groups followed a normal distribution. If all of the analyzed groups passed the 
normality test, then we used either the Student’s T test (for comparing 2 groups) or one way 
ANOVA (for more than 2 groups) followed by Bonferroni’s multiple comparison test as a post-
hoc test. If any of the analyzed groups did not pass the normality test, then the corresponding 
non-parametric test was used: the Mann-Whitney test for comparing 2 groups and the Kruskal-
Wallis test (with the Dunn’s multiple comparison test as post-hoc) for more than 2. In general, 
graphs depict mean value ± standard error (SEM) and the p-values shown on them are coded as 
follows: *p<0.05, **p<0.01, ***p<0.001. 
Gene Species Context Sequence Assay ID 
IGF-1 Mus musculus GCTTTTACTTCAACAAGCCCACAGG Mm00439560_m1 
IGF-1 Rattus norvegicus GCTTTTACTTCAACAAGCCCACAGG Rn00710306_m1 
IGF-1R Mus musculus GGCCAGAAGTGGAGCA-GAATAATCT Mm00802831_m1 
IGF-1R Rattus norvegicus 
GCCA-
GAAAATGTGCCCAAGTGT
GTG 
Rn00583837_m1 
TNFα Mus musculus  Mm00443258_m1 
Table 2.3. List of Taqman probes used for the qPCR experiments. 
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 3.1. Physiological characterization of the entrance of peripheral IGF-1 into the brain 
 
   3.1.1.  Activation of hippocampal IGF-1R due to EE is region-specific and time- 
  dependent. 
It has been known for a number of years now that IGF-1 is able to penetrate the barriers 
isolating the CNS from the rest of the organism. It may do so through the endothelial cell layer 
within the microvasculature of the brain (i.e. brain capillaries) (Frank et al., 1986; Reinhardt 
and Bondy, 1994) or through the choroid plexus epithelium that gives further access to the ven-
tricles containing the CSF (Carro et al., 2000; Reinhardt and Bondy, 1994). Based on previous 
results of the laboratory describing a novel mechanism for IGF-1 brain input dependent on neu-
ronal activity (Nishijima et al., 2010), we decided to explore in more detail the entrance of IGF-
Figure 3.1 Regional profile of IGF-1R activation in the CNS of WT mice after acute environmental enrich-
ment (EE). Tissue lysates of both non-enriched controls (white) and mice enriched for 2h (black) were immuno-
precipitated with anti-IGF-1R antibody and blotted against anti-phosphotyrosine 4G10 and anti-IGF-1Rβ antibo-
dies. The hippocampus was the area most engaged by EE. A, quantification of phospho-IGF-1R/total-IGF-1R ra-
tios estimated by densitometry (control n = 72, 10 and 10; enriched n = 13, 10 and 10 respectively). Two-way 
ANOVA (EE: F = 20.49, p<0.0001. Brain region: F = 5.94, p<0.01. Interaction: F = 5.535, p<0.01). Post hoc: 
Bonferroni’s multiple comparison (control vs enriched), *p<0.05, ***p<0.001. B, representative immunoblots (C = 
control, E = enriched). Total IGF-1R was used as loading control. 
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1 when promoted by environmental enrichment (EE), which is an experimental protocol for 
physiological brain stimulation (van Praag et al., 2000; Sale et al., 2009). Accordingly, animals 
were exposed to an enriched environment for 2 hours before sacrifice as described in the met-
hods. We first replicated prior findings showing that, after EE, IGF-1R was activated in the hip-
pocampus. Indeed we saw an increase in the phosphorylated-IGF-1R/total-IGF-1R ratio as mea-
sured by immunoprecipitation followed by western blot. Afterwards, we checked whether the 
same would happen elsewhere in the brain. Subsequently, we observed that the strong activa-
tion of IGF-1R in the hippocampus (~2.3 fold increase over control non-enriched animals) was 
paralleled by a modest response in the cerebellum (~1.7 fold increase) whereas no change was 
detectable in the rest of the cortical hemisphere, probably due to dilution of the effect (Fig. 3.1). 
Thus, for future experiments we chose to focus on the hippocampus, which has also been 
shown by others to be one of the areas most affected by EE, even generating new neurons as a 
result (Kempermann et al., 1997). 
To verify that hippocampal IGF-1R was being activated by serum IGF-1 crossing the 
BBB in response to EE, we used LID mice (a liver specific IGF-1 knock out) (Yakar et al., 
1999) in a parallel experiment. As seen in Fig. 3.2A, in animals with the same age as WT not 
Figure 3.2 Aberrant hippocampal response to acute EE in liver-IGF-1 deficient (LID) mice. We stimulated 
LID mice with the same EE protocol as WT and similarly analyzed pIGF-1R/IGF-1R. A, densitometric quantifica-
tion of western blot data from LID mice age-matched to controls (young). Basal unstimulated pIGF-1R levels in 
the hippocampus of LID mice were equal to WT (dotted line). Unpaired t test vs control: **p<0.01 (control n = 6, 
enriched n = 9). B, densitometry of data from LID mice older than 18 months (control n = 5, enriched n = 6). C, 
representative immunoblots (C = control, E = enriched). D, blood IGF-1 concentration in WT and LID mice as 
determined by ELISA. Unpaired t test vs WT: ***p<0.001 (WT n = 13, LID n = 12).  
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only there was no IGF-1R activation but there was a decrease in basal activity. This surprising 
response was lost in old LID individuals (Fig. 3.2B), in which no induction of pIGF-1R by EE 
was observed. Therefore, we may conclude that EE was unable to import peripheral IGF-1 into 
the brain of LID animals due to the severe reduction (~90%) in circulating IGF-1 levels charac-
teristic of these (Fig. 3. 2D). As a consequence, it is evident that WT animals exposed to EE do 
take IGF-1 from the blood. 
Next, we decided to explore whether this effect was stable over time and when could we 
detect it first. For this, animals were exposed to the same EE paradigm for several extra time 
points simulating both acute (1 h, 6 h, 24 h) and chronic (1 month) situations of brain stimula-
tion. We found that until 2 hours of enrichment there was no activation of the IGF-1 pathway 
and from then on it became progressively reduced until there was no response at all after 4 we-
eks. This points out to the long-term development of tolerance to the phosphorylation of hippo-
campal IGF-1R due to EE (Fig. 3.3).  
Figure 3.3 Time-course study of the EE-evoked IGF-1R activation within the hippocampus of WT mice. We 
further studied the pattern of phosphorylation of IGF-1R across different time periods of EE finding it active at 2h 
and 24h of EE. A, densitometry of western blot results (control n= 51, enriched n = 10, 13, 10, 10 and 17 respecti-
vely). One-way ANOVA (F = 7.296, p<0.0001) Post hoc: Bonferroni’s multiple comparison (vs control) *p<0.05, 
***p<0.001. B, representative blots. We gathered all control animals for each EE time in the same group after con-
firming that there were no differences among them. C = control, E = enriched, h = hour, M = month. 
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   3.1.2.  Hippocampal IGF-1 levels fluctuate out of EE length, what suggests a  
  complex autoregulation of its brain Access 
Because of this peculiar time-dependent pattern of IGF-1R activation we hypothesized 
that thre might be changes in brain IGF-1 levels reflecting the dynamics of the process. Thus, 
we measured hippocampal IGF-1 by ELISA and found that there were no detectable increments 
which paralleled the phosphorylation of IGF-1R at 2h or 24h. However, there was a slight accu-
mulation after chronic enrichment for one month (Fig. 3.4A), which would probably contribute 
to the delayed desensitization observed in Fig. 3.3. Rising tendencies could also be seen in IGF-
1 levels in the serum and CSF of WT animals enriched for one month (Fig. 3.4B and C). Nota-
bly, after 6 h of EE there was a sudden decrease (~50%) in brain IGF-1 (Fig. 3.4A) which could 
Figure 3.4 Time-dependent fluctuations in IGF-1 concentration due to EE in WT mice. Protein levels of IGF-
1 were quantified by ELISA in enriched animals showing that in the hippocampus it is greatly reduced after 6h of 
EE and slightly increased after one month. A, measurements of hippocampal peptide extracts (control n = 60; enri-
ched n = 5, 25, 10, 10 and 17 respectively). Kruskal-Wallis test (p<0.0001, KW statistic = 40.42). Post hoc: 
Dunn’s multiple comparison test (vs control) *p<0.05, ***p<0.001. B and C, determination of IGF-1 concentration 
in the serum (B, Mann Whitney test: p-value = 0.1051) and CSF (C, unpaired t test: p-value = 0.0997) of WT mice 
enriched for 1 month (control n = 10, enriched n = 10). We gathered all control animals for each EE time in the 
same group after confirming that there were no differences among them. h = hour, M = month. 
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explain the transient inactivation of the IGF-1R at this time. By 24 h of EE, circulating IGF-1 
would continue entering into the hippocampus to recover local levels and re-activate the path-
way (Fig. 3.3, 3.4A). 
To explore the molecular mechanisms regulating brain import of peripheral IGF-1, we stu-
died the relative expression levels of IGF-1 and IGF-1R mRNAs either in the in vivo situation 
of EE stimulation and in an in vitro approximation using several brain cultured cells treated 
with IGF-1. This was performed as an attempt to dissect cell-specific mechanisms participating 
of IGF-1 brain uptake. 
In vivo, we detected no significant change in IGF-1 or IGF-1R expression after 24 h or 
even 1 month of EE (Fig. 3.5). This suggests that peripheral IGF-1 was the responsible for both 
the activation of IGF-1R at 24 h and the small IGF-1 accumulation seen in the one month enri-
ched group. On the other hand, in the last there was no downregulation of IGF-1R, what could 
have explained the lack of sensitivity to the increasing hippocampal IGF-1. As a result, we 
thought that either there were cell-specific mechanisms that we could not detect in the whole 
tissue preparation or that there were downstream signaling compensations.  
 
 
 
 
 
 
 
 
   
 
  3.1.3.  In vitro, IGF-1 is able to autoregulate its own gene expression as well as that 
 of its receptor in brain cells. 
To check this hypothesis, we isolated several cell types from the brain of early postnatal 
rat pups, both neuronal (cerebellar granule neurons or CGN) and non-neuronal (brain endot-
helial cells or BEC, astrocytes and microglial cells), and treated them with 100 nM IGF-1 for 6, 
Figure 3.5 EE did not exert any effect on the hippocampal expression of IGF-1 and IGF-1R. We isolated 
mRNA from the hippocampus of WT mice (controls, white/n = 10, and enriched for 24h, gray/n = 10, or one 
month, black/n = 9) and analyzed the relative changes in IGF-1 and IGF-1R expression by quantitative real-time 
PCR (qPCR). Non-significant differences were detected by the Kruskal-Wallis test in both studied genes  
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Figure 3.6 In vitro autoregulation of IGF-1 and IGF-1R in primary CNS cells treated with IGF-1. Cultured 
postnatal primary CNS cells were serum-starved and treated with 100 nM IGF-1 for 6, 15 or 30 h. We then isolated 
total mRNA and analyzed it by qPCR. A, relative expression of IGF-1 mRNA in IGF-1 treated cells compared to 
unstimulated controls (dotted line). Neurons (n ≥ 3): 2-way ANOVA (IGF-1: F = 8.571, *p<0.05; treatment length/
interaction: F = 0.1968, p>0.05). Astrocytes (n ≥ 3): 2-way ANOVA (IGF-1: F = 1.209, p>0.05; treatment length/
interaction: F = 5.284, ##p<0.01). BECs (n = 4): 2-way ANOVA (IGF-1: F = 37.31, ***p<0.0001; treatment 
length/interaction: F = 1.338, p>0.05). Microglia (n = 3), paired t test vs control (ns, p > 0.05). B, relative expres-
sion of IGF-1R mRNA in IGF-1 treated cells compared to unstimulated controls (dotted line). Neurons (n ≥ 3): 2-
way ANOVA (IGF-1: F = 154.4, ***p<0.0001; treatment length/interaction: F = 2.769, p>0.05). Astrocytes (n ≥ 
3): 2-way ANOVA (IGF-1: F = 400.5, ***p<0.0001; treatment length/interaction: F = 8.765, ###p<0.001). BECs 
(n = 4): 2-way ANOVA (IGF-1: F = 7.314, *p<0.05; treatment length/interaction: F = 1.88, p>0.05). Microglia (n 
= 3), paired t test vs control (*p<0.05). C, basal IG-1 and IGF-1R mRNA expression in unstimulated serum-
starved CNS cells (controls for 6h time point). *, effect of IGF-1 treatment. #, effect of treatment length and inte-
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15 and 30 h simulating the entrance of serum IGF-1 into the CNS compartment. As we can see 
in Fig 3.6 there were different patterns of response to IGF-1 treatment depending on the cell 
type. Only neurons and BECs showed a significant downregulation of IGF-1 expression after 
IGF-1 treatment (Fig. 3.6A). This started as early as 6h after IGF-1 addition to culture media 
and was maintained for longer times. On the other hand, in astrocytes we detected a significant 
effect of the time of treatment, what may account for the compensatory upregulation in IGF-1 
expression after 30 h of treatment (yet non-significant). Altogether, this dissimilar response to 
exogenous IGF-1 among CNS cells could explain the lack of changes in the hippocampal IGF-1 
expression of enriched animals. Microglia was the cell type showing the highest constitutive 
expression for IGF-1 in vitro (Fig. 3.6C); what remained unchanged by IGF-1 treatment (Fig. 
3.6A). This may possibly be due to the fact that microglia in culture is not completely resting 
but slightly activated (“primed”) (Becher and Antel, 1996).  
 
As for IGF-1R expression, what we observed in all cell types was a strong downregula-
tion induced by IGF-1 treatment at most time points. The only exception to this was the 30h 
treated BECs, what might reflect the fact that a chronic increase in serum IGF-1 would not af-
fect its transport across the microvascular endothelium due to restored IGF-1R synthesis in 
BECs. On the other hand, these results do not explain the normal levels of IGF-1R found in the 
hippocampus of chronically enriched animals. One explanation may be that even though WT 
mice enriched for one month exhibited a discrete accumulation of hippocampal IGF-1 (Fig 3.4), 
IGF-1R was not active (Fig 3.3) and thus there would be no downstream signaling downregula-
ting it.  
 
A reasonable flaw of these in vitro experiments is that we used pharmacological concen-
trations of IGF-1. Hence, it could be argued that our results may not be physiologically relevant 
given that at 100 nM IGF-1 is known to stimulate both IGF-1R and IR. To rule out this possibi-
lity we reproduced the 6h experiment in astrocytes using physiological concentrations of IGF-1 
(1 nM) and found the same effect in both genes as when using 100 nM (Fig 3.7A). Furthermore, 
we analyzed astrocyte lysates by western blot and discovered that these changes in mRNA ex-
pression did lead to similarly altered protein levels (Fig 3.7B). Also, a preliminary experiment 
on astrocytes showed that IR might as well be downregulated by IGF-1 in brain cells (Fig 
3.7B). 
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 3.1.4.  GSK3β activity controls IGF-1 uptake by astrocytes, neurons and brain  
  endothelial cells in vitro. 
In other set of in vitro experiments we aimed to identify the intracellular signaling casca-
des activated by IGF-1 that might potentially be involved in its uptake by brain cells. Therefore, 
we blocked the main ones downstream of the IGF-1R with selective pharmacological inhibitors 
(see methods: table 2) before incubating the cells with biotinylated IGF-1. Western blot analysis 
evidenced that GSK3β inhibition using NP12 dramatically induced IGF-1 internalization in all 
cell types tested, especially in BECs. This suggests that, even though this mechanism might be 
general for all brain cells, it is vital for IGF-1 blood-to-brain transport as demonstrated by the 
~14 fold induction in BECs versus the ~5 fold seen in astrocytes and neurons (Fig 3.8). There 
was also a tendency towards increased IGF-1 internalization when inhibiting the MAPK path-
way in astrocytes, what could point out to the existence of additional mechanisms in some cell 
types. 
Figure 3.7 IGF-1 effects on IGF-1/IGF-1R are dose-independent. We treated serum-starved astrocytes with 
different doses of IGF-1 (1 nM and 100 nM) for 6 h and analyzed mRNA and protein changes of IGF-1, IGF-1R 
and IR. A, qPCR results showing IGF-1 and IGF-1R mRNA downregulation after IGF-1 treatment relative to un-
treated controls (dotted line). One way ANOVA for IGF-1 expression (n ≥ 3): F = 8.182, p<0.01; Bonferroni’s 
multiple comparison vs untreated controls (*p<0.05, **p<0.01). One way ANOVA for IGF-1R expression (n ≥ 3): 
F = 53.72, p<0.0001; Bonferroni’s multiple comparison vs untreated controls (###p<0.001). B, western blot results 
showing consequent IGF-1R decrements after IGF-1 treatment. Preliminary experiments showed that IR was as 
well decreased.  One way ANOVA for IGF-1R (n = 4): F = 13.97, p<0.01; Bonferroni’s multiple comparison vs 
untreated controls (**p<0.01). One way ANOVA for IR (n = 3): F = 14.6, p<0.01; Bonferroni’s multiple compari-
son vs untreated controls (#p<0.05, ##p<0.01). C, representative immunoblots. β actin was used as loading control. 
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Figure 3.8 GSK3β regulates IGF-1 internalization in several CNS primary cells. Neurons, astrocytes and 
BECs were serum-starved and pretreated for 1h with either vehicle (C, control) or selective inhibitors for GSK3β 
(NP12, NP), MEK1/2 (U0126, U) or PI3K (LY294002, LY) before evaluating the internalization of exogenously 
added bhIGF-1 (see Methods). We detected a general potentiation in cellular uptake of bhIGF-1 in cells treated 
with the GSK3β inhibitor (NP12). A, densitometry of western blot measuring bhIGF-1 accumulated intracellularly 
(after 1h of incubation). One way ANOVA for Neurons (n ≥ 2): F = 5.912, p<0.05; Bonferroni’s multiple compari-
son vs control (*p<0.05). One way ANOVA for Astrocytes (n≥3): F = 5.71, p<0.01; Bonferroni’s multiple compa-
rison vs control (##p<0.01). One way ANOVA for BECs (n = 4): F = 23.66, p<0.001; Bonferroni’s multiple com-
parison vs control (+++p<0.001). B, representative immunoblots. Synthetic bhIGF-1 was loaded to assure band 
specificity (input), “-“ represented a control lysate with no bhIGF-1. Loading controls: βIII tubulin (specific for 
neurons), glial fibrillary acidic protein (GFAP, specific for astrocytes), β actin. 
 3.2. In asymptomatic stages, AD pathology features a prominent reduction of  
  serum IGF-1 access to the brain. 
In the second and larger part of the project we decided to investigate how a neurodegene-
rative condition such as Alzheimer’s disease would impact on the system we have been stud-
ying so far. Besides, our final goal was to translate this knowledge into a potentially useful cli-
nical tool. In the literature it had been reported that GSK3β inhibition promoted IGF-1 transport 
into the brain, both in vivo and in vitro as we and others have shown (Bolós et al., 2010), that it 
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improved AD pathology in mice (Serenó et al., 2009) and that AD patients displayed alterations 
within the IGF system (Aleman and Torres-Alemán, 2009). Furthermore, it had been proposed 
that there is IGF-1 resistance in AD brains (Moloney et al., 2010). Therefore, we hypothesized 
that peripheral IGF-1 brain input would be impaired in this dementia and it might be used as a 
biomarker of disease onset. 
 3.2.1.  Soluble Aβ differently modulates IGF-1 brain entrance in cellular models  
  of the BBB. 
Our first approach to the issue was to test how Aβ treatment would impact on IGF-1 inter-
nalization by BBB cells in vitro (i.e. choroid plexus and brain endothelial cells, BECs). We 
treated confluent monolayers of primary cultured BECs and choroid plexus cells with soluble 
Aβ1-40. We did so in order to simulate the earliest stages of AD rather than the latest in disease 
progression by using fibrillar Aβ. When measuring the amount of bhIGF-1 internalized by cells 
we found that there was a decrease in BEC uptake of bhIGF-1 that was directly proportional to 
Aβ concentration in culture media (Fig 3.9A). On the contrary, choroid plexus cells showed an 
increase in bhIGF-1 uptake also directly proportional to Aβ concentration (Fig 3.9B). These 
Figure 3.9 Aβ[1-40] differently modulates IGF-1 brain entrance in cellular models of the main interfaces of 
the BBB. We treated confluent monolayers of BECs and choroid plexus epithelial cells with soluble Aβ1-40 and 
determined the amount of exogenous IGF-1 internalized as compared to vehicle treated cells (dotted line). A, den-
sitometry of western blot measuring bhIGF-1 accumulated by BECs. We observed a dose-dependent decrease in 
IGF-1 uptake upon Aβ treatment. One way ANOVA (n ≥ 3): F = 10.95, p<0.0003; Bonferroni’s multiple compari-
son vs control (*p<0.05, ***p<0.001). B, densitometry of western blot measuring bhIGF-1 accumulated by cho-
roid plexus cells. Here there was a dose-dependent increase in IGF-1 uptake after treating choroid plexus cells with 
Aβ. One way ANOVA (n = 4): F = 4.738, p<0.05; Bonferroni’s multiple comparison vs control (*p<0.05). Repre-
sentative immunoblots are depicted below the graphs. 
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results evidenced the presence of early alterations in brain transport of peripheral IGF-1 in AD 
pathology. 
 3.2.2.  Early stages of AD already present a basal disruption of serum IGF-1 traffic  
  to the CSF. 
Subsequently we thought of validating these results in animal models of AD. For that we 
used two transgenic mice strains (APP & APP/PS1) at young ages (3.8 ± 0.67 and 3.96 ± 0.61 
months old respectively, mean ± SD). At this time they didn’t yet display cognitive impairment 
(Fig. 3.10A) but showed different degrees of amyloidopathy: APP had no Aβ accumulation 
whereas APP/PS1 displayed profuse Aβ brain deposits (Fig 3.10B). Thus, animals were still in 
a pre-symptomatic stage of the disease and so they modelled early AD. 
Firstly, we measured IGF-1 in the CSF and serum of the animals using ELISA. We obser-
ved no differences in circulating IGF-1 (Fig 3.11B) but at the same time we detected a promi-
nent decrease in IGF-1 concentration in the CSF of AD mice when compared to WT animals 
(Fig 3.11A). This would reflect an impaired transport of IGF-1 from the blood as confirmed by 
the reduced CSF/serum ratio found in both strains (Fig 3.11C), agreeing with our in vitro fin-
dings.  
Furthermore, we were able to validate animal data using human samples provided by the 
Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). In them, the CSF/plasma IGF-1 ratio 
was also decreased in AD patients (MMSE score of 16-26) as compared to age-matched healthy 
controls (Fig 3.12C) surely as a result of alterations in both serum and CSF IGF-1: the first was 
increased (Fig 3.12B) while the second was reduced (Fig 3.12A). This may ultimately constitu-
te an indirect indication of early IGF-1 resistance affecting IGF-1 transport into the CNS. A re-
Figure 3.10 Young APP and APP/PS1 transgenic animals model early stages of AD pathology. In all of our 
experiments we used 4 month old AD mice (APP and APP/PS1). A, these presented no cognitive impairment de-
tectable by the Y-maze. One way ANOVA (n = 13, 9 and 9 respectively): F =0.7519, p>0.05 (non-significant). B, 
representative microphotographs of DAB immunostaining of human Aβ depicting different degrees of Aβ plaque 
load in the brains of AD mice. Scale bar, 500 µm. 
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cent report (Johansson et al., 2013) has obtained similar results in serum and CSF/serum ratio 
offering as well a similar interpretation (see Discussion). This reinforces our hypothesis and the 
validity of transgenic mouse models to study the early loss of serum IGF-I input to the brain 
associated to AD pathology. 
Figure 3.11 APP and APP/PS1 young mice display reduced IGF-1 levels in the CSF due to reduced blood-to-
CSF transport of circulating IGF-1. We measured IGF-1 protein by ELISA in the serum and CSF compartments 
of WT and AD mice. A, IGF-1 is reduced in the CSF of AD mice. One way ANOVA (n = 10, 6 and 17 respective-
ly): F = 8.538, p<0.01. Bonferroni’s multiple comparison vs WT (**p<0.01). B, serum IGF-1 determinations sho-
wed no differences between genotypes. One way ANOVA (n= 17, 8 and 16): F = 0.8236, p>0.05 (non-significant). 
C, we calculated the ratio between IGF-1 levels in the CSF and the serum in animals with both measurements. One 
way ANOVA (n = 10, 6 and 12): F = 9.832, p<0.001. Bonferroni’s multiple comparison vs WT (*p<0.05, 
***p<0.001). 
Figure 3.12 AD and MCI patients show similar alterations to APP and APP/PS1 animals concerning blood-
to-CSF transport of IGF-1. We determined IGF-1 quantity by ELISA in plasma and CSF samples from AD pa-
tients (n = 35), subjects with MCI (n = 15) and age-matched controls (n = 10). A, the calculated ratio between CSF 
and plasma IGF-1, an indicative of blood-to-CNS transport, is decreased in people with AD (similarly to transge-
nic animals). B, IGF-1 levels were reduced in the CSF of AD cases whereas plasma IGF-1 was increased. Unpai-
red t test: *p<0.05, **p<0.01 vs control. MCI = mild cognitive impairment, AD = Alzheimer’s disease. 
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 3.2.3.  Coupling of neuronal activity to peripheral IGF-1 brain input is impaired in  
  mice modeling presymptomatic AD due to the presence of IGF-1 resistance. 
As a final proof-of-concept we subjected mice from both AD strains to our previously 
described paradigm of multisensory stimulation (i.e. acute EE for 2h) and compared phosphory-
lation of IGF-1R in the hippocampus to that of WT animals. Matching our previous data, both 
transgenic models exhibited disturbances in their response. On the one hand, animals with more 
advanced pathology (APP/PS1) presented no activation of the IGF-1 pathway at all in response 
to EE (Fig 3.13), possibly resenting from a severely affected input of serum IGF-1 into the hip-
pocampus. Conversely, animals with no clear signs of pathology (APP) did exhibit an increase 
in hippocampal phospho-IGF-1R, even though it was clearly attenuated and around half of that 
of WT (Fig 3.13). This and the fact that they had less CSF IGF-1 in basal conditions (Fig 
3.11A) suggests that circulating IGF-1 is able to enter the hippocampus of APP mice after EE 
Figure 3.13 The hippocampus of AD mice exposed to acute EE depicts impaired IGF-1R phosphorylation. 
We stimulated the hippocampus of 4 month old APP and APP/PS1 animals with 2h of EE, which we have demons-
trated to phosphorylate IGF-1R. A, densitometric quantification of phospho-IGF-1R/total IGF-1R ratio in the hip-
pocampus of mice, assessed by western blot (controls: n = 72 controls, 7 APP and 17 APP/PS1; enriched: n = 13, 9 
and 18 respectively). We observed that non-enriched controls had similar levels of pIGF-1R independently of ge-
notype. One way ANOVA for controls (F = 0.0851, p>0.05, non-significant). Contrarily, the EE-stimulated hippo-
campus of AD transgenic animals showed either a significantly decreased response (in APP) or no activation of the 
IGF-1R (in APP/PS1). One way ANOVA for enriched (F = 17.18, p<0.0001); Bonferroni’s multiple comparison 
vs WT enriched (*p<0.05, ***p<0.001). B, representative immunoblots, pTyr4G10 pictures the 97kDa band co-
rresponding to the phosphorylated IGF-1R after immunoprecipitation of the lysates. 
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albeit to a lesser extent and with more difficulty than in controls.  
Furthermore, we ascertained that neither was this deficit due to low serum IGF-1 levels, 
since both strains had normal IGF-1 blood levels (Fig 3.11B), nor to reduced total IGF-1R in 
the hippocampus of AD transgenics, which we found indistinguishable from WT (Fig 3.14A). 
We also checked LRP1 levels, a multicargo protein that may serve as co-receptor for IGF-1 
transcytosis through the BBB at the microvascular interface, and found that were normal as 
well (Fig 3.14B)  
Because it might be argued that EE was not properly stimulating the brains of AD animals 
we challenged this possibility by studying the induction of c-fos (an early marker of neuronal 
activity) in the hippocampus after enrichment. Surprisingly, we found no obvious difference in 
the hippocampus of enriched APP/PS1 as compared to WT enriched subjects (Fig 3.15). This 
suggests that the brains of AD mice are still responsive to EE stimulus in other IGF-1 indepen-
Figure 3.14 There are no differences in total IGF-1R and LRP1 levels in the hippocampus of APP and APP/
PS1 mice as compared to WT. We analyzed hippocampal lysates by western blot to measure the total amount of 
IGF-1R and LRP1, which is a multicargo protein involved in receptor-mediated IGF-1 transcytosis. A, densitome-
try of IGF-1R data showed no significant changes. Kruskal-Wallis test p-value>0.05 (WT, n = 15; APP, n = 11; 
APP/PS1, n = 13). B, densitometry of LRP1 data also revealed no differences. One way ANOVA (n = 15, 6 and 5 
respectively): F = 1.23, p>0.05. 
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Figure 3.15 Enriched APP/PS1 display an induction of hippocampal c-fos similar to that of WT after EE. 
We immunostained coronal sections of WT and APP/PS1 enriched animals against c-fos, an early marker of neuro-
nal activity, and discovered that EE also induced c-fos in APP/PS1. Representative pictures of the hippocampus 
along the septotemporal axis are shown. Scale bar, 500 µm. 
dent pathways. Therefore, we did not proceed with further analysis in APP mice, given that this 
strain presents a slower progression than the double transgenic. 
One last possibility was that, similarly to what have been reported in later stages of AD 
(Talbot et al., 2012), there would already be a central resistance to IGF-1 this early in pathology 
development. Therefore, we checked for a classical marker of insulin/IGF-1 resistance: the in-
creased phosphorylation of the IRS-1 at serine 616 (612 in mice). As seen in Fig 3.16, we ob-
served a significant increase in this specific phosphorylation in both APP and APP/PS1 strains. 
Because IGF-1 access to the brain takes place through a receptor-mediated transcytosis, the ob-
served resistance in its signaling would ultimately impair it. As a consequence, this implies that 
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central IGF-1 resistance was the responsible mechanism because of which circulating IGF-1 
was unable to properly enter the brain of AD mice after EE stimulation. 
3.3.  Development of an EEG-based biomarker of AD 
Once the lack of activity-induced entrance of IGF-1 into the brains of AD mice was con-
firmed (which we will refer to as “neurotrophic uncoupling”), we decided to explore the trans-
lational potential of this knowledge within the field of AD diagnosis. 
In recent times, several of the most promising therapeutic strategies to halt AD have turn 
out to be a major failure (Marchesi, 2012; Mullane and Williams, 2013), at least in the dementia 
phases in which the clinical assays are normally conducted. One possible explanation strives in 
that treatments may not be completely useless but that they are applied to patients too late in the 
course of the disease to be able to really modify its progression. Thus, because current core AD 
diagnosis relies on common clinical scales detecting an already advanced pathology (Albert et 
al., 2011; McKhann et al., 2011), there is a great need to characterize earlier stages of AD befo-
re any symptomatology is evident by the development of more accessible and validated biomar-
kers (Sperling et al., 2011). The two main sorts of efforts in this direction are either based on 
advanced imaging (such as PET, fMRI…) or on a wider approach using genomics and/or pro-
teomics. However, none of them has yet reached daily use in clinical settings except maybe for 
the case of Florbetapir, which is a drug recently approved by the FDA for the detection of Aβ 
brain deposits using positron emission tomography (PET). Finally, there are additional impor-
tant disadvantages for the general application of these techniques: they are extremely costly and 
Figure 3.16 A molecular marker for IGF-1 resistance is increased in 4 month old APP and APP/PS1 ani-
mals. Hippocampal lysates were resolved by SDS-PAGE and immunoblotted with an antibody specific for IRS-1 
phosphorylated at serine 616, which has been found to be increased in states of insulin/IGF-1 resistance such as 
T2DM. A, both transgenic models showed increased phospho-Ser616 IRS-1 when compared to WT animals. One 
way ANOVA (n = 13 WT, 7 APP & 13 APP/PS1): F = 5.694, p<0.01; Bonferroni’s multiple comparison vs WT 
(*p<0.05). B, representative immunoblots. 
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require specific settings/instrumentation not present in most of the clinics. 
As a result, we consider there is an unmet need to better define a multidimensional risk 
assessment in preclinical AD and develop accurate prediction models so as to decide who 
should or should not receive a specific treatment and when. 
 3.3.1.  A single i.p. dose of IGF-1 directly stimulates brain electrical activity in WT  
  mice as detected by ECoG recordings. 
Subsequently, we thought of analyzing changes in brain electrical activity using an easily 
accessible technique (i.e. recordings of the electroencephalogram or EEG), which is routinely 
used in hospitals for a number of means. We based this decision on reported findings showing 
that systemically injected insulin rapidly modifies EEG patterns in humans (Tschritter et al., 
2006) and on previous data of the laboratory demonstrating that serum IGF-1 modulates neuro-
nal excitability (Nuñez et al., 2003). 
Firstly, we corroborated that systemically injected IGF-1 was able to modify the electrical 
activity of the cortex (electrocorticogram or ECoG) of anaesthetized mice. For that, we gave the 
animals a single intraperitoneal injection of IGF-1 (1µg/g in 100µl) to ensure its rapid access to 
the brain within a short time. We tested a lower dose of IGF-1 (0.4 µg/g) but it did not induce 
any effect within the first hour after injection (Fig 3.17C). We obtained the power spectrum of 
the recorded ECoG using a Fourier transform analysis and decomposed it into the main four 
frequency bands (delta, theta, alpha and beta; see Methods). Next, we calculated the contribu-
tion of each band to the global ECoG recording and its variation with respect to the baseline 
(fold change), and plotted it against time. In our experimental setting the delta wave was the 
more prominent due to anesthesia: low frequencies reflect, when abundant, a high degree of 
neuronal synchrony and a state of deep sleep. The rest of the bands accounted for less than 30-
40% of the global EEG (higher frequencies start increasing with different degrees of brain acti-
vation: REM sleep, awakeness…). 
When we compared the saline injected animals with those injected with IGF-1, it was ob-
vious the robust effect exerted by IGF-I on the ECoG. After a latency period of around 15-20 
minutes (compatible with the absorption and distribution kinetics), we observed a time-
sustained potentiation of all the three bands characteristic of an active brain (theta, alpha and 
beta waves). At the same time the delta wave slightly decreased (Fig 3.17) as theoretically ex-
pected. An easy way to explain this is that IGF-1 is somehow “awakening” the anaesthetized 
mice even though these were kept at a constant rate of isoflurane:O2 mixture inhalation throug-
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Figure 3.17 Intraperitoneally administered IGF-1 promotes a time-sustained potentiation of brain electrical 
activity in anaesthetized WT mice. We recorded the basal ECoG of WT animals under isoflurane anesthesia for 
20 min, injected them with either saline (A, n = 9) or IGF-1 (B: 1µg/g, n = 14; C: 0.4µg/g, n = 3) and continued to 
record the ECoG for one extra hour. Only the highest dose of IGF-1 (1µg/g) was able to arouse the ECoG of mice. 
These graphs show the fold change over baseline in the contribution of each frequency band (δ, delta; θ, theta; α, 
alpha; β, beta) to the global ECoG, every 5 minutes. 
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hout the experiment.  
To check for a possible mechanism by which IGF-1 may be working we pretreated anot-
her batch of animals with atropine to prevent cholinergic neurotransmission, which is known to 
regulate the sleep-wake cycle transition by promoting neuronal desynchronization (i.e. wakeful-
ness) (Steriade, 2004). Nevertheless, atropine did not abolish IGF-1 induced brain activation, 
even though it limited it (Fig 3.18). Thus, what we are probably observing in these recordings is 
mainly the result of a direct stimulatory effect of IGF-1 over cortical neurons through a mecha-
nism yet to be fully understood. 
Figure 3.18 Inhibiting cholinergic neurotransmission in vivo does not avert the activation of the electrocorti-
cogram (ECoG) by peripheral IGF-1. We pretreated isoflurane anaesthetized WT mice with atropine (n = 6), 
which is an inhibitor of muscarinic acetylcholine receptors capable of overpassing the BBB, and injected them 
with 1µg/g IGF-1. A, during the post-injection hour, we did not observe a big change in the ECoG profile when 
compared to atropine-untreated animals injected with IGF-1. B, this was especially evident for the last 20 min of 
the recording. Thus it seems that activation of the ECoG by IGF-1 is independent of acetylcholine.  
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 3.3.2.  Presymptomatic AD mice can be identified by an altered ECoG signature  
  after IGF-1 injection as compared to WT. 
Once we knew that IGF-1 did produce measurable changes within the brain electrical sig-
nature, we proceeded to evaluate how this would be affected by APP overexpression in AD 
transgenic models. Again using the APP & APP/PS1 strains, we subjected the animals to the 
same protocol as WT. In the APP model we detected only a small induction of ECoG activity 
by peripheral IGF-1 (Fig 3.19A), even less than 50% of that seen in WT for certain frequency 
bands, which perfectly correlated to what happened to them after enrichment (Fig 3.13). Accor-
Figure 3.19 IGF-1-induced activation of brain electrical activity is greatly impaired in asymptomatic AD 
mice. We performed the same ECoG test in 4 month old APP (A, n = 7) and APP/PS1 (B, n = 7) animals and dis-
covered that in the first the effect of IGF-1 on the ECoG was significantly reduced whereas in the second it was 
completely absent. 
3. Results 
90 
dingly, in the double transgenic APP/PS1 mice we could detect no significant increase in ECoG 
activity over the baseline 1 h after injection (Fig 3.19B); what was even reminiscent of the sali-
ne injected WT group (Fig 3.17A). This most likely means that IGF-1 stimulation of neuronal 
activity was abrogated, clearly reflecting above findings characterizing the early state of IGF-1 
resistance in this model (Figs 3.13 & 3.16). When we quantified and compared the cumulative 
response to IGF-1 over the 20-60 min post-injection (removing the latency period), we unveiled 
a clear tendency towards less IGF-1-induced brain activation following pathology progression 
(Fig 3.20).  
However, we cannot assess a true correlation between EE & ECoG results since these 
have been extracted from different cohorts of animals: both procedures end up in animal sacrifi-
ce and thus they cannot be performed simultaneously. Anyway, we can consider the relations-
hip between them and state that recording brain electrical activity after systemic IGF-1 injection 
is a valid non-invasive approach to determine central sensitivity to circulating IGF-1 as shown 
in Fig 3.21. 
 Even though there is plenty of evidence about insulin/IGF-1 disturbances within AD 
(some authors even call it type 3 diabetes), it may be argued against the specificity of our re-
sults in AD mice versus other humanized mouse models of neurodegenerative diseases. To rule 
Figure 3.20 Differences between WT and AD mice injected with IGF-1 are maximal within the frequency 
range of the beta wave. Average response within the 40-60 min period after injection better illustrates the changes 
in the ECoG due to IGF-1. When comparing ECoG fluctuations against individual baselines (discontinuous gray 
line) only the WT+IGF-1 group showed significant differences (paired t test vs baseline: *p<0.0.5, **p<0.01, 
***p<0.001). This resembles what would need to be done for each patient in the clinics. Because APP animals did 
show a slight non-significant activation of the theta and alpha waves, the best potential biomarker of preclinical 
AD which we identified would be the potentiation of the beta wave due to IGF-1 stimulation. 
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out this possibility we used a genetic model for Friedrich’s ataxia. This expresses a truncated 
form of human frataxin in a yeast artificial chromosome (or YAC) substituting the wild type 
form (Al-Mahdawi et al., 2006). We found an ECoG response to IGF-1 similar to that of WT 
(Fig 3.22). 
Figure 3.21 The ECoG response to IGF-1 injection is a good non-invasive approach to predict brain sensiti-
vity to IGF-1. The AUC (area under the curve) of the beta wave response to IGF-1 injection was strongly associa-
ted to the phosphorylation of IGF-1R induced by environmental enrichment (EE) in WT and AD mice, what results 
in an accurate estimation of the brain response to incoming IGF-1 from the bloodstream. 
Figure 3.22 A mouse model of Friedrich’s ataxia depicts the same response to IGF-1 than WT animals. We 
performed an additional ECoG experiment to control for the specificity of our results in AD mice. We used another 
humanized mice overexpressing a truncated form of human frataxin, YAC mice (n = 2). Their ECoG showed a 
response to IGF-1 comparable to WT and, therefore, we may claim that the diagnostic test we have developed se-
ems to be quite specific for AD. 
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On the other hand, all these experiments have been carried out in young animals whereas, 
among the general population, the elder (>65 years old) are the ones at higher risk of AD. Thus, 
we replicated the ECoG protocol in mice older than 18 months of age. We found out that even 
though aging reduces brain response to IGF-1 in WT animals (Fig 3.23) its effect is still detec-
table as opposed to APP/PS1 mice. This may resemble what happens in normal aging versus 
AD: in both there is a progressive cognitive impairment but AD patients develop an earlier on-
set and faster degradation of normal brain function. According to this hypothesis, IGF-1 dys-
function in the APP and APP/PS1 models would be but an accelerated version of the one hap-
pening during normal aging. 
Figure 3.23 ECoG signature in response to IGF-1 seems to be affected by normal aging. The activation of 
brain activity induced by peripheral IGF-1 in aged WT animals (≥ 18 month, n = 7) was decreased when compared 
to that of young WT mice (Fig. 3.17B). However it was still higher than that of APP/PS1 (Fig. 3.19B). 
3. Results 
93 
Figure 3.24 Macaque monkeys do also display a potentiation of the electroencephalogram (EEG) as a result 
of IGF-1 intravenous administration. We injected isoflurane anaesthetized macaques with either saline (n = 7) or 
IGF-1 (n = 5) through a bolus in the saphenous vein. Brain electrical activity (i.e the EEG) was transcranially 
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 recorded through scalp electrodes placed along the midline at 3 different anteroposterior coordinates (see dia-
grams): frontal (Fpz, A & D), central (Cz, B & E) and occipital (Oz, C & F). We found that the effect of IGF-1 
was regionalized towards anterior areas, being maximal in the frontal electrode. 
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3.3.3.  EEG response to IGF-1 is conserved in healthy macaques, being maximal in  
 frontal brain areas. 
A final proof-of-concept to validate our hypothesis before promoting a clinical trial in 
humans was to replicate our results in non-human primates (NHP). For this we were only able 
to assess whether IGF-1 stimulated the brain of healthy NHP as in rodents. This was because up 
to date there is no widely accepted and/or available primate model of AD. In fact, even though 
NHPs usually develop Aβ pathology with age (including plaques and cerebral amyloid angio-
pathy), they exhibit a clear resistance to tauopathy, neurodegeneration and the resulting AD de-
mentia (Heuer et al., 2012). Hence, there is intense ongoing research trying to develop toxic 
models of AD in NHPs by for example injecting Aβ-oligomers intracerebroventricullarly 
(Forny-Germano et al., 2014).  
Data on Fig 3.24 confirmed that IGF-1 was also able to activate the electroencephalogram 
(EEG) of anaesthetized macaques. Moreover, thanks to the better spatial resolution we achieved 
with these recordings, we identified a regional specificity of IGF-1-induced EEG activation. 
This was maximal in frontal areas (Fig 3.24A) and it progressively fell along the anteroposte-
rior axis until it was non-existent in occipital areas (Fig 3.24 B & C). 
Taking all previous results into account, we may conclude that we have developed an ea-
sy-to-use tool to detect impaired brain access of IGF-1. This seems to be specific for AD and is 
susceptible of further clinical validation and development. 
 
3.4.  Role of the IGF-1 system in early brain changes induced by MetS as a risk  
 factor for dementia. 
One major concern of working with transgenic animals overexpressing human AD muta-
tions such as APPswe and PSEN1dE9 is that these are only found in autosomal dominant here-
ditary forms of AD, which accounts for less than 5% of total AD cases (Goldman et al., 2011), 
being the remaining 95% sporadic. Many risk factors, either genetic (i.e. APOE4 and several 
other loci newly associated to late onset AD) or environmental, have been described for spora-
dic AD. Among the latter there are many lifestyle risk factors (i.e. obesity, smoking) and diver-
se medical conditions associated to AD (i.e. diabetes, stroke, midlife hypertension and/or hyper-
cholesterolemia) (Ballard et al., 2011). Conversely, it has been hypothesized the existence of 
several protective lifestyle habits including light to moderate alcohol intake (Anstey et al., 
2009), physical exercise (Hamer and Chida, 2009) and intellectual activity generating cognitive 
reserve (Valenzuela and Sachdev, 2006). 
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Several of the above mentioned risk factors coexist in a relatively modern endocrine di-
sorder called metabolic syndrome (MetS). This is characterized by the concurrence of obesity, 
insulin resistance (or pre-diabetes), hypertension and dyslipidaemia (Alberti et al., 2009). Its 
prevalence has been greatly increased in the last decades due to the bad dietary habits and se-
dentary lifestyle of the population and it is now a major public health concern. As it would be 
expected, it is known to increase morbidity and many studies link it with a higher risk of deve-
loping AD. However, the molecular pathophysiology underneath this link remains to be eluci-
dated.  
On the other hand, serum IGF-1 is a neurotrophic hormone intimately related to metabo-
lism and diabetes (Clemmons, 2012), and whose input to the brain we have found to be reduced 
in AD mutants. Thus, we decided to further built on previous data showing that an unhealthy 
diet reduced the entrance of exogenously IGF-1 into the CSF when injected in the periphery 
(Dietrich et al., 2007). Specifically, we aimed to unveil a potential role of circulating IGF-1 in 
brain changes caused by MetS that may predispose to AD dementia. 
3.4.1.  After 10 weeks of HFD, WT animals develop a MetS-like disorder 
We set up an experimental protocol to induce the development of MetS in C57BL/6 wild 
type mice by changing their food habits in resemblance of the human situation. Thus, when ani-
mals entered adulthood (at 8 weeks) we formed two groups: one received a control diet (10% 
kcal from fat) and the other received a high fat diet supplemented with cholesterol (HFD, 45% 
Figure 3.25. High fat diet (HFD) induces progressive weight gain in male C57BL/6 adult mice. We measured 
weekly the body weight of 2 month old WT mice exposed to a HFD for a maximum period of 10 weeks. A slight 
overweight was evident as early as 3 weeks after diet change. Repeated measures ANOVA (control n = 16, DIO n 
= 20): HFD effect (F=29.66, P<0.0001), Bonferroni’s multiple comparison vs Control: **p<0.01, ***p<0.001. 
DIO = diet-induced obese mice 
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kcal from fat plus 1.25% cholesterol). Because we hypothesized that early compensatory me-
chanisms would take place we decided to study two time points: 5 and 10 weeks. We found a 
significant weight gain of ~20% of whole body mass as a result of the HFD (Fig 3.25) as early 
as 5 weeks after dieting,  mimicking the overweight of MetS.  
Over-fed mice developed early glucose intolerance (after only 4 weeks of HFD) as eviden-
ced by their inability to manage a sudden increase in glycaemia induced by i.p. injection of glu-
cose (Fig 3.26). Conversely, systemic insulin sensitivity was maintained until 9 weeks. At this 
Figure 3.26 HFD promotes the development of early whole body glucose intolerance. After 4 and 9 weeks of 
HFD we performed the glucose tolerance test (GTT) in 6h-fasted awake animals. We injected an overload of glu-
cose intraperitoneally and measured glycaemia evolution over time. The results indicated that poor management of 
glucose was an early event in the pathogenesis of this MetS model. A, time-course of the experiment. Repeated 
measures ANOVA (control n = 12, DIO 4W n = 10, DIO 9W n = 10): HFD effect (F = 9.539, p<0.001), 
Bonferroni’s multiple comparison (*, DIO4W or #, DIO9W) vs control: */#p<0.05, **/##p<0.01, ***p<0.001). B, 
quantification of the area under the curve (AUC). One way ANOVA: F = 9.814, p<0.001; Bonferroni’s multiple 
comparison vs control: **p<0.01, ***p<0.001. DIO = diet-induced obese mice, W = week. 
Figure 3.27 There is slight whole body insulin insensitivity after 9 weeks of HFD. We did the insulin sensitivi-
ty test (ITT) in control and DIO mice by intraperitoneally injecting them with insulin and monitoring glycaemia. 
A, there is a significant delay in insulin-induced lowering of blood glucose after 9 weeks of HFD, what points out 
to peripheral insulin resistance. Repeated measures ANOVA (control = 12, DIO 4W n = 10, DIO 9W n = 10): HFD 
effect (F = 6.117, p<0.01), Bonferroni’s multiple comparison vs control (DIO 9W: #p<0.05). B, quantification of 
the AUC. One way ANOVA: F = 5.78, p<0.01; Bonferroni’s multiple comparison vs control (**p<0.01). DIO = 
diet-induced obese mice, W = week. 
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time, diet-induced obese (DIO) mice did not properly respond to i.p. insulin as compared to 
control (Fig 3.27). Here it is important to consider that the first 30 min after injection are the 
crucial ones in the ITT test (Ayala et al., 2010),  because those are the ones reflecting insulin 
sensitivity and not additional counter-regulatory mechanisms (i.e. glucagon-mediated restora-
tion of normoglycemia). Moreover, when measuring insulin levels by ELISA we detected fas-
ting hyperinsulinemia only after 10 weeks of diet (Fig 3.28). This means that even though there 
is poor glucose management, fasting normoglycemia can be maintained by normal levels of in-
sulin until 4 weeks of HFD. Nonetheless, after 10 weeks of diet, extra insulin secretion into the 
bloodstream is needed to keep blood glucose within a normal range. Hence, we can conclude 
that our experimental model is still in a pre-diabetic stage compatible with human MetS. 
Because several authors had reported central inflammation affecting cognitive status 
when exposing rodents to a HFD (Boitard et al., 2014; Dinel et al., 2011; Pistell et al., 2010), 
we determined brain levels of TNF-alpha, a canonical pro-inflammatory cytokine. By means of 
qPCR analysis of its mRNA expression, we found no changes in the cortex of DIO mice (Fig 
3.29). 
Figure 3.28 Fasting serum insulin is 
increased after 10 weeks of HFD. We 
measured the levels of insulin in the 
bloodstream by ELISA and detected a 
robust increase in them only in mice fed 
a HFD for 10 weeks as compared to 
normal fed controls. Kruskal-Wallis test 
(control n = 17, DIO 5W n = 10, DIO 
10W n = 17): KW statistic = 23.83, 
p<0.0001; Dunn’s multiple comparison 
vs control (***p<0.001). 
Figure 3.29 There is no apparent sign of 
neuroinflammation in the brains of 
DIO animals. We extracted total mRNA 
from the cortex of mice and analyzed by 
qPCR the relative quantity of TNF-alpha 
mRNA. We found that it was unchanged 
by HFD. One way ANOVA (control n = 
10, DIO 5W n = 10, DIO 10W n = 10): F 
= 0.385, p>0.05.  
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3.4.2.  MetS alters the permeability of the CSF-BBB to IGF-1 passage into the CNS 
We measured serum IGF-1 concentration by ELISA and found it also increased by 10 we-
eks of HFD paralleling the above hyperinsulinemia, albeit to a lesser extent. We observed that 
insulin blood levels augmented around 360% (Fig 3.28) whereas circulating IGF-1 levels were 
only 20% higher than controls (Fig 3.30). Besides, earlier in time there was a raising tendency 
in blood insulin that was not detectable in serum IGF-1. Another intriguing fact was that serum 
insulin and serum IGF-1 significantly correlated in the control group; however, this physiologi-
cal relationship was lost in DIO animals after 10 weeks of diet when both were abnormally 
high. 
 
 
Subsequently, we analyzed potential changes in brain IGF-1 (both in brain parenchyma 
and in cerebrospinal fluid, CSF).  Previous data indicate a relationship between serum and brain 
IGF-I (Carro et al., 2000, 2005; Muller et al., 2012; Nishijima et al., 2010). Surprisingly, we 
observed that brain IGF-1 did not change according to its plasma oscillations but showed a 
completely distinct pattern. First, we observed a transient increase in IGF-1 levels in the CSF 
after only 5 weeks of HFD that was lost when the imbalanced diet prolonged in time (Fig 
3.31A). When calculating the ratio of CSF to serum IGF-1 concentration, which we used as an 
indirect measure of blood-to-CSF transport of IGF-1, we could detect a matching increase in 
IGF-1 transport selectively at this early time point (Fig 3.31B). 
On the contrary, when analyzing IGF-1 in brain parenchyma, specifically in cortex, there 
were no significant changes compared to controls (Fig 3.32A&B). This also correlated with 
unaffected local synthesis as determined by qPCR (Fig 3.32C). These findings suggest that cir-
culating IGF-1 is coming into the brain in response to HFD through the choroid plexus/CSF and 
not through the microvasculature. 
Figure 3.30 In DIO animals, an in-
crease in serum IGF-1 paralleled that 
of insulin. We determined IGF-1 levels 
in the blood of mice by ELISA and ob-
served a small but significant increase in 
DIO mice at 10 weeks of diet. One way 
ANOVA (control n = 22, DIO 5W n = 
10, DIO 10W n =18): F = 13.2, 
p<0.0001; Bonferroni’s multiple compa-
rison vs control (***p<0.001). 
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Figure 3.31 An increase in CSF IGF-1 levels precedes the rise in serum IGF-1 in HFD-fed mice. We extracted 
CSF from control and DIO animals and measured IGF-1 by ELISA. A, there was a significant increase in IGF-1 
levels in the CSF after 5 weeks of HFD that is lost afterwards. One way ANOVA (control n = 16, DIO 5W n = 10, 
DIO 10W, n = 11): F = 5.732, p<0.01; Bonferroni’s multiple comparison vs control (**p<0.01). B, the ratio of 
CSF over serum IGF-1 concentration is selectively increased by 5 weeks of HFD, what suggests an increase in its 
transport through the choroid plexus at this time point. One way ANOVA One way ANOVA (control n = 10, DIO 
5W n = 10, DIO 10W, n = 10): F = 7.118, p<0.01; Bonferroni’s multiple comparison vs control (**p<0.01). 
Figure 3.32 Brain levels of IGF-1 remain unaffected by HFD. We also measured the levels of IGF-1 in brain 
parenchyma. A, we discovered that these were similar between DIO and controls. Kruskal-Wallis test (control n = 
12, DIO 5W n = 10, DIO 10W, n = 10): KW statistic = 3.202, p>0.05. B, the transport of IGF-1 into the brain was 
normal. Kruskal-Wallis test (control n = 12, DIO 5W n = 10, DIO 10W, n = 10): KW statistic = 1.342, p>0.05. C, 
local IGF-1 synthesis was the same in DIO animals relative to controls as evaluated by qPCR. One way ANOVA 
(control n = 10, DIO 5W n = 10, DIO 10W, n = 10): F = 0.217, p>0.05. 
3. Results 
101 
3.4.3.  IGF-1 brain signaling seems to be enhanced in DIO animals 
Our next step was to test whether this increase in CSF IGF-1 at 5 weeks of diet would 
impact on the brain. Thus, we immunoprecipitated hippocampal lysates with an antibody 
against total IGF-1R and analyze its activity by calculating the phospho-IGF-1R/IGF-1R ratio 
by western blot. To our surprise, the data showed a tendency towards progressive receptor acti-
vation (Fig 3.33A) and a significant increase in IRS-1 recruitment to the active receptor after 10 
weeks of unhealthy diet (Fig 3.33B). 
Conversely, at 5 weeks of HFD we detected a decrease in IRS-1 phosphorylation in seri-
ne 616 (Fig 3.34A) paralleling the increased entrance of IGF-1 into the CSF. This phosphoryla-
tion has been classically used as a molecular marker of resistance of the insulin/IGF-1 signaling 
(IIS) pathway (Boura-Halfon and Zick, 2009; Zick, 2005). Thus, when decreased, it would me-
an that the pathway has become hypersensitive as a result of lesser negative feedback, possibly 
implying that IGF-1 signal is prolonged in time. Implications of these findings of IIS in DIO 
mice remains to be further explored and replicated and are discussed further on.  
Figure 3.33 Hippocampal IGF-1R signaling appears to be more active in DIO mice after 10 weeks of diet. 
We immunoprecipitated hippocampal lysates with anti-IGF-1R antibody and determined by western blot the 
amount of: A, phosphorylated IGF-1R (active) vs total IGF-1R. One way ANOVA (control n = 11, DIO 5W n = 
10, DIO 10W, n = 10): F = 2.388, p = 0.1103; B, IRS-1 bound to IGF-1R (recruited and so active) vs total IGF-1R. 
Kruskal-Wallis test (control n = 11, DIO 5W n = 10, DIO 10W, n = 10): KW statistic = 7.52, p<0.05. Dunn’s mul-
titple comparison vs control (*p<0.05). Representative immunoblots are shown on the right: D = DIO, diet-induced 
obese mice. 
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3.4.4.  HFD disrupts several molecular markers of neuronal function including  
 mitochondrial dynamics, tau hyperphosphorylation, dendritic structure and spine density. 
Finally we wanted to ascertain the level of brain damage unleashed by HFD, making 
emphasis on potential elements related to dementia (i.e. molecular markers of neuronal dys-
function). In a first approach, we focused on one of the pathogenic events of AD: tau hyperp-
hosphorylation. However, there are confounding reports as to whether HFD promote it or not 
(Bhat and Thirumangalakudi, 2013; Calvo-Ochoa et al., 2014; Leboucher et al., 2013; Sharma 
et al., 2008). As observed in Fig 3.35A our diet did induce abnormal phosphorylation of tau in 
a residue related to AD dementia (i.e. serine 262) that has been directly identified in brain ex-
tracts from AD patients (Hanger et al., 2009). Total murine tau levels remained normal (Fig 
3.35B). As previously shown by others (Planel et al., 2007a, 2007b), one plausible explanation 
for the abnormal phosphorylation of tau was the light hypothermia induced by HFD (Table 
3.1), which may relate to the above noted insulin dysfunction (Fig 3.27 & 3.34). 
Figure 3.34 Brain hypersensitivity to IGF-1 signaling occurs early and transiently in DIO mice. We measu-
red by western blot the degree at which IRS-1 was phosphorylated specifically at serine 616, a classical molecular 
marker of insulin/IGF-1 resistance. A, we found a decrease in this marker after 5 weeks of HFD. Kruskal-Wallis 
test (control n = 12, DIO 5W n = 10, DIO 10W, n = 10): KW statistic = 10.59, p<0.01; Dunn’s multiple compari-
son vs control (*p<0.05). B, total IRS-1 levels were similar in all the groups. One way ANOVA (control n = 12, 
DIO 5W n = 10, DIO 10W, n = 10): F = 0.408, p>0.05. Representative immunoblots are shown on the right: D = 
DIO, diet-induced obese mice. 
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Figure 3.35 Aberrant tau phosphorylation occurs in the brain after 10 weeks of HFD. We analyzed cortical 
lysates by western blot and discovered that an abnormal phosphorylation of tau is increased in DIO animals fed a 
HFD for 10 weeks (A). One way ANOVA (control n = 11, DIO 5W n = 10, DIO 10W, n = 10): F = 5.645, p<0.01; 
Bonferroni’s multiple comparison vs control (*p<0.05). B, tau levels were normal in DIO animals. One way ANO-
VA (control n = 6, DIO 5W n = 7, DIO 10W, n = 6): F = 0.1506, p>0.05. 
Table 1. Temperature of control animals and 
DIO mice exposed to a HFD for 10W. Paired t test 
vs control: *p<0.05. 
Figure 3.36 HFD unbalances mitochondrial dynamics in the brain of DIO mice. We calculated the ratio bet-
ween cortical levels of mitofusin 2 (MFN-2), a protein related to mitochondria fusion, and Fis1, which is involved 
in the inverse process (i.e. fission). With this preliminary data we detected an excess of mitochondria fragmenta-
tion (hyperfission, A). Kruskal-Wallis test (control n = 10, DIO 5W n = 6, DIO 10W, n = 7): KW statistic = 8.57, 
p<0.05; Dunn’s multiple comparison vs control (*p<0.05). B, representative immunoblots are shown  
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Other very important marker of neuronal dysfunction is mitochondrial dynamics, which 
establishes the balance between the fission and fusion of these complex organelles (Cerveny et 
al., 2007). The first relates to mitochondria destruction (mitophagy) as a result of received da-
mage, and the second is aimed to increase mitochondrial function to optimize neuronal activity 
due to specific requirements. In our MetS model we found a significant imbalance towards an 
increased fission of mitochondria (Fig 3.36), possibly unveiling the increased oxidative damage 
produced by HFD in the brain. However, this remains to be analyzed in greater detail. 
As a result of the observed hyperphosphorylated tau and mitochondrial hyperfission, which 
would very possibly disrupt neuronal function, we decided to look into potential morphological 
alterations within hippocampal neurons that may involve a predisposition to dementia. We did 
Figure 3.37 3D reconstruction of hippocampal neurons for the study of the dendritic arbour and its spines. 
The upper panel depicts the fluorescent immunostaining of 200 µm-thick coronal sections of the hippocampus sho-
wing neurons injected with Lucifer-yellow under low magnification. High-magnification photographs for the ana-
lyzed regions CA1 and DG are placed below. 
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so by intracellularly injecting the fluorescent dye Lucifer-yellow in the dentate gyrus (DG) and 
Cornu Ammonis 1 and 3 (CA1 and CA3) regions of the hippocampus, followed by 3D recons-
truction and morphological analysis with Neurolucida software (Fig 3.37) (Elston et al., 2001; 
Suárez et al., 2014). In the DG of animals exposed to 10 weeks of HFD we observed that basal 
dendrites (nearer to cell soma) were larger and more complex (with a higher number of bifurca-
tions), whereas spine density was increased throughout the dendritic arbour (Fig 3.38 & 
3.40A). Similarly, in the CA1 region, dendrites seemed to be larger, more complex and displa-
yed a significant increase in spine density specifically within the stratum radiatum (Fig 3.39 & 
3.40B). Nevertheless, further experiments need to be conducted in order to determine the elec-
trophysiological and behavioural implications of these findings and whether this is related to 
IGF-1 fluctuations in DIO animals. 
Figure 3.38 Dendrites nearer cell soma become larger and more complex in neurons of the dentate gyrus 
(DG) after 10 weeks of HFD. The Sholl analysis of the dendritic arbour confirmed that the size of somas and the 
total length of dendrites of DG neurons were not affected by HFD (A & B). However, it also unveiled that the 
length and number of nodes of the dendrites near the cell body are significantly higher in DIO animals (C & E), 
even though the number of intersections only displayed a tendency (D). Length: two-way ANOVA (HFD effect: F 
= 6.994, p<0.01). Nodes: two-way ANOVA (HFD effect: F = 3.937, p<0.05). Bonferroni multiple comparison vs 
control (*p<0.05, **p<0.01). The image represents a DG neuron injected with Lucifer-yellow after DAB immu-
nostaining for the 3D reconstruction and posterior analysis. Animals used: control, n = 10; HFD, n = 8. 
Figure 3.39 Dendrites of the CA1 region exhibit a slight tendency towards higher length and complexity in 
DIO mice. Soma area and total length of dendrites of CA1 neurons were similar to controls (A & B). We observed 
a non-significant increase in the length and intersections of the dendrites in the stratum oriens and stratum radia-
tum in DIO mice (C & D). Interestingly, the number of nodes did only change in the stratum radiatum (E2). The 
image represents a CA1 neuron injected with Lucifer-yellow after DAB immunostaining for the 3D reconstruction 
and posterior analysis. Animals used: control, n = 10; HFD, n = 8. 
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Figure 3.40 HFD promotes an increase of spine density both in the DG and CA1 regions of the hippocampus 
of DIO mice. We counted the number of spines in the DAB immunostained sections for Lucifer-yellow 
(representative images shown: up, control; bottom, HFD). We found that the average density of spines was increa-
sed in the DG (A1) and in the stratum radiatum of CA1 (B1). Mann-Whitney test vs control (*p<0.05, **p<0.01). 
Besides, Sholl analysis also revealed that this happened in both at more than 45 µm of distance from the soma (A2 
& B3). Two-way ANOVA for DG (HFD effect: F = 8.275, p<0.01). Two-way ANOVA for stratum radiatum (HFD 
effect: F = 8.501, p<0.01), Bonferroni’s multiple comparison vs control (*p<0.05). Animals used: control, n = 10; 
HFD, n = 8. 
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  4.1.  Physiological characterization of the entrance of peripheral IGF-1 into the 
 brain 
Environmental enrichment and IGF-1 input to the brain 
When characterizing how circulating IGF-1 enters the CNS due to environmental enrich-
ment (EE) we first corroborated that EE indeed promoted IGF-1 input into the brain of WT mi-
ce (Nishijima et al., 2010). To this regard, we replicated the increased phosphorylation of IGF-
1R after 2h of EE which was not detected earlier and which may be considered an indirect mea-
sure (a surrogate) of the entrance of serum IGF-1 into the hippocampus. However, we were 
unable to find any increase in hippocampal IGF-1 levels by ELISA after EE, what finally clari-
fies the non-significant tendency which had been previously reported (Nishijima et al., 2010).  
When the same experiment was carried out in LID mice (with 90% less circulating IGF-
1) we provided additional evidence that it is indeed peripheral IGF-1 the responsible for activa-
ting its receptor in the hippocampus after acute EE. These animals didn’t display any increase 
in phospho-IGF-1R, what matches the lack of exercise-induced neurogenesis seen in LID ani-
mals (Trejo et al., 2001) and the lack of EE-dependent recovery from spinal cord injury in ani-
mals treated with a blocking anti-IGF-1 antiserum (Koopmans et al., 2006). 
In fact, when comparing 2h enriched LID mice to those standard-housed (control), there 
was a significant decrease in phospho-IGF-1R, that is, a dephosphorylation of IGF-1R. Thus, 
the absence of IGF-1 brain input in LID animals revealed the existence of additional underlying 
mechanisms triggered by EE that limits the EE-evoked IGF-1 signaling in WT. One of these 
might be the activation of IGF-1R phosphatases secondary to the stimulation of insulin (Dadke 
et al., 2001) or other growth factor pathways, such as BDNF/NGF which are known to be acti-
vated by EE (Alwis and Rajan, 2014; Hu et al., 2013b; van Praag et al., 2000) and IGF-1 itself 
(Trejo et al., 2007). Nonetheless, this would need to be further tested by, for instance, looking 
into PTP1B and SHP2 activities (the only known phosphatases for IGF-1R) (Buckley et al., 
2002; Hanke and Mann, 2009; Rocchi et al., 1996) after EE both in WT animals and in models 
for reduced BDNF/NGF/insulin brain signaling, while at the same time monitoring IGF-1R 
phosphorylation. 
On the other hand, WT animals exposed to EE for times greater than 2h displayed com-
plex time-dependent fluctuations supportive of that interpretation. Specifically after 6h of en-
richment phospho-IGF-1R was similar to controls, whereas after 24h it became increased again. 
A possible explanation may be that the above referred mechanisms which oppose to prolonged 
IGF-1R activation (manifest at 6h in WT and at 2h in LID animals) would be overran by a 
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constant entrance of serum IGF-1. Indeed, this seems to be happening given that, after 24h of 
enrichment, IGF-1 levels in the hippocampus were fully recovered from the drop at 6h of EE. 
Moreover, IGF-1 would accumulate in the long term as evidenced by the slight increase of hip-
pocampal IGF-1 after one month of EE. We knew it to be IGF-1 from the blood because its 
mRNA remained unchanged at both 24h and one month. 
Nevertheless, after chronic enrichment for one month, a tolerance response settled so that 
even though the animals presented slightly more hippocampal IGF-1, there was no change in its 
signaling through IGF-1R. This seems to be contrary to published data reporting an increase in 
pAkt/Akt ratio in the brain of chronically enriched mice (Hu et al., 2013b). Yet, this mismatch 
could be explained by the activation of several other Akt-converging pathways stimulated by 
long-term EE (i.e. BDNF/TrkB or NGF/TrkA), and which might be potentially dependable on 
the early EE-evoked IGF-1 signaling. Besides, these authors didn’t find an increase in local pro-
duction of IGF-1 in WT animals and neither did us. 
As for IGF-1 itself, our results suggest that after crossing the blood-brain barrier (BBB), it 
would interact with its receptor in the hippocampus, activate it, be internalized with it and fina-
lly be degraded by lysosomal proteases (Brisson and Barton, 2013; Hede et al., 2012) without 
further chance to accumulate inside brain parenchyma in the short-term. This idea is reinforced 
by the decrease in hippocampal IGF-1 found after 6h of EE, which may respond to either an 
increase in its degradation (e.g. by secreted peptidases), a decrease in its local synthesis or a 
combination of both. Additional experiments are required to establish the exact mechanism. Ne-
vertheless, at longer times of EE IGF-1 kept on entering the brain, as above mentioned, and 
even accumulated in the hippocampus. 
Similarly, mice exercised for one month displayed an increase in hippocampal and corti-
cal IGF-1 (unpublished results from our laboratory), and rats running in a treadmill 1 h/day for 
15 days showed a tendency towards increased IGF-1 in the CSF (Trejo et al., 2001) , both mat-
ching our results. A possible flaw of this comparison with exercise lies in the limited exercise 
component in our EE protocol due to the absence of a running wheel. Nonetheless, our EE still 
involves more physical activity than the standard-housed controls and at the same time poten-
tiates the cognitive element. To this regard it has been argued that the mechanisms by which EE 
improves brain function are different depending on the presence or absence of exercise. As a 
matter of fact, exercise was shown to improve hippocampal-dependent memory in rats by pro-
moting BDNF upregulation and neurogenesis in the DG, whereas 3 weeks of EE with no exer-
cise did also improve hippocampal-dependent memory but through distinct mechanisms 
(Bechara and Kelly, 2013).  
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Moreover, other authors have found that IGF-1 mediates the beneficial effects of EE on 
visual cortex development (Ciucci et al., 2007; Landi et al., 2009) and its plasticity in the adult 
(Maya-Vetencourt et al., 2012). The last reports that, after monocular deprivation, mice enri-
ched for 2 weeks displayed a transient increase in IGF-1 mRNA that was essential for the plas-
ticity induced by EE in the adult visual cortex. This does not oppose to the normal IGF-1 synt-
hesis we have observed after one month of EE, because they claim that after brain injury the 
enriched brains synthesized more IGF-1 than the non-enriched. They did not compare the level 
of IGF-1 expression in naïve controls vs enriched as was our case. 
More recently, it has been described that after an enriched housing of around 3-4 weeks, 
hippocampal IGF-1 levels increased in sham rats and so did the phospho-IGF-1R/IGF-1R and 
phospho-Akt/Akt ratios (Wadowska et al., 2014). However, for measuring phospho-IGF-1R by 
western blot this study used an antibody that cross-reacts with the phosphorylated insulin recep-
tor (IR), thus making it difficult to interpret the specificity of their results. Nevertheless, it is 
interesting that we observed a similar increase of hippocampal IGF-1 but not of pIGF-1R. This 
may respond to the combination of a more stimulating EE protocol (including everyday change 
of objects plus 30 min of open field cognitive stimulation) and the behavioral training (water 
maze) performed just before sacrifice, which is known to induce IR phosphorylation (Zhao et 
al., 1999). As a result, their animals are not naive and so their experimental results are not enti-
rely comparable with ours. Anyway, these findings add to the body of evidence reinforcing the 
important role of IGF-1 in EE.    
Taking all these into account, we propose that the early brain input of circulating IGF-1 is 
one of the key mechanisms through which EE induces brain plasticity and the subsequent cog-
nitive reserve (i.e. brain resilience against disease) (Petrosini et al., 2009; Stern, 2002). A plau-
sible experiment to test this hypothesis would be to infect the cerebrovascular tree and/or the 
choroid plexus with a lentivirus transfecting a dominant negative mutant of the IGF-1R (via in-
tracarotid and/or intracerebroventricular injection) so as to block the entrance of peripheral IGF
-1 into brain parenchyma or CSF. Then, the animals would undergo acute or chronic EE and 
postmortem analysis of molecular, morphological and/or behavioral correlates of EE (Alwis 
and Rajan, 2014) to finally determine the role of peripheral IGF-1 in EE effects. 
IGF-1 auto-regulation of IGF-1 system in the brain 
Because of the complex dynamics regulating brain IGF-1 system after the entrance of cir-
culating IGF-1, we decided to study the relationship between peripheral and central IGF-1 in 
more detail. For that we used an in vitro assay in which exogenous IGF-1 administration to the 
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culture media simulated peripheral IGF-1 input to the brain. 
Previous reports in the literature have thoroughly described that IGF-1 is able to downre-
gulate IGF-1R transcriptional expression in several cell types of the body outside the CNS 
(Hernandez-Sanchez et al., 1997; Rosenfeld and Dollar, 1982; Rosenfeld and Hintz, 1980). Be-
sides, IGF-1 has been observed to induce its own gene expression in chondrocytes (Nixon et al., 
2001) and more recently that IGF-1R activation is also able to auto-induce IGF-1R expression 
in breast cancer cells (Sarfstein et al., 2012), whereas insulin repressed it. We found that IGF-1 
downregulates IGF-1R in neurons, brain endothelial cells, microglia and astrocytes mostly in-
dependent of treatment duration, matching former results in other cell types outside the nervous 
system. It also coincides with recent experiments done in adrenal chromaffin cells in which a 
24h treatment with IGF-1 reduced IGF-1R levels through a mechanism dependent on mTOR 
activation and GSK3β inhibition (Nemoto et al., 2010).  
Surprisingly, we detected that IGF-1 reduced its own expression in some of the assayed 
cells, contrary to its self-stimulating effect in IGF-1 treated chondrocytes (Nixon et al., 2001). 
Specifically, it did so in neurons and brain endothelial cells (BECs) at all times, and also in as-
trocytes but only at 6h. After 30h, these cells developed a compensatory increase in IGF-1 ex-
pression. This may be the reason why, in the whole tissue lysate, we did not observe any change 
in hippocampal Igf1 expression after 24h or one month of EE. Nevertheless, in vitro primary 
cells are cultured perinatally and are still in a developmental phase. Thus, this makes it difficult 
to compare them to the in vivo situation given that CNS cells greatly reduce IGF-1 expression 
in adulthood (Bondy and Lee, 1993). A plausible outcome from these experiments is that, when 
acutely stimulating brain cells, peripheral IGF-1 suppresses its own synthesis in some of them 
(neurons, astrocytes and BECs) but not in others (microglia). This would be reinforced by the 
notion that BECs are constantly exposed to blood IGF-1 and thus bears the lowest constitutive 
expression of Igf1 among the studied cells. Therefore, the decrease in hippocampal IGF-1 levels 
after 6h of EE might then be, at least in part, due to a reduction in its synthesis. 
Consequently, it is important to note that if IGF-1-induced IGF-1R downregulation is wi-
despread in the organism, this should be considered for its pharmacotherapy. To this regard, a 
12 year follow-up study of IGF-1 treated IGF-1 deficient children, with impaired body growth, 
showed that IGF-1 was indeed effective for some time, but not until the end of the trial. The 
mean height velocity after IGF-1 treatment was superior to the pretreatment period for 8 years, 
but it was maximal during the first and it progressively decreased during the subsequent years 
of treatment (Chernausek et al., 2007). Besides, it has been suggested that IGF-1 supplementa-
tion in IGF-1 deficiencies is useful to restore IGF-1 levels within a normal range, but when it 
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comes to use it in other conditions without this deficiency (i.e. amyotrophic lateral sclerosis) 
results are not that promising (Puche and Castilla-Cortázar, 2012). This may respond to a hy-
pothetical early desensitization of IGF-1R over a certain threshold of IGF-1. Such desensitiza-
tion has already been observed at least in vitro for L6 myoblasts treated with insulin for 24h, in 
which both the PI3K/Akt and the p42/p44 MAPK pathways were resistant to a second round of 
stimulation (Pirola et al., 2003). Accordingly, it is well known that chronic hyperinsulinemia 
leads to insulin resistance as part of the natural history of T2DM. Further evidence supporting 
this interpretation is that IGF-1 treatment has never been directly related to oncogenesis (Puche 
and Castilla-Cortázar, 2012), what might be in part due to this strong auto-regulation. 
GSK3β and IGF-1 cellular uptake 
Internalization assays performed on primary astrocytes, neurons and BECs identified 
GSK3β, a downstream component of the IGF-1 signaling pathway, as a major responsible for 
IGF-1 uptake. Similarly to what happens in choroid plexus cells (Bolós et al., 2010), inhibition 
of GSK3β (using the NP12 molecule from Noscira) led to massive intracellular accumulation of 
IGF-1. This evidences the general nature of this mechanism for the regulation of IGF-1 uptake, 
at least within the CNS. Because GSK3β is a constitutively active protein, it probably configu-
res a key step limiting brain access of peripheral IGF-1 in homeostasis. An additional experi-
ment to further confirm this in vivo would be to measure IGF-1 levels in the brain and CSF of 
transgenic mice overexpressing GSK3β (Lucas et al., 2001), which should be decreased as 
compared to WT.  
Conversely, active IGF-1R inhibits GSK3β through canonical activation of Akt (Bondy 
and Cheng, 2004; Welsh and Proud, 1993) and thus IGF-1 might reinforce its own brain uptake 
once initiated. However, when using a PI3K inhibitor (LY294002) we observed no change in 
IGF-1 uptake. This may be explained by the low basal activity of the Akt pathway in unstimula-
ted cells. Thus, to clarify this it would be useful to transfect cells with a constitutively active 
form of Akt (Dávila and Torres-Aleman, 2008) and check whether that makes them prone to 
accumulate IGF-1.  
Furthermore, it has just been reported that active GSK3β upregulates IGF-1R through 
transactivation of FOXO1/3/4 in hepatoma cells (Huo et al., 2014). The same effect was repli-
cated under serum starvation or Akt inhibitory conditions and blunted with GSK3β inhibition. 
Hence, this may explain the mechanism by which IGF-1 in vitro treatment greatly reduced IGF-
1R expression.  To confirm this, it should be assayed whether the inhibition of GSK3β by NP12 
treatment downregulates IGF-1R. If true, it may oppose to the GSK3β-derived increase in IGF-
1 uptake in the long term, given that IGF-1 uptake is fully dependent on its interaction with IGF
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-1R (Nishijima et al., 2010). Eventually, this would prove that IGF-1 does not reinforce its 
brain uptake but actually limits it to a phasic entrance and not a tonic one, as in a classical feed-
back mechanism. This matches the timeline of hippocampal IGF-1 signaling after EE and is 
contrary to what has been hypothesized for the choroid plexus-CSF interface. 
4.2.  In asymptomatic stages, AD pathology features a prominent reduction of serum 
 IGF-1 access to the brain  
 Our preliminary in vitro experiments on BBB cells showed that Aβ interfered with IGF-1 
internalization in a dose-dependent manner. However it did so in opposite directions when com-
paring BECs (blood to brain barrier) to choroid plexus cells (blood to CSF barrier). In the first 
case, Aβ treatment reduced IGF-1 uptake. This is compatible with the inhibitory effect of solu-
ble Aβ oligomers over IGF-1/insulin signaling described in neurons (Zhao et al., 2008), even 
though these only impaired IR (and not IGF-1R) autophosphorylation. More recently, it has be-
en reported that soluble Aβ oligomers (either synthetic or contained in soluble fractions of 
brains from transgenic PS1/APP mice) also block IGF-1/IGF-1R signaling (Jimenez et al., 
2011). Contrarily, in choroid plexus cells, Aβ treatment increased IGF-1 internalization. Con-
versely, it may be extrapolated that the lower Aβ levels in the CSF, the lower IGF-1 entrance 
through the choroid plexus. This apparent contradiction might be explained as follows: Aβ is 
known to increase and aggregate in brain parenchyma, which is in direct contact with brain mi-
crovasculature, whereas it disappears from the CSF (Blennow et al., 2010). Besides, it is known 
that IGF-1 promotes Aβ clearance from the CSF through a mechanism involving megalin at the 
choroid plexus (Carro et al., 2002, 2005), what is complementary to our findings. As a result, 
IGF-1 access through both brain gates would be decreased in AD pathology. Other possible in-
terpretation is that Aβ might be regulating serum IGF-1 entrance to the CSF in homeostasis. 
When assessing this possibility, we observed that IGF-1 levels were diminished in the 
CSF of both AD mice (APP & APP/PS1) and AD patients. Furthermore, we saw that serum 
IGF-1 was increased in AD patients agreeing with previous reports (Johansson et al., 2013), 
while normal aging is actually characterized by a decrease in circulating IGF-1 levels (Xu and 
Sonntag, 1996). It has just been discovered in a longitudinal study including 3582 subjects that 
people within the lowest quartile of serum IGF-1 were predisposed to develop AD dementia 
with a 51% more risk than the rest during a follow-up period of 7.5 years (Westwood et al., 
2014). Complementarily, those with higher serum IGF-1 had bigger brain volumes, what is sug-
gestive of better resilience against brain insults (i.e. more cognitive/brain reserve). On the con-
trary, a family-based study much smaller than the previous (406 offspring) detected a slight re-
lationship between higher serum IGF-1 in midlife and increased risk of AD independently of 
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APOE genotype (van Exel et al., 2014). Hence, it is still uncertain as whether serum IGF-1 
might be usable as a biomarker for AD. 
 The fact that serum IGF-1 was increased in demented patients but not in AD mice could 
be because these last mimic an early presymptomatic stage. Actually, at the age of 4 months in 
which we used them they did not yet display obvious cognitive impairment, even in the presen-
ce of abundant Aβ plaques (i.e. in APP/PS1). Nonetheless, the IGF-1 CSF:blood ratio (an indi-
rect index of IGF-1 transport across the BBB) was decreased in both animals and patients, con-
firming a decrement of IGF-1 neurotrophic support in AD. A likewise altered ratio has been 
reported in a different cohort of AD patients and MCI-to-AD converters but not in those with 
stable MCI (Johansson et al., 2013). Therefore, this suggests that the reduced IGF-1 transport 
into the CSF may not be an early event in the human disease or that stable MCI would not be a 
prodromal stage of AD. However, this study excluded patients with T2DM, therefore underesti-
mating the impact of its high comorbidity in late onset AD (Janson et al., 2004; Nicolls, 2004) 
on IGF-1 brain transport. Conversely, it may be added that even when omitting T2DM contri-
bution to sporadic AD  pathology (Biessels et al., 2006) there was a genuine decrease in IGF-1 
brain uptake in AD demented patients. As a conclusion, more research is needed to thoroughly 
describe brain/CSF IGF-1 levels in preclinical and prodromal stages of AD. 
Altogether, these findings reflect a state of IGF-1 resistance in AD patients because despi-
te the increase in serum IGF-1 there is either no change or a decrease in CSF IGF-1. Supporting 
this notion it has been observed that the temporal cortex of AD patients contains decreased 
IGFBP2 and increased IGF-1R protein levels, what was replicated in old AD mice (Moloney et 
al., 2010). This was specially true for Aβ plaques surroundings, albeit IGF-1R was aberrantly 
distributed within NFTs containing neurons. These authors did also report higher serine phosp-
horylated (inactivated) IRS-1 in AD cortex and at the same time lower total IRS-1/2, suggestive 
of brain resistance to IGF-1/insulin action. Direct evidence of this resistance was indeed obser-
ved in the disrupted IGF-1R signaling found in post-mortem AD brains stimulated with either 
insulin or IGF-1 as compared to healthy controls (Talbot et al., 2012). Coincidentally, the latter 
did not show any increase in total IGF-1R, what agrees with our own results in APP and APP/
PS1 animals. Similarly, APP/PS1 brain slices were found to be resistant to ex vivo IGF-1 stimu-
lation by showing reduced phospho-IGF-1R and pAkt responses (Zhang et al., 2013). Resistan-
ce was already observed at the youngest age assayed, which was 6 months. In this case, the aut-
hors reported an increased expression of IGF-1R in hippocampal but not in cerebral cortical sli-
ces. It should be noted that up to date it is not clearly established whether total IGF-1R in AD 
brains is either increased, unchanged or even decreased as was described some years ago (Steen 
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et al., 2005). Nevertheless, our animals did replicate the increase in phospho-Ser616 IRS-1 detec-
ted by Talbot and colleagues in the hippocampal formation of AD cases, which is commonly 
used as a biomarker of IGF-1/insulin resistance (Fröjdö et al., 2009; Sun and Liu, 2009). 
Surprisingly, in the past years and out of experiments in animal models of AD it has been 
proposed that reduction of IGF-1 brain signaling (and so IGF-1 resistance) may be protective 
against Aβ accumulation and toxicity (Cohen et al., 2009; Freude et al., 2009; Killick et al., 
2009). These studies were based on genetic manipulations within the IGF-1 signaling pathway 
including 50% downregulation of IGF-1R (Cohen et al., 2009), its complete removal from neu-
rons (Freude et al., 2009) or deletion of IRS-2 (Freude et al., 2009; Killick et al., 2009). They 
described an improvement of overall AD phenotype characterized by better performance in the 
Morris water maze, reduced gliosis, protection against neuronal/synaptic loss and reduced Aβ 
accumulation. At the same time some of them contained confounding results showing increased 
Aβ plaques or increased phospho-tau immunoreactivity. It is interesting to acknowledge that 
none of them have directly addressed an in vivo reversible inhibition of IGF-1R activity by for 
example using one of the several available specific pharmacological inhibitors. If there is inde-
ed an adaptive response decreasing IGF-1 signaling in the brain to protect it from AD, it should 
be evident in AD mouse models early treated with these inhibitors. To my knowledge, that ex-
periment is still missing and thus this claim is still weakly supported , despite preliminary re-
sults on nematodes overexpressing APP (El-Ami et al., 2014). On the contrary, IGF-1 treatment 
of similar AD mice has been reported to effectively recover cognitive dysfunction and several 
molecular markers of AD pathology (e.g. total amyloid burden, neuroinflammation) (Carro et 
al., 2006a; Fernandez et al., 2012). More recently it has been demonstrated that gene-therapy 
approaches delivering either IGF-1 or IGF-2 in the hippocampus of APP mice through adeno-
associated viral infection greatly reversed their memory and synaptic deficits (Pascual‐Lucas et 
al., 2014). Besides, when instead of downregulating or removing IGF-1R in the brain we ex-
pressed a dominant negative form of IGF-1R (binding IGF-1 but not eliciting downstream sig-
naling) in the choroid plexus, an AD-like syndrome developed including Aβ accumulation, tau 
hyperphosphorylation and neuroinflammation (Carro et al., 2006b). Besides, a microRNA upre-
gulated in mouse models of AD and promoting Aβ overproduction has been found to target IGF
-1 mRNA (Hu et al., 2013a). One possible reconciling explanation for this opposite streams lies 
in the fact that empty IGF-1R has per se a signaling role related to apoptosis (Boucher et al., 
2010), which is totally independent of IGF-1 signaling.  
Anyway, in this project we were not interested in the etiology of this resistance but in ex-
ploiting it to develop a method through which AD could be detected earlier than it is currently 
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done. We confirmed the existence of IGF-1 resistance in AD mice by subjecting them to acute 
EE, above shown to activate IGF-1R in the hippocampus. Both AD mouse strains depicted eit-
her no IGF-1R response at all or a significantly reduced hippocampal phospho-IGF-1R/total 
IGF-1R ratio. This agrees with a resistant state to IGF-I in AD (Talbot et al., 2012; Zhang et al., 
2013) and also with recent reports showing an increase in pAkt/Akt only in WT animals and not 
in APP/PS1 after chronic EE (Hu et al., 2013b). In the latter there was an increase in IGF-1 
mRNA in enriched APP/PS1 but not in WT, what matches our data of enriched WT not sho-
wing increased IGF-1 expression. Nonetheless, they did not measure if this change in mRNA 
translated in an actual increase in local IGF-1 protein levels. If so, this may mean that because 
APP/PS1 were unable to import IGF-1 from the blood during EE, central IGF-1 expression 
would not be chronically repressed by incoming peripheral IGF-1 as in WT (see IGF-1 auto-
regulation in vitro experiments).  
To sum up, brain IGF-1 resistance in AD mice prevented circulating IGF-1 from entering 
the CNS in response to neuronal activity as in WT (Nishijima et al., 2010), what we denominate 
“neurotrophic uncoupling in AD” . We believe that the early disruption in activity-dependent 
entrance of serum IGF-I into the brain of AD mice supports a pathogenic significance of this 
disturbance in AD and not only an adaptive counter-regulatory response from the organism as 
proposed by others (Zemva and Schubert, 2014). Our aim was to develop an early diagnosis for 
AD based on now extensively documented brain IGF-1 resistance, which we have here found to 
exist earlier than expected along disease progression in AD mice (Trueba-Sáiz et al., 2013). An 
early IGF-1/insulin signaling impairment in AD has been recently confirmed by others (Jackson 
et al., 2013; Pedrós et al., 2014).  
4.3.  Development of an EEG-based biomarker of AD  
Based on the facts that systemic insulin was found to alter the electroencephalogram 
(EEG)  (Hallschmid et al., 2004; Tschritter et al., 2006) and that serum IGF-1 modifies neuro-
nal excitability in the brain stem (Nuñez et al., 2003)  and in the cortex (unpublished data), we 
thought of using the EEG and the related ECoG to develop a diagnostic test for AD. This non-
invasive technique is commonly used and widely available in clinical settings throughout the 
world. Firstly, we observed that in WT animals the electrocorticogram (ECoG) displayed a sus-
tained activation after only 20 min of intraperitoneal administration of IGF-1 and until the end 
of the experiment.  This latency is consistent with the kinetics of IGF-1 absorption from the pe-
ritoneum and its distribution towards the brain. Besides, it coincides with previous reports des-
cribing a relatively fast accumulation of IGF-1 in the CNS after peripheral IGF-1 injection 
(Carro et al., 2000). The bands most affected by IGF-1 were the alpha and the beta, which are 
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those with the highest frequencies and related to wakefulness and information processing. It is 
interesting that these same frequencies were reduced in patients with untreated acromegaly as-
sociated to GH/IGF-1 hypersecretion (Martín-Rodríguez et al., 2013), a condition in which the 
severity of cognitive complications strongly correlates with plasmatic levels of GH and IGF-1 
(Leon-Carrion et al., 2010; Tanriverdi et al., 2009). In contrast, it was described that high serum 
IGF-1 was associated in healthy senior men with more delta sleep (Prinz et al., 1995). These 
contradictions may be explained because of the chronic exposure to elevated circulating IGF-1 
as opposed to our acute injection, which among other detrimental effects might result in a de-
sensitization of IGF-1-induced IGF-1R signaling according to our in vitro and in vivo data. In-
versely, our report that acute IGF-1 injection stimulates overall brain activity accords with the 
acute alterations suppressing sleep observed in rats after IGF-1 intracerebroventricular injection 
(Obál et al., 1998, 1999).  
Potential mechanisms driving these changes are still under research. Specifically, when 
we injected atropine to block muscarinic neurotransmission (Liou et al., 2003), it was obvious 
that IGF-1 effect on the ECoG was not fully mediated by cholinergic stimulation of the cortex, 
which is known to desynchronize (activate) the EEG/ECoG (Steriade, 2004; Steriade et al., 
1993). Thus we suspected that IGF-1 directly impacted on cortical neurons. In this regard, pre-
vious supportive data from the laboratory (Nuñez et al., 2003) was  recently confirmed thanks 
to a study demonstrating that IGF-1 stimulates neuronal excitability via inhibition of the hyper-
polarizing A-type K+ current (IA) through sequential activation of the IGF-1R/PI3K/Raf/
ERK1/2 pathway (Wang et al., 2014). Besides, preliminary results from our group confirm that 
IGF-I increases cortical neuronal excitability by modulating K+ currents and glutamatergic neu-
rotransmission. 
When we performed the ECoG test on APP and APP/PS1 mice, they displayed a severely 
disrupted or even no response at all to IGF-1 stimulation in parallel to the lack of IGF-1R au-
tophosphorylation evoked by acute EE detected in these animals. We could not perform both 
tests on the same cohort of animals because both procedures ended in animal sacrifice. Howe-
ver, there was a clear predictive value of ECoG response to IGF-1 to predict the corresponding 
response to the physiological cognitive stimulation by EE. This ultimately means that monito-
ring changes within brain activity (e.g. EEG) after peripheral IGF-1 administration is a valid 
non-invasive way to explore brain IGF-1 sensitivity and thus may be used as its surrogate in the 
clinics. We believe this lack of response to be the direct consequence of the brain IGF-1 resis-
tance we have above discussed. Moreover, there are many processes that may elicit brain endot-
helial cell dysfunction in sporadic AD such as peripheral infections, unhealthy diets or age-
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associated oxidative stress, which may even directly affect serum IGF-I traffic to the brain (e.g. 
sedentary life, peripheral infections (Fernandez and Torres-Alemán, 2012) or western-style di-
ets (Dietrich et al., 2007)). We suggest that in sporadic AD, these multiple factors negatively 
impinge on serum-to-brain IGF-I traffic. Nevertheless, it is possible that other electrophysiolo-
gical disturbances known to occur in AD (Dauwels et al., 2010; Hort et al., 2010) may play a 
role in the observed aberrant reaction of the ECoG to IGF-1, even masking it among them. An 
EEG with diffuse abnormalities has been observed to be related to AD, whereas EEG with only 
focal abnormalities supports MCI and if both are present at the same time it has been proposed 
to be indicative of other sorts of dementia (e.g. vascular dementia, dementia with Lewy bo-
dies…) (Liedorp et al., 2009). 
The fact that the EEG signature of systemic IGF-I in healthy animals was maintained in 
non-human primates, who are evolutionarily nearer to us than mice, opens the possibility to find 
a similar EEG signature in healthy humans. Nevertheless, experimenting on non-human prima-
tes models of AD is complex and extremely costly, even though these have been reported to 
spontaneously develop an AD-like pathology with aging (Van Dam and De Deyn, 2011). The-
refore clinical trials on humans are needed to determine the potential use of EEG recordings 
after IGF-I challenge as an early screening system to define a population at risk of AD. Even 
though APP and APP/PS1 transgenic animals model only the amyloidopathy of AD, the transla-
tability of our findings may extend to late onset AD given that Aβ accumulation has been 
shown to reproduce in induced pluripotent stem cells (iPS) derived from spontaneous AD pa-
tients (Israel et al., 2012). Furthermore, other systemic elements of the IGF-1 system have also 
been identified as potential biomarkers of AD even through unbiased proteomic analysis 
(Johansson et al., 2013; Toledo et al., 2013). 
Summing up, our findings open the possibility to diagnose AD earlier than it is currently 
done using available methods. We believe that the EEG-based test we have developed could be 
implemented in humans for the following three reasons: 1) there is extensive safety data sup-
porting the usage of IGF-I pharmacological doses, it is already approved for chronic use in chil-
dren with Laron's dwarfism (see: http://www. drugs.com/pro/increlex.html) and our method is 
based on a single acute injection of IGF-I; 2) EEG recordings are routinely carried out in clini-
cal practice because of being easy, cheap and non-invasive explorations; and 3) the validation 
of the diagnostic procedure may be performed longitudinally along the AD continuum in sAD 
and also in familial AD cases. An abnormal EEG response to IGF-I might therefore prove use-
ful to better define a subpopulation of patients at risk of AD still in a preclinical stage (Sperling 
et al., 2011). Hence, it may become an additional biomarker complementing the multidimensio-
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nal risk assessment of AD recently proposed for middle-aged subjects which integrates all diag-
nostic approaches (e.g. neuropsychological testing, neuroimaging, genetics, CSF and plasma 
measurements…) (Holtzman et al., 2012; Jack et al., 2010). Besides, it may even be used as an 
indicator of therapeutic efficacy in response to potential treatments. Perhaps more importantly, 
such a biomarker might be useful to develop preventive schemes including physical exercise, 
nutritional intervention or even early treatment with IGF-I or its mimetics in a population in 
which these might have special interest and rationale in order to prevent or ameliorate AD pat-
hology progression. 
 
4.4.  Role of IGF-1 system in early brain changes induced by MetS as a risk factor  
 for dementia  
Because of the limitations of using transgenic animal models of AD and the impossibility 
of working with sporadic models of AD in our current setting (i.e. aged NHPs), we thought that 
the best approach to tackle the sporadic form of the disease was to study how the vascular risk 
factors associated to AD would affect IGF-1 system in the brain. An easy way to do that was to 
model many of them simultaneously by inducing a metabolic syndrome (MetS)-like in mice, 
altering their diet. The MetS is a relatively modern endocrine disorder, described as the concu-
rrence of obesity, insulin resistance (pre-diabetes), hypertension and dyslipidemia (Alberti and 
Zimmet, 1998; Alberti et al., 2009). Its prevalence has been greatly increased in the last decades 
due to the bad dietary habits and sedentary lifestyle and now it is a major public health concern. 
It is known to increase morbidity and many studies link it (and the related type 2 diabetes melli-
tus, T2DM) with the development of Alzheimer’s disease (AD) (Ballard et al., 2011). However, 
the molecular pathophysiology underneath this link remains to be elucidated.  
By exposing WT male mice to a high fat diet (HFD) with extra cholesterol for 5 or 10 we-
eks we obtained a model of pre-diabetes with early brain changes potentially predisposing to 
dementia. We found that our mild high fat diet (containing 45% kcal from fat, 45%HFD) indu-
ced an increase in body weight of around 20% that is compatible with most of the studies of this 
type. Anyway, the important fact about diet-induced obese (DIO) mice is that these are over-
weighed, similarly to unhealthy diet effects in humans, as opposed to the morbid obesity caused 
by genetic models of obesity such as the ob/ob mice, which are a poor model of the human 
MetS (Buettner et al., 2007; Fellmann et al., 2013).  
Serum insulin levels and the metabolic tests we performed were indicative of a situation 
bordering the development of full-scale T2DM as in several other studies using the same diet. 
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We found that, parallel to that of serum insulin, there was a significant increase in circulating 
IGF-1. Even though there are still conflicting results as to whether serum IGF-1 is increased, 
unchanged (Lukanova et al., 2004) or decreased by obesity (Hochberg et al., 1992; Rasmussen 
et al., 2007), it has been proposed that there is an initial compensatory raise in its levels that de-
creases over time with the increase in adiposity and hence with disease progression (Imrie et al., 
2009; Utz et al., 2008). Interestingly, we found a correlation between circulating IGF-1 and in-
sulin in control animals that was lost with obesity progression. Altogether, this agrees with a 
pre-diabetic stage of our DIO animals and reflects whole-body IGF-1/insulin resistance, which 
is now widely considered to be a key step in the pathogeny of obesity (Spielman et al., 2014).  
Obesity is defined as a chronic low-grade systemic inflammatory disease (Das, 2001). In 
line with this, central inflammation caused by peripheral inflammation has been proposed to be 
of capital importance in the pathogenesis of obesity-derived brain complications (André et al., 
2014; Milanski et al., 2009). However, possibly because of the lower fat content of our HFD 
(45% kcal from fat) with respect to others more aggressive and immunogenic (60% kcal from 
fat) and the relatively short exposure to it (max. 10 weeks), we have found so far no clue of 
brain inflammation in our mice. This agrees with previous reports showing that immunogenici-
ty happens upon juvenile exposure to a similar HFD but not in the adult (Boitard et al., 2012, 
2014). Overall, it further confirms the pre-diabetic stage of our animals. Even though we have 
only measured TNFα expression in the cortex and we might complement it with determinations 
of other pro-inflammatory cytokines (e.g. IL-1β, IL-6) in plasma, hippocampus and hypothala-
mus, it is unlikely that these will be altered. With this we would be completely sure of the in-
flammatory status of our animals, especially to confirm peripheral inflammation. 
 The transient increase in IGF-1 permeability in the choroid plexus that we found after 5 
weeks of HFD seems to confront with previously reported decrements in IGF-1 blood to brain 
transport due to western-style diets (Dietrich et al., 2007). A suitable explanation is that we now 
measured changes in endogenous IGF-1 levels in the CSF after HFD, whereas before it was 
exogenous human IGF-1 that was injected and measured. It is known that exogenous IGF-1 
competes with endogenous IGF-1 in its transport across the blood-brain barrier (Banks et al., 
1997). As a result, the decrease in the transport of exogenous IGF-1after HFD is easily explai-
nable by the increase in the endogenous IGF-1 circulating in the blood of DIO animals. Besi-
des, in the previous study (Dietrich et al., 2007), it was observed that HFD improved the sensiti-
vity of the choroid plexus to IGF-1 stimulation, what was evidenced by the enhanced phospho-
Akt levels after intracarotid injection of IGF-1 compared to rats receiving a standard diet. 
On the other hand, the transient increment of IGF-1 into the CSF may be related to the 
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recently reported fact that insulin brain transport is dually regulated by nitric oxide synthase 
(NOS) isoenzymes (Banks et al., 2008). It was shown that a pro-inflammatory stimulus (i.e. 
LPS) activates NOS in the brain, and that whereas NO released by the inducible (i) and endot-
helial (e) isoforms of NOS indirectly increased brain insulin transport, NO released by neuronal 
(n) NOS directly prevented it. Thus, it is possible that peripheral inflammation due to obesity at 
first activates eNOS/iNOS to increase IGF-1/insulin input into the CSF, but later in time nNOS 
activation, added to the potential development of insulin resistance by HFD, finally limits it. To 
this regard, it is known that eNOS, and more abundantly nNOS, are expressed in the choroid 
plexus (Lin et al., 1996; Sivakumar et al., 2008), that NO regulates the surrounding blood flow 
affecting the production of CSF (Szmydynger-Chodobska et al., 1996) and that iNOS can also 
be expressed within this brain structure in response to systemic inflammation (McCann et al., 
2005; Wong et al., 1996). 
As a result, we believe that the increase in CSF IGF-1 might be an adaptive mechanism 
trying to cope with central damage promoted by HFD. This idea is supported by findings in ro-
dents virally-transfected with a dominant-negative form of IGF-1R in the choroid plexus, thus 
abrogating constitutive IGF-1 CSF entrance. These mice developed systemic glucose intoleran-
ce 6 months after the initial infection, even though they were still normoinsulinemic 
(unpublished results from the laboratory). This suggests that CSF-incoming serum IGF-1 also 
participates of central regulation of energy homeostasis. 
It has been reported that after being injected inside the ventricles, IGF-1 is rapidly elimi-
nated from the CSF without extensive distribution into the brain (Nagaraja et al., 2005). Howe-
ver, it is not clear whether IGF-1 increase in the CSF after 5 weeks of HFD might be related to 
the increased tendency in IGF-1 signaling we detected in the hippocampus. The last is in direct 
opposition with literature concerning HFD effects on central insulin signaling. These include 
diminished phospho-IR levels (Jeon et al., 2012), decreased phospho-Akt and 
phosphoSer9GSK3β (or increased pTyrGSK3β) (Bhat and Thirumangalakudi, 2013; Sharma et 
al., 2008) or even no change at all (Becker et al., 2012; Leboucher et al., 2013). Yet, none of 
them directly measured phospho-IGF-1R/IGF-1R ratio.  
Interestingly, in mice overexpressing a mutated form of tau related to frontotemporal de-
mentia but not in WT mice, HFD increased pAkt (Leboucher et al., 2013). Conversely, it has 
been recently published that WT mice exposed to 17 days of 60% HFD (60% kcal from fat) de-
picted increased pAkt signal in frontal brain tissue lysates (Arnold et al., 2014), whereas those 
under 45% HFD for 8 weeks showed no change. Thus, it seems that HFD effects on IGF-1/
insulin brain signaling are not entirely consistent across studies and so this issue needs to be 
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further investigated and characterized in each case. Differences may emanate from the augmen-
ted IGF-1/insulin levels in the blood which may hypothetically lead to an initial increase in its 
brain signaling. This would be afterwards abrogated when IGF-1/insulin brain resistance fully 
develops. As a result, in our model we would be detecting the first event, since brain resistance 
to IGF-1/insulin is not yet stablished at 10 weeks of diet. In fact, we perceived a decrease in a 
molecular marker of IGF-1/insulin resistance (i.e. pS616IRS-1) at 5 weeks in the cortex of DIO 
animals. We interpret this as a transient increase in central IGF-1 sensitivity parallel to that of 
IGF-1 in the CSF. On the other hand, serine phosphorylation of IRS proteins is related to termi-
nation of IGF-1R signaling and thus it is possible that the decrease in pS616IRS-1 may alter the 
duration of IGF-1 brain signaling, extending it in time. Nevertheless, this hypersensitivity was 
lost when HFD was continued, showing a tendency towards the development of IGF-1/insulin 
resistance as it is generally accepted for these models (Gatenby and Kearney, 2010; de la Monte 
and Tong, 2014). 
When seeking for neuronal abnormalities induced by HFD we have so far detected tau 
hyperphosphorylation, which has long been known to be the main component of the paired heli-
cal filaments within the NFTs in AD, and mitochondria hyperfission in the cortex of DIO ani-
mals plus an increase in hippocampal dendritic spine density. Hyperphosphorylation of tau after 
10 weeks of HFD may be related to the decrease in body temperature displayed by DIO animals 
at this time. With respect to tau, it has been previously shown that insulin resistance-induced 
hypothermia is able to promote tau hyperphosphorylation (Planel et al., 2007). Besides, tau hy-
perphosphorylation has been shown to co-localize with pS616IRS-1, a marker of IGF-1/insulin 
resistance, in human brain samples of patients with AD and other tauopathies (Yarchoan et al., 
2014). However, there is no consensus in the bibliography as to whether HFD induces or not 
tau hyperphosphorylation in WT animals (Gendron et al., 2013). Some argue that it does (Bhat 
and Thirumangalakudi, 2013; Calvo-Ochoa et al., 2014; Jeon et al., 2012; Ma et al., 2009; Peng 
et al., 2013; Yarchoan et al., 2014), whereas others have not found such an effect (Becker et al., 
2012; Leboucher et al., 2013; Ramos-Rodriguez et al., 2013). One of those reported that HFD 
did worsen tau phosphorylation and tau-related pathology independently of insulin resistance in 
a tau transgenic mouse, which overexpressed a mutated form of tau prone to hyperphosphoryla-
tion, but not in WT mice (Leboucher et al., 2013). As a result, the authors hypothesized that the 
MetS potentiates AD pathology but is unable to trigger it per se. Supporting this proposal, HFD
-induced early hyperinsulinemia has been detected to aggravate brain amyloid pathology in 
APP/PS1 mouse model of AD (Ramos-Rodriguez et al., 2014), while it only promoted minor 
central alterations in WT animals (Ramos-Rodriguez et al., 2013). 
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 Interestingly, we observed that the mitochondrial balance of fusion/fission dynamics was 
early disrupted in the cortex of DIO mice, as evidenced by the reduced MFN-2/Fis1 ratio. This 
increase in mitochondrial fission might mean that brain mitochondria are being damaged by 
HFD, which would potentially lead to an increase in its degradation (i.e. mitophagy). Yet, this 
is a preliminary result and should be validated with further experiments directly assessing mito-
chondrial DNA damage or molecular markers of mitophagy. Conversely, it has been recently 
discovered that mitochondrial dynamics (especially mitofusins) play an important role in cen-
tral regulation of whole-body energy metabolism. Specifically, HFD induced mitochondrial fu-
sion in Agrp neurons in the hypothalamus (Dietrich et al., 2013) whereas it did the opposite in 
POMC neurons (Schneeberger et al., 2013). Mitochondrial dysfunction is known to contribute 
to the pathophysiology of IGF-1/insulin resistance and MetS in the genesis of T2DM and other 
of its vascular complications, including metabolic heart disease (Bournat and Brown, 2010; Ren 
et al., 2010). Our findings agree with previous reports showing decreased mitochondrial density 
as being one of the earliest events driving T2DM development (Morino et al., 2005). Besides, 
others have found that rats exposed to HFD for 12-14 weeks also exhibited brain mitochondrial 
dysfunction (Pintana et al., 2013; Pipatpiboon et al., 2012) . Nevertheless, it has been shown 
that mitochondria dysfunction results in insulin resistance but depending on the cell-type 
(Martin et al., 2014). For that reason, more research is needed to know if the early unbalance 
we found is responsible for the later predicted IGF-1/insulin resistance in DIO animals. 
Finally, the increase in hippocampal spine density elicited by HFD is intriguing and adds 
to the body of controversial results in the field. Golgi staining of CA1 region from rats fed a 
high fat/high glucose diet and supplemented with 20% fructose in the drinking water showed a 
reduction in spine density (Stranahan et al., 2008). It has also been published that after only 7 
days of high fat/high fructose diet, the CA1 of rats displayed a decrease in dendritic arboriza-
tion, a reduction in dendritic spine number and in synaptophysin levels (Calvo-Ochoa et al., 
2014). Moreover, western blot in hippocampal lysates studies have identified that HFD supple-
mented with cholesterol (as it is ours) decreased protein levels of PSD95 and drebrin (a dendrite 
spine-specific protein) in the hippocampus, but not of synaptophysin (Bhat and Thirumangala-
kudi, 2013). Similarly, CA3 region from animals under 45% HFD for 8 weeks showed decrea-
sed PSD95 immunostaining and no change in synaptophysin (Arnold et al., 2014). On the con-
trary, it has been recently reported that 5 week old mice under 45% HFD for 8 weeks had an 
increase in CA1 total spine density as determined by Golgi staining (Valladolid-Acebes et al., 
2013). This was not recovered after switching the animals back to a healthy diet for 5 extra we-
eks and it accompanied behavioral difficulties in the novel location recognition test. However, 
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this was not replicated in adult mice (8 weeks old) and because our animals started the HFD at 
8 weeks of age (already in adulthood) our results are not entirely comparable. With exception to 
those using Golgi staining, most of these studies used indirect methods to count the dendritic 
spines and none of them are as accurate as the method we have used. On the other hand, even 
though it has been proposed that an increase in dendritic spines correlates with improved lear-
ning (Phan et al., 2012) and decreased cognitive impairment (Chen et al., 2010; del Valle et al., 
2012), this is not always true. For example, rats prenatally exposed to cocaine displayed increa-
sed anxiety, cognitive impairment and increased spine density in the prefrontal cortex and nu-
cleus accumbens (Salas-Ramirez et al., 2010). Disruption of the spine dynamics throughout life 
is involved in the pathogenesis of several neuropsychiatric conditions such as autism spectrum 
disorders (with exaggerated spine formation in childhood), schizophrenia (with excessive spine 
pruning in adolescence) or AD (with rapid loss of spines in late adulthood) (Penzes et al., 
2011). Hence, we may be detecting an early excess in immature or dysfunctional spines (empty 
or silent), which is also detrimental for cognitive functions due to a compromised brain plastici-
ty. In fact, the increase in spine density may respond to a compensatory mechanism to deal with 
HFD which tries to maintain synaptic homeostasis against other intracellular deficits affecting 
proper neuronal impulse transmission. Therefore, we would need to perform additional elec-
trophysiological and behavioral experiments to assess how the increase in spine number due to 
HFD impacts on brain physiology. 
To sum up it is important to note that even though some of our HFD results are in discor-
dance with part of the literature, there is coherence among them. We saw that IGF-1 was increa-
sed in the CSF after 5 weeks of HFD and that its signaling tended to be slightly increased in the 
hippocampus of DIO mice. Besides, it is known that IGF-1 is able of generating new synapses 
in the DG of postnatal mice (O’Kusky et al., 2000) and that its neutralization abrogates the in-
crease in CA1 spine density induced by treadmill running (Glasper et al., 2010). We may there-
fore conclude that IGF-1 plays an important role in the adaptive response of the brain to HFD. 
As a consequence, it may be speculated that abrogation of IGF-I signaling in obesity may con-
tribute to cognitive decline. 
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1. Environmental enrichment evokes the entrance of peripheral IGF-1 into the hippocampus 
following a region-specific and time-dependent pattern. This is evidenced by the specific 
activation of hippocampal IGF-R after enrichment, which does not occur in liver IGF-1 
deficient mice. 
2. IGF-1 downregulates IGF-1 and IGF-1R expression in brain cells in vitro, possibly as part of 
a complex auto-regulatory loop that controls both IGF-1 levels and its brain signaling after 
environmental enrichment.  
3. GSK3β activity seems to be a key element, at least in vitro, in the physiological regulation of 
IGF-1 uptake by brain cells including neurons, astrocytes and brain endothelial cells. 
4. Preclinical animal models of Alzheimer’s disease (i.e. 4 month old APP and APP/PS1 mice) 
depict an early state of brain IGF-1 resistance in basal conditions compatible with human 
findings in MCI and AD, which explains the reduced blood-to-CSF IGF-1 ratio. 
5. IGF-1 access to the brain in response to neuronal activity is early impaired in AD mice as 
shown by the lack of response of hippocampal IGF-1R to environmental enrichment. A 
potential trigger might be the overproduction of Aβ, which in vitro leads to the dysregulation 
of BBB permeability to IGF-1. 
6. Recordings of brain electrical activity (ECoG/EEG) may be used to explore brain sensitivity 
to IGF-1 in a non-invasive fashion by peripherally injecting one single high dose of IGF-1 
and measuring the potentiation of the fast component of the ECoG/EEG, mainly of the beta 
frequency band. Because mice and monkeys exhibit a similar IGF-1-induced ECoG/EEG 
signature we hypothesize that humans will perform similarly. 
7. Failure of exogenous IGF-1 injection to activate the ECoG/EEG may be used as a biomarker 
of disease onset and progression in AD, given that asymptomatic APP/PS1 had no reaction at 
all and APP mice did respond but rather weakly. However, because old mice also displayed a 
lessened effect, risk assessment of AD in the elder should be carried out with caution and in 
correlation with other biomarkers of AD. 
8. The metabolic syndrome, a risk factor of dementia, induces early changes in the input of 
circulating IGF-1 to the brain. It transiently and specifically increases the permeability of the 
choroid plexus to its entry and as a result it accumulates in the CSF after 5 weeks of HFD. 
This might be the consequence of the hypersensitivity to IGF-1 detected in the cortex and the 
cause of the increase in its hippocampal signaling. 
9. Further research is needed to assess the true role of IGF-1 in the disruption of morphological 
and molecular markers of neuronal dysfunction unleashed by MetS such as mitochondria 
hyperfission, tau hyperphosphorylation and dendritic abnormalities . 
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1. El enriquecimiento ambiental promueve la entrada de IGF-1 periférico al hipocampo 
siguiendo un patrón espaciotemporal concreto. Esto se demuestra por la activación específica 
del IGF-1R después del enriquecimiento, lo que no ocurre en ratones deficientes para la 
producción hepática de IGF-1. 
2. En células cerebrales in vitro IGF-1 regula a la baja la expresión de IGF-1 y del IGF-1R, 
probablemente como parte de un complejo circuito de autoregulación que controla tanto los 
niveles de IGF-1 como su señalización después del enriquecimiento ambiental. 
3. La actividad de GSK3β parece ser un elemento clave, al menos in vitro, en la regulación 
fisiológica de la captación de IGF-1 por las células del sistema nervioso, incluyendo 
neuronas, astrocitos y células endoteliales cerebrales. 
4. Modelos animales de etapas preclínicas de la enfermedad de Alzheimer (ratones APP y APP/
PS1 de 4 meses) muestran un estado temprano de Resistencia cerebral a IGF-1 en condiciones 
basales que es compatible con los hallazgos en pacientes con deterioro cognitivo leve y 
Alzheimer, lo que explica la reducción en el ratio de IGF-1 sangre-líquido cefalorraquídeo.  
5. El acceso de IGF-1 al cerebro en respuesta a la actividad neuronal está impedida 
tempranamente en los ratones Alzheimer como demuestra la falta de respuesta del IGF-1R 
hippocampal al enriquecimiento. Un desencadenante potencial podría ser la sobreproducción 
de Aβ de estos modelos, lo que conlleva in vitro a la desregulación de la permeabilidad a IGF
-1 de la barrera hematoencefálica. 
6. El registro de la actividad eléctrica cerebral (ECoG/EEG) puede usarse para explorar la 
sensibilidad cerebral a IGF-1 de forma no invasiva a través de la injección periférica de una 
única dosis de IGF-1 y la posterior medida de la potenciación del componente rápido del 
ECoG/EEG, principalmente de la banda beta. Puesto que monos y ratones exhiben una firma 
similar en el ECoG/EEG tras el IGF-1, hipotetizamos que los humanos también lo harán. 
7. El fallo de la administración exógena de IGF-1 para activar el ECoG/EEG podría usarse 
como biomarcador del comienzo de la enfermedad de Alzheimer y de su progresión, ya que 
los APP/PS1 asintomáticos no mostraron ninguna respuesta y los APP lo hicieron débilmente. 
No obstante, debido a que los ratones envejecidos tuvieron un efecto disminuido de IGF-1, la 
evaluación del riesgo de Alzheimer en los mayores debería llevarse a cabo con precaución y 
en correlación con otros biomarcadores de la enfermedad.  
8. El síndrome metabólico (un factor de riesgo para la demencia), induce cambios tempranos en 
la entrada de IGF-1 circulante al cerebro. Incrementa de forma temporal y específica la 
permeabilidad del plexo coroideo a IGF-1 y como resultado éste se acumula en el líquido 
cefalorraquídeo después de 5 semanas de dieta grasa. Esto podría ser consecuencia de la 
hipersensibilidad a IGF-1 que se observa en el córtex y la cause de la mayor señalización 
hipocampal. 
9. Más trabajo es necesario para determinar el verdadero papel de IGF-1 en la disrupción de 
marcadores morfológicos y moleculares de disfunción neuronal desencadenados por el 
síndrome metabólico, tales como la hiperfisión mitocondrial, la hiperfosforilación de tau y las 
anormalidades dendríticas. 
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